Bicuspid aortic valve and associated aortopathy: a combined biomechanics, histological and genetic analysis by Prapa, Stamatia
1 
 
 
Bicuspid aortic valve and associated aortopathy: 
a combined biomechanics, histological and genetic 
analysis 
 
 
 
A thesis submitted to Imperial College London 
for the degree of Doctor of Philosophy 
by 
Stamatia Prapa 
June 2013 
Department of Adult Congenital Heart Disease 
National Heart and Lung Institute 
Imperial College London 
 
2 
 
Declaration   
I hereby certify that all material in this dissertation is the product of original research. 
Any presented work which is not my own has been appropriately acknowledged. 
The copyright of this thesis rests with the author and is made available under a Creative 
Commons Attribution Non-Commercial No Derivatives licence. Researchers are free to 
copy, distribute or transmit the thesis on the condition that they attribute it, that they do 
not use it for commercial purposes and that they do not alter, transform or build upon it. 
For any reuse or redistribution, researchers must make clear to others the licence terms of 
this work. 
 
 
 
 
 
 
 
 
3 
 
Abstract 
Bicuspid aortic valve (BAV) is the most common inborn heart defect and a continuum of 
a disease process affecting the aortic valve and the thoracic aorta with an increased risk 
of thoracic aortic aneurysm (TAA) formation and dissection. Aortic dilatation may be 
related to haemodynamic perturbations or intrinsic wall abnormalities. The aim of this 
thesis was to investigate the relative contribution of these parameters to BAV aortopathy 
via integrated analyses. 
Distribution of circumferential stress in the aorta of BAV patients planned to undergo 
surgery was analysed using computed tomography imaging and computational modelling. 
During surgery, aortic biopsies were taken from discrete areas and examined for 
histological abnormalities. Maximal mechanical stress occurred in the medial ascending 
aorta in the majority of cases with integrated analyses exhibiting a positive correlation 
between aortic fibrosis and mechanical stress, both in the root and the ascending aorta. The 
degree of histological abnormalities and transforming growth factor beta (TGFβ) 
activation was also assessed in collected tissue biopsies. Patients with either root 
dilatation and/or predominant regurgitant valve disease had greater levels of medial wall 
degeneration in their ascending aorta whereas enhanced TGFβ signalling was present in 
aneurysmal but also, non-dilated BAV aortic segments, pointing to a genetic trigger. 
Copy number variation (CNV) analyses in a larger BAV cohort revealed a large 
heterozygous deletion in the angiotensin converting enzyme (ACE) gene and targeted 
next-generation sequencing  revealed previously reported variants in NOTCH1, COL3A1, 
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and APOE genes with additional discovery of a large number of likely pathogenic 
variants in genes related to BAV formation and aortopathy.  
In conclusion, different BAV aortic phenotypes were recognised and further analysed. 
The presence of multiple likely pathogenic variants in sequenced patients suggests a 
polygenic nature of BAV disease which, in conjuction with local haemodynamic 
perturbations, supports a mutlifactorial origin of BAV aortopathy. 
 
 
 
 
 
 
 
 
 
 
 
5 
 
 
List of contents 
    Title……………………………………………………………………….....................1 
Declaration..................................................................................................................... 2 
Abstract .......................................................................................................................... 3 
List of contents .............................................................................................................. 5 
List of Figures .............................................................................................................. 13 
List of Tables ............................................................................................................... 15 
Abbreviations .............................................................................................................. 17 
Acknowledgements ..................................................................................................... 20 
Chapter 1: Introduction……………………………………………………………..22 
Abbreviations .............................................................................................................. 22 
1.1 Valve anatomy and disease .................................................................................. 24 
1.2 Aortic anatomy and disease ................................................................................. 26 
1.3 Structure and ontology of the bi-leaflet aortic valve ......................................... 28 
1.4 Mechanisms underlying BAV aortopathy .......................................................... 37 
1.4.1 Haemodynamic theory................................................................................... 39 
1.4.2 Genetic theory ................................................................................................ 42 
6 
 
1.5 Future directions in management of BAV aortopathy ...................................... 50 
1.5.1 Pharmacological treatment ........................................................................... 50 
1.5.2 Emerging risk stratification tools in BAV-TAA ......................................... 52 
1.4 Study aims.............................................................................................................. 54 
Chapter 2: General methods………………………………………………………...56  
Abbreviations .............................................................................................................. 56 
2.1 Patient Population ................................................................................................. 57 
2.1.1 Inclusion criteria ............................................................................................ 57 
2.1.2 Exclusion Criteria .......................................................................................... 57 
2.1.3 Phenotyping .................................................................................................... 58 
2.1.4 BAV patient cohort characteristics .............................................................. 59 
2.2 Computational modelling ..................................................................................... 61 
2.3 Aortic tissue sampling ........................................................................................... 65 
2.4 Histology and immunohistochemistry ................................................................. 66 
2.4.1 Processing of aortic sections .......................................................................... 66 
2.4.2 Histological examination ............................................................................... 66 
2.4.3 Immunohistochemical protocol .................................................................... 67 
2.4.4 Immunohistochemical grading ..................................................................... 69 
2.5 Purification and quantification of DNA .............................................................. 70 
7 
 
2.6 Statistical analyses ................................................................................................ 72 
2.7 Genetic analyses .................................................................................................... 72 
2.7.1 Array comparative genomic hybridization ................................................. 72 
Chapter 3: Finite element analysis………………………………………………….77 
Abbreviations .............................................................................................................. 77 
3.1Abstract ................................................................................................................... 78 
3.2 Introduction ........................................................................................................... 79 
3.3 Methods .................................................................................................................. 81 
3.3.1 Summary ......................................................................................................... 81 
3.3.2 Technical difficulties over course of the study ............................................ 82 
3.4 Results .................................................................................................................... 85 
3.4.1 Patient characteristics ................................................................................... 85 
3.4.2 Maximal Mechanical Stress .......................................................................... 87 
3.4.3 Histological abnormalities ............................................................................. 91 
3.4.4 Integrated analyses ........................................................................................ 92 
3.5 Discussion............................................................................................................... 93 
3.5.1 Maximal mechanical stress ........................................................................... 93 
3.5.2 Integrated analyses ........................................................................................ 96 
3.5.3 Limitations ...................................................................................................... 97 
8 
 
3.6 Conclusions ............................................................................................................ 99 
Chapter 4: BAV aortic phenotypes………………………………………………. 100 
Abbreviations ............................................................................................................ 100 
4.1 Abstract ................................................................................................................ 101 
4.2 Introduction ......................................................................................................... 102 
4.3 Methods ................................................................................................................ 105 
4.3.1 Aortic specimens .......................................................................................... 105 
4.4 Results .................................................................................................................. 106 
4.4.1 Patient characteristics ................................................................................. 106 
4.4.2 Histological findings..................................................................................... 107 
4.4.3 Immunohistochemical findings ................................................................... 109 
4.5 Discussion............................................................................................................. 115 
4.5.1 The dilated root phenotype ......................................................................... 115 
4.5.2 TGFβ signalling ............................................................................................ 117 
4.5.3 Limitations .................................................................................................... 120 
4.6 Conclusions .......................................................................................................... 120 
Chapter 5: PAH model of aortopathy……………………………………………..122 
Abbreviations ............................................................................................................ 122 
5.2 Abstract ................................................................................................................ 123 
9 
 
5.3 Introduction ......................................................................................................... 124 
5.4 Methods ................................................................................................................ 125 
5.4.1 Tissue specimens .......................................................................................... 125 
5.4.2 Macroscopic analysis ................................................................................... 126 
5.4.3 Microscopic analysis .................................................................................... 126 
5.4.4 Histology grading scores.............................................................................. 127 
5.5 Results .................................................................................................................. 127 
5.5.1 Pulmonary trunk .......................................................................................... 128 
5.5.2 Main pulmonary artery branches .............................................................. 129 
5.5.3 Aorta.............................................................................................................. 130 
5.5.4 Elastic components of the media ................................................................ 131 
5.6 Discussion............................................................................................................. 132 
5.5.1 Medial wall abnormalities in the elastic pulmonary arteries ................... 134 
5.5.2 Determinants of aortopathy in CHD lesions ............................................. 135 
5.5.2 Clinical implications of PT wall abnormalities ......................................... 135 
5.6 Study limitations ............................................................................................. 137 
5.7 Conclusion ....................................................................................................... 137 
Chapter 6: Copy number variation………………………………………………..138 
Abbreviations ............................................................................................................ 138 
10 
 
6.1 Abstract ................................................................................................................ 139 
6.2 Introduction ......................................................................................................... 140 
6.3 Methods ................................................................................................................ 141 
6.3.1 Patient recruitment ...................................................................................... 141 
6.3.2 CNV discovery .............................................................................................. 141 
6.4 Results .................................................................................................................. 141 
6.4.1 Patient characteristics ................................................................................. 141 
6.4.2 CNV calling................................................................................................... 142 
6.4.3 CNV Burden Analysis.................................................................................. 148 
6.4.4 Identification of likely pathogenic CNVs ................................................... 151 
6.4.5 Candidate genes ........................................................................................... 154 
6.4.6 CNV calling for X chromosome .................................................................. 158 
6.4.7 Supplementary data ..................................................................................... 158 
6.5 Discussion............................................................................................................. 161 
6.5.1 CNVs in CHD ............................................................................................... 161 
6.5.2 ACE gene ....................................................................................................... 163 
6.5.3 X- chromosome linkage theory ................................................................... 166 
6.5.4 Limitations .................................................................................................... 167 
6.6 Conclusion ........................................................................................................... 167 
11 
 
Chapter 7: Next-generation sequencing…………………………………………..168 
Abbreviations ............................................................................................................ 168 
7.1 Abstract ................................................................................................................ 169 
7.2 Introduction ......................................................................................................... 169 
7.3 Methods ................................................................................................................ 170 
7.3.1 Sample collection .......................................................................................... 170 
7.3.2 Next-generation sequencing ........................................................................ 170 
7.3.3 Data analysis ................................................................................................. 177 
7.4 Results .................................................................................................................. 178 
7.4.1 Analysis of variants ...................................................................................... 178 
7.5 Discussion............................................................................................................. 184 
7.5.1 Genetic risk factors for aortic stenosis ....................................................... 184 
7.5.2 Genes related to BAV formation ................................................................ 186 
6.5.3 Genes related to aneurysm formation ........................................................ 187 
7.5.4 Syndromic forms of BAV disease ............................................................... 189 
7.5.5 Towards a uniform theory .......................................................................... 190 
7.5.6 Limitations .................................................................................................... 195 
7.6 Conclusion ........................................................................................................... 195 
Chapter 8: Conclusion……………………………………………………………...196 
12 
 
Abbreviations ............................................................................................................ 196 
8.1 Haemodynamic influence ................................................................................... 197 
8.2 Developmental aspects ........................................................................................ 199 
8.3 Genetic aberrations ............................................................................................. 201 
8.4 Conclusion ........................................................................................................... 203 
Chapter 9: Appendices……………………………………………………………..204 
9.1 Personal contribution to the research ............................................................... 204 
9.2 Prizes and grants ................................................................................................. 205 
9.3 Publications ......................................................................................................... 205 
9.3.1 Published abstracts ...................................................................................... 206 
9.3.2 Chapters in Books ........................................................................................ 207 
9.4 Presentations ....................................................................................................... 207 
International/national ........................................................................................... 207 
Local ....................................................................................................................... 208 
Bibliography .............................................................................................................. 209 
 
 
 
 
 
 
13 
 
List of Figures 
Figure 1.1 Human heart morphology............................................................................ 28 
Figure 1.2 BAV morphological subtypes ...................................................................... 29 
Figure 1.3 Distinct aetiology of functional BAVs ......................................................... 33 
Figure 1.4 Molecular pathways involved in BAV formation ...................................... 36 
Figure 1.5 Evidence of haemodynamic influence on BAV aortopathy ...................... 40 
Figure 1.6 Molecular pathways involved in inherited forms of aortopathy .............. 49 
Figure 2.1 Representation of thresholding ................................................................... 62 
Figure 2.2 Three-dimensional (3D) aortic models ....................................................... 63 
Figure 2.3 Meshing .......................................................................................................... 63 
Figure 2.4 Summary of structural finite element analysis .......................................... 64 
Figure 2.5 Examples of aortic tissue labelling .............................................................. 65 
Figure 2.6 Histological grades of medial elastic fragmentation .................................. 67 
Figure 2.7 Array comparative genomic hybridization ................................................ 74 
Figure 2.8 Sureselect target enrichment system for next-generation sequencing ..... 76 
Figure 3.1 Circumferential stress measurements. ....................................................... 82 
Figure 3.2 Pilot three-dimentional (3D) reconstruction employing magnetic 
resonance imaging (MRI). .............................................................................................. 84 
Figure 3.3 Analyzed BAV aortic phenotypes and corresponding maximal stress 
values. ............................................................................................................................... 87 
Figure 3.4 Overview of range (KPa) and location of circumferential stress in studied 
BAV subjects ................................................................................................................... 90 
14 
 
Figure 3.5 Percentage of severe medial wall abnormalities (≥ grade 2) in collected 
tissue biopsies. ................................................................................................................. 91 
Figure 3.6 Representative overview of correlations between the degrees of medial 
wall abnormalities and mean circumferential stress in the corresponding areas of 
aortic wall tissue biopsies ............................................................................................... 92 
Figure 3.7 Computational modelling in abdominal aortic aneurysm (AAA). ........... 95 
Figure 4.1 Canonical (Smad-dependent) transforming growth factor-β (TGFβ) 
signalling pathway. ....................................................................................................... 103 
Figure 4.2 Developmental field boundaries in the thoracic ascending aorta. ......... 105 
Figure 4.3 Correlation between medial pSmad2 signalling and histology grading 
score ................................................................................................................................ 113 
Figure 4.5 Representative overview of medial wall abnormalities and pSmad2 
signalling in adjacent serial sections of the aortic root and the ascending aorta .... 114 
Figure 5.1 A. The vicious circle of vascular remodelling in pulmonary arterial 
hypertension .................................................................................................................. 130 
Figure 5.2 Histological changes in the great arteries ................................................. 131 
Figure 5.3 Histology grading scores (HGS) for the great arteries ............................ 132 
Figure 5.4 Correlation between pulmonary trunk HGS, vessel diameter and medial 
hypertrophy. .................................................................................................................. 133 
Figure 6.1 Quality calling (QC) statistics of copy number variation (CNV) calling in 
BAV patients.................................................................................................................. 144 
Figure 6.2 Number of CNV calls as a function of sample’s level of noise. ............... 145 
Figure 6.3 Distribution of deletion-to-duplication ratio ............................................ 146 
15 
 
Figure 6.4 Example of array data from BAV samples with excessive CNV calls. .. 147 
Figure 6.5 “Dropped” duplication on chromosome 17. ............................................. 152 
Figure 6.6 Rare recurrent duplication on chromosome 2. ........................................ 154 
Figure 6.7 Deletion on angiotensin-converting enzyme (ACE) gene. ....................... 157 
Figure 6.8 Family pedigrees ......................................................................................... 159 
Figure 6.9 Overall distribution of rare autosomal deletions and duplications in BAV 
cases and controls .......................................................................................................... 162 
Figure 6.9 The expression of ACE gene in the embryonic mouse heart .................. 165 
Figure 7.1 Analysis of variants .................................................................................... 179 
Figure 7.2 Previously investigated genes for association with BAV disease and/or 
hypoplastic left heart syndrome. ................................................................................. 185 
Figure 7.3. Proposed genotype-phenotype correlartions ........................................... 193 
Figure 7.4. Hypothetical multifactorial model for BAV phenotypic expression ..... 194 
Figure 8.1 Proposed novel risk stratification tools in BAV aortopathy ................... 203 
 
List of Tables 
Table 1.1 Summary of inherited forms of thoracic aortic aneurysm (TAA) ............. 48 
Table 2.1 Bicuspid aortic valve (BAV) patient cohort characteristics ....................... 60 
Table 3.1 Patient characteristics .................................................................................... 86 
Table 3.2 Maximal circumferential stress. ................................................................... 88 
Table 3.3 Absolute values of maximal stress and aortic radius measurements ........ 89 
Table 4.1. Patient characteristics. ................................................................................ 107 
16 
 
Table 4.2 Histological abnormalities in examined aortic specimens ........................ 108 
Table 4.3 Percentage of pSmad2 signalling in patients and controls ....................... 109 
Table 4.4 Histological and immunohistochemical findings divided by aortic valvular 
disease............................................................................................................................. 111 
Table 4.5 Histological and immunohistochemical findings divided by absence (z-
score < 2) or presence (z-score ≥ 2) of aortic dilatation ............................................. 112 
Table 4.6 Next-generation sequencing results (selected genes) in BAV patients. ... 118 
Table 5.1 Patient characteristics. ................................................................................. 128 
Table 6.1 Patient characteristics .................................................................................. 143 
Table 6.2 Global CNV burden analysis: CNV event (CNVE) type and frequency 
(annotated CNVs size 100-200kb)................................................................................ 149 
Table 6.3 Global CNV burden analysis: CNV event (CNVE) type and size 
(annotated CNVs frequency <1%) .............................................................................. 150 
Table 6.4 Rare recurrent deletions in BAV cases ...................................................... 153 
Table 6.5 Rare recurrent duplications in BAV cases ................................................. 153 
Table 6.6. Investigated genes of interest associated with BAV disease and TAA 
formation ....................................................................................................................... 155 
Table 6.7 Rare deletions and duplications on the X chromosome ............................ 160 
Table 7.1 Summary of sequenced genes ...................................................................... 172 
Table 7.2 Next-generation sequencing preliminary results. ...................................... 180 
  
17 
 
Abbreviations 
3D Three-dimensional 
4D Four-dimensional 
AAA Abdominal aortic aneurysm 
ACE Angiotensin converting enzyme 
ACTA A-smooth actin 
ALP Alkaline phosphatase  
Ao Aortic 
APC Adenomatosis polyposis coli  
AR Aortic regurgitation 
ARB Angiotensin receptor blocker  
AS Aortic stenosis 
ASD Atrial septal defect 
ASI Aortic size index 
ASO arterial switch operation  
ATI Angiotensin II type I receptor 
AVR Aortic valve replacement  
BAC Bacterial artificial chromosome  
BAV Bicuspid aortic valve 
BMP Bone morphogenic protein 
BRU Biomedical research unit 
BSA Body surface area 
cDNA Complementary DNA 
CGH Comparative genomic hybridization  
CHD Congenital heart disease 
CMR Cardiac magnetic resonance 
CNC Cardiac neural crest 
CNS Central nervous system  
CNV Copy number variation 
CNVE Copy number variation event 
CMR Cardiac magnetic resonance  
CoA Coarctation of the aorta 
COL3A1 Type III procollagen 
COL3A1 Type III procollagen 
18 
 
CT Computed tomography 
DAB chromogen 3,3’-diaminobenzidine 
DDR Deletion-to-duplication ratio 
ECM Extracellular matrix 
EMT Endothelial mesenchymal transformation 
ENG Endoglin 
eNOs Endothelial nitric oxide synthase 
ES Eisenmenger syndrome 
EVG Elastic Van Gieson 
FBN1 Fibrillin-1 
FEA Finite element analysis  
FN1 Fibronectin-1 
Fz Frizzled 
GABA gamma-aminobutyric acid  
GPCR G-protein coupled receptor 
GSK3 glycogen synthase kinase-3 
HGS Histology grading score 
HLHS Hypoplastic left heart syndrome 
IMS Industrial Methylated Spirits 
KPa Kilopascals 
LDS Loeys Dietz syndrome 
LLC Large latent complex 
LPA Left pulmonary artery 
LOD score Logarithm (base 10) of odds 
LRP Lipoprotein receptor-related 
LV Left ventricular 
LVOTO Left ventricular outflow tract obstruction  
MAD Median absolute deviation 
MAF Minor allele frequency 
MAPK Mitogen activated protein kinase 
MFS Marfan syndrome 
MMP Matrix metalloproteinase 
MRI Magnetic resonance imaging  
NFATc1 Activated T-cell protein 1 
NGS Next generation sequencing 
19 
 
PAH Pulmonary arterial hypertension 
PBS Phosphate buffered saline  
PCR polymerase chain reaction 
PDA Patent arterial duct 
pSmad2 Phosphorylated Smad2 
PT Pulmonary trunk 
PT/Ao MT Pulmonary trunk-to-aortic media thickness 
PWS Peak wall stress 
QC Quality control 
RAS Renin angiotensin system 
RhoA Ras homolog gene family 
R-L Fusion of right- and left-coronary leaflets 
R-N Fusion of right- and non-coronary leaflets 
ROCK Rho kinase 
RPA Right pulmonary artery  
SAC Sum of auto-correlation  
SNP Single nucleotide polymorphism 
SOX9 Sex determining region Y box-9 
STJ Sinutubular junction 
TAA Thoracic aortic aneurysm 
TAV Trileaflet aortic valve 
TGA Transposition of the great arteries 
TGFβ Transforming growth factor beta 
TGFBR Transforming growth factor-beta receptor 
TIMP Tissue inhibitor of matrix metalloproteinase 
TOF Tetralogy of Fallot 
UTR Prime untranslated region 
VEGF Vascular endothelial growth factor 
VSD Ventricular septal defect 
VSMC Vascular smooth muscle cell 
WSS Wall shear stress 
 
  
20 
 
Acknowledgements 
First and foremost, I would like to thank my primary supervisor, Prof. Gatzoulis, for his 
endless support, motivational advice, warmth, and kindness. He has acted as an excellent 
supervisor but also, as a fatherly figure throughout these challenging years, seeing me 
through my first academic steps and transition to clinical training. I am indebted to him 
for giving me the opportunity to become part of his team and investing me with his 
knowledge.  
Likewise, I would like to thank Prof. Ho, my secondary supervisor, who has also 
graciously supported me all the way through and continues to provide me with exciting 
new academic challenges. Prof. Ho also introduced me to the wonderful team of the 
Cardiac Morphology Unit, Royal Brompton Hospital, and in particular to Karen 
McCarthy, whom I thank for her teaching and for making this work seem effortless. My 
special thanks go to the rest of my supervisors, Prof. Johnson and Dr. Babu-Narayan for 
giving me instrumental advice in the beginning of this project and supporting me all the 
way through to key edits of this dissertation. I am lucky to consider Sonya a personal 
friend and could not have made it without her warm smile during challenging moments of 
this research. I am also grateful to Prof. Collins, my mentor, who guided me from the 
very beginning of this project and made sure that I was well supported.  
During these years, I was also lucky to have a number of informal supervisors. Just to 
name a few, I would like to thank Dr. Dimopoulos who introduced me to key research 
methodology but also, acted as a mentor and generously gave me numerous opportunities 
to complete exciting work with him. I am also thankful to Mr. Shore for making this 
21 
 
project possible and introducing me to a number of key ICL faculty members. Mr. Shore, 
along with Mr. Sethia and Mr. Uemura, have also provided key surgical support to this 
study and facilitated the collection of targeted tissue biopsies. Finally, I am thankful to 
Dr. Kilner and Dr. Rubens for their generous help with pre-operative imaging, without 
which the computational modelling aspects of this study would not have been possible.   
A number of key collaborators were necessary to complete this multidisciplinary 
research. Prof. Pepper has acted as an informal supervisor of this thesis, providing me 
with essential academic support, and led the way to exciting collaborations. Prof. Xu 
kindly welcomed me to the Chemical Engineering department, ICL, and with the support 
of Dr. Torii, taught me the fundamentals of computational modelling. I am especially 
thankful to Prof. Cook, who not only introduced me to the field of clinical genetics but 
also, gave me tremendous opportunities to extend this work, via collaborations with the 
Wellcome Trust Sanger Institute and the Cardiovascular Biomedical Research Unit of the 
Royal Brompton Hospital. 
Finally, I am thankful to a number of old and new friends, including fellows of the Adult 
Congenital Heart Disease Unit, Royal Brompton Hospital, who were there when most 
needed. This research is dedicated to my family; my parents, Sotiris and Evangelia, for 
their immense support and for teaching me that “the sky is the limit” and my sisters, 
Vicky and Iliana, for standing by me throughout the joyful and stressful moments of this 
journey. 
  
22 
 
Chapter 1. Introduction 
 
 
Abbreviations 
4D Four-dimensional 
ACE Angiotensin converting enzyme 
ACTA A-smooth actin 
ALP Alkaline phosphatase 
APC Adenomatosis polyposis coli  
ASD Atrial septal defect 
ATI Angiotensin II type I receptor 
BAV Bicuspid aortic valve 
BMP Bone morphogenic protein 
CGH Comparative genomic hybridization  
CHD Congenital heart disease 
COL3A1 Type III procollagen 
ECM Extracellular matrix 
EMT Endothelial mesenchymal transformation 
ENG Endoglin 
eNOs Endothelial nitric oxide synthase 
FBN1 Fibrillin-1 
FN1 Fibronectin-1 
Fz Frizzled 
GABA gamma-aminobutyric acid  
GPCR G-protein coupled receptor 
GSK3 glycogen synthase kinase-3 
LDS Loeys Dietz syndrome 
LLC Large latent complex 
LRP Lipoprotein receptor-related 
23 
 
MAPK Mitogen activated protein kinase 
MFS Marfan syndrome 
MMP Matrix metalloproteinase 
MRI Magnetic resonance imaging  
NFATc1 Activated T-cell protein 1 
PAH Pulmonary arterial hypertension 
PDA Patent arterial duct 
PWS Peak wall stress 
RAS Renin angiotensin system 
RhoA Ras homolog gene family 
R-L Fusion of right- and left-coronary leaflets 
R-N Fusion of right- and non-coronary leaflets 
ROCK Rho kinase 
SOX9 Sex determining region Y box-9 
TAA Thoracic aortic aneurysm 
TAV Trileaflet aortic valve 
TGFβ Transforming growth factor beta 
TGFBR Transforming growth factor-beta receptor 
TIMP Tissue inhibitor of matrix metalloproteinase 
VEGF Vascular endothelial growth factor 
VSD Ventricular septal defect 
VSMC Vascular smooth muscle cell 
WSS Wall shear stress 
  
24 
 
1.1 Valve anatomy and disease 
The human heart is a key component of the cardiovascular system acting as a beating 
pump that circulates blood around the body. Its anatomy can be considered in three 
segments: the collecting chambers, known as atria, the pumping chambers, known as 
ventricles, and the great arteries, namely the aorta and pulmonary artery. A muscular 
layer called septum separates the heart into right and left, with each side facilitating the 
pulmonary and systemic circuits, respectively. Unidirectional blood flow through these 
chambers is ensured by the presence of four heart valves; two atrioventricular valves 
separate the atria from the ventricles, with the tricuspid valve on the right and the mitral 
valve on the left, and two semilunar valves, including the pulmonary and aortic valves, 
separate the ventricles from the respective great arteries.  
Despite their similar function, valve anatomies differ with the atrioventricular valves 
made up of two (mitral) or three (tricuspid) valve leaflets resembling circular curtains 
with the external support of chordae tendineae attaching the leaflets to the ventricular 
papillary muscles (Anderson et al., 2000). In contrast, the term “cusps” is used to 
describe the three leaflets of the semilunar valves (aortic and pulmonary) situated in the 
great arteries leaving the heart. The latter lack external support with the exception of the 
aortic annulus, a fibrous structure attaching the root of the aorta to the left ventricle.  
With an average adult heart rate of 70 beats per minute, heart valves open and close more 
than 100,000 times per day determining the pathway of blood flow through the heart. In 
order to withstand this continuous cyclic shear stress, valve leaflets develop an intricate 
connective tissue architecture comprised of interstitial cells, stratified extracellular matrix 
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(ECM), and a peripheral layer of endothelial cells responsive to biomechanical stimuli 
(Armstrong and Bischoff, 2004). Disruption of this architecture at birth or later in life 
results in development of valve disease, either in the form of regurgitation, with 
incomplete coaptation of the leaflets leading to backward flow, or stenosis, with 
narrowing of the valve opening leading to outflow obstruction.  
Congenital valve defects are inborn abnormalities occurring during fetal life disrupting 
valve formation. Bicuspid aortic valve (BAV) (OMIM # 109730, Figure 1.1) is the most 
common congenital cardiac malformation with a prevalence of 0.5% - 2% in the general 
population (Basso et al., 2004, Braverman et al., 2005). BAV is characterised by the 
presence of two instead of three valve leaflets with an increased predisposition to a 
number of complications including infective endocarditis and valvular dysfunction 
(Ward, 2000). The majority of BAV patients will require valve surgery during their 
lifetime, predominantly due to significant aortic stenosis in early childhood, aortic 
regurgitation into adolescence and calcific valve disease later in adulthood (Lewin and 
Otto, 2005). 
The incidence of aortic stenosis in BAV varies from 5 to 50% based on surgical series 
and is affected by the age of studied populations, with increased prevalence in older 
subjects (Braverman et al., 2005).  Despite the same underlying mechanisms of senile 
valve degeneration, involving lipid deposition, inflammation, and ultimate calcification, 
BAV leaflets are more susceptible to the above process with higher rates of progressive 
aortic stenosis compared to trileaflet aortic valves (Braverman et al., 2005, Robicsek et 
al., 2004). In contrast, aortic regurgitation in BAV is less common with an incidence of 
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1.5 to 10% (Roberts et al., 1981) and can be the inherent result of redundant leaflet 
architecture or the secondary outcome of endocarditis, aortic dilatation, and dissection, as 
described later (Ward, 2000).  Overall, up to 33% of BAV patients will require valve 
surgery during their lifetime, for either aortic stenosis or regurgitation (Fernandes et al., 
2007, Keane et al., 1993). 
1.2 Aortic anatomy and disease 
Over the past decades, perception of BAV has shifted from an isolated valve defect to a 
continuum disease process affecting the entire aortic root and ascending aorta (Tadros et 
al., 2009). These two segments are the proximal parts of the thoracic aorta, the main 
artery arising from the left ventricle supplying the human body with oxygenated blood to 
the level of the diaphragm. The aortic root forms a bridge between the left ventricle and 
the ascending aorta guarded by the aortic valve leaflets with three small dilatations 
immediately above it called sinuses. Out of the anterior and left posterior sinuses rise the 
mouths of the right and left coronary arteries, respectively, supplying the heart, with the 
third bulge called the non-coronary sinus (Anderson, 2007). The anatomical border 
between the aortic root and the ascending aorta is defined as the sinutubular junction. At 
this point the ascending aorta becomes a tubular structure with an approximate length of 
5cm followed by the aortic arch, supplying the chest, upper limbs, head, and neck with 
numerous branching vessels.     
All arterial walls have the same triple layer composition of an innermost layer constituted 
by endothelial cells on a basic membrane (intima), a middle layer containing muscle 
tissue and elastic fibres (media), and an outer layer comprising connective tissue 
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(adventitia). BAV patients are at an increased risk of developing thoracic aortic aneurysm 
(TAA), which is a localized balloon-like bulge in the vessel wall. TAA is a silent disease 
that can progress over the years with no symptoms. As aneurysm size increases, so does 
the risk of developing a tear in the intima (called aortic dissection) allowing blood flow 
into the media with complete separation of the two layers. These tears can propagate 
antero- or retro- gradely leading to reduced organ perfusion, haemodynamic compromise 
and ultimately, complete rupture of the aortic wall with subsequent death in the absence 
of timely intervention. Severe aortic regurgitation can also occur due to incomplete 
coaptation of the valve leaflets when the tear extends to the aortic root.  
Aortic dilatation in BAV disease is present in early stages of life with TAA formation in 
approximately 40% of adult patients (El-Hamamsy and Yacoub, 2009b, Beroukhim et al., 
2006). The estimated risk of aortic dissection in BAV patients is 5-10 times higher 
compared to the general population, based on necropsy series (Larson and Edwards, 
1984, Ward, 2000). Review of the Yale clinical series revealed higher aneurysm annual 
growth rate in BAV compared to tricuspid aortic valve (TAV) patients but similar rates of 
aortic dissection and rupture (Davies et al., 2007). As discussed later, identification of 
risk factors for aneurysm formation in BAV patients is fundamental to avoid the 
catastrophic complications of aortic wall dissection. 
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Figure 1.1 Human heart morphology. In this section, all three segments of the left heart can be 
seen including the smooth walled collecting chamber (left atrium), the muscular walled pumping 
chamber (left ventricle), and the aortic valve leaflets (yellow arrows) within the aortic root. The 
root extends from the ventriculo-aortic to the sinutubular junction (marked with red dotted line), 
after which the aorta becomes a tubular structure (Anderson, 2007).  
 
1.3 Structure and ontology of the bi-leaflet aortic valve 
The term BAV has been used to describe a broad spectrum of aortic valve malformations 
with the diagnostic criteria of a BAV first classified by Osler in 1886 (Braverman et al., 
2005). According to general consensus, there are two morphological types of BAV, 
determined by the number of commissures. In the case of complete absence of one 
commissure, the result is a ‘true’ BAV with either anterior-posterior or lateral-lateral 
orientation of the free edges of the leaflets. In a ‘functional’ BAV, there are three 
commissures, one of which is often hypoplastic. In these cases, the malformed 
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commissure, also known as a raphe, represents the fused area between the two adjacent 
leaflets. The orientation of the raphe in relation to the sinuses, defines the further subtype 
of a functional BAV, with the commonest type being right-left (R-L) followed by right-
non coronary (R-N) functional BAV (Figure 1.2) (Russo et al., 2008). Less frequent types 
of BAV with two raphes have also been described (Sievers and Schmidtke, 2007). 
 
Figure 1.2 BAV morphological subtypes. The commonest subtypes of BAV are exhibited, as 
seen in human specimens (Cardiac Morphology Unit, Royal Brompton Hospital). A normal tri-
leaflet aortic valve is comprised of three leaflets and three commissures (a). In the case of 
complete absence of one commissure, the result is a ‘true’ BAV consisting of only two sinuses, 
two leaflets and two fully developed commissures (b). In a functional BAV (c and d), there are 
three sinuses and three leaflets, but two of the leaflets and sinuses are underdeveloped leaving a 
raphe in between as a putative commissure. The commonest morphologic types of BAVs are the 
right-left (c) and right-non coronary (d) functional BAVs. The black arrow marks the raphe, the 
red arrow the left coronary artery, and the blue arrow the right coronary artery. 
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The process of valvulogenesis initiates when the heart is a tube consisting of an inner 
layer of endothelial cells, an outer layer of myocardial cells, and the in-between ECM 
(cardiac jelly) (Armstrong and Bischoff, 2004). Following right-ward looping of the 
heart, endothelial-mesenchymal transformation (EMT) takes place, with proliferation and 
differentiation of a special subset of endothelial cells into mesenchymal cells. The EMT 
results in thickening of the cardiac jelly in the regions of the atrioventricular and outflow 
tract and subsequent formation of the endocardial cushions.  
A large number of signalling pathways have been involved in EMT and endocardial 
cushion formation, including family members of transforming growth factor beta (TGFβ) 
and vascular endothelial growth factor (VEGF), NOTCH1, Wnt/β-catenin, and nuclear 
factor of activated T-cell protein 1 (NFATc1) (Armstrong and Bischoff, 2004, 
Chakraborty et al., 2010). Complex signalling interactions between the above pathways 
give rise to the mitral and tricuspid valves in the atrioventricular canal. In the outflow 
tract, neural crest cells migrate from the branchial arches to the endocardial cushions and 
contribute to the formation of the aortic and pulmonary valves and the aorticopulmonary 
septation of the outflow tract (Kirby et al., 1983). In a healthy fetus, the EMT process and 
subsequent endocardial cushion remodelling lead to the formation of a trileaflet aortic 
valve. As described in the following sections, disruptions in key embryological pathways 
can lead to congenital valve defects and in particular, development of BAV. 
TGFβ family members, including bone morphogenetic proteins (BMPs) and TGFβs, act 
as signaling partners in endocardial cushion formation. They interact with transmembrane 
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TGFβ receptors via phosphorylation, which in turn, phosphorylate and activate Smad 
proteins in the cytoplasm (Shi and Massague, 2003).  The downstream transcription 
factors of TGFβ and BNP signalling activated by Smads are currently not well defined 
(Armstrong and Bischoff, 2004). However, there is evidence of hypoplastic cardiac 
cushion formation in mice genetically disrupted for BMP, including double mutants for 
BMP-6 and BMP-7 (bmp6_/_; bmp7_/_) and mutants for ALK3 gene (ALK3_/_) 
encoding a BMP receptor with additional decrease of TGFβ expression (Gaussin et al., 
2002, Kim et al., 2001).  
VEGF, a key regulator of physiological angiogenesis during embryologic development, is 
also thought to be a specific mediator of cardiac valve development via signaling on the 
endothelial cell surface in the cushion forming regions (Miquerol et al., 1999). Lack of 
VEGF during valve development leads to insufficient endothelial cell proliferation and 
thus, inadequate number of endothelial cells for EMT with hypoplastic/absent cardiac 
cushion formation. Environmental conditions, such as hyperglycaemia, can reduce VEGF 
expression with subsequent inhibition of EMT of the atrioventricular cushions (Enciso et 
al., 2003).  
Transcription factor NFATc1 is part of the nuclear factor of activated T-cell (NFAT) 
protein family involved in the regulation of cell differentiation and endocardial cushion 
development (Armstrong and Bischoff, 2004). Expression of NFATc1 in the developing 
heart overlaps spatiotemporally with that of VEGF with evidence of interaction between 
the two factors in cultures of human pulmonary valve endothelial cells (Johnson et al., 
2003). NFATc1 signalling is also part of the calcineurin/NFAT pathway (Figure 1.4), 
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with knockout of calcineurin gene in mice resulting in complete absence of the aortic and 
pulmonary valves (Lin et al., 2012). 
A number of transcription factors have been associated specifically with BAV formation. 
A characteristic example is that of a transcription factor central to the EMT process, 
NOTCH1, associated with development of BAV and calcific aortic valve disease in 
humans (Garg et al., 2005). NOTCH1 gene encodes a transmembrane protein regulating 
cell fate decisions involved in the development of the atrioventricular canal, ventricular 
myocardium and cardiac outflow tract (Niessen and Karsan, 2008). Downregulation of 
NOTCH1 and its receptor ligand, JAG1 (Figure 1.4), has been exhibited in GATA5 null 
mice with BAV (Laforest et al., 2011). NOTCH1 regulation of aortic valve calcification, 
a pathology commonly seen in BAV patients, appears to take place via a sex determining 
region Y (SRY)-box 9 (SOX9)-dependent pathway (Acharya et al., 2011). Of note, 
NOTCH1 signalling also participates in the differentiation of cardiac neural crest cells 
into smooth muscle cells contributing to the development of the great vessels, thus 
providing a genetic linkage to the BAV-TAA phenotype, as discussed later (Laforest and 
Nemer, 2012).  
Lack of another transcription factor expressed in the atrioventricular and outflow tract 
endocardial cushions, GATA5, results in partial penetrance of BAV with a prevalence of 
26% in null mice (Laforest et al., 2011). Heterozygous mice for NKX2.5, a cardiac 
homeobox gene associated with a number of congenital heart disease (CHD) lesions in 
humans, have an 8-fold increased prevalence of stenotic BAVs compared to wild-type 
mice (Biben et al., 2000).  
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Nitric oxide synthase enzymes convert L-arginine to L-citrulline leading to production of 
nitric oxide (Figure 1.4), a signalling molecule involved in multiple processes including 
cell proliferation, differentiation and apoptosis. Release of eNOs is primarily regulated by 
Ca+2/CaM (calcium/calmodulin) in an autoinhibitory manner (Salerno et al., 1997). 
Endothelial nitric oxide is involved in both cardiac embryogenesis and post-
developmental vascular remodelling (Liu et al., 2013). A strong association has been 
exhibited between eNOs deficiency and development of BAV in mice (Lee et al., 2000). 
Expression of eNOs is shear-dependent (by the protein kinase B/Akt (Akt)-dependent 
mechanism), which is similar to the EMT process, and thus, deficiency of its activation 
might affect cardiac cushion formation (Groenendijk et al., 2004).  
The Wnt/β-catenin signal transduction pathway, initially linked to carcinogenesis, has 
many additional disease connections as well as an established role in embryologic 
development (Clevers and Nusse, 2012). Wnt signalling initiates when Wnt proteins bind 
to a heterodimeric receptor complex, consisted of a Frizzled (Fz) protein, part of the G-
protein coupled receptors (GPCRs) family, and a lipoprotein receptor-related protein 
(LRP)-5/6 (Figure 1.4). Activation of the receptor leads to cytoplasmic accumulation of 
β-catenin which would otherwise not be possible due to its degradation by a destruction 
complex, including Axin-1, adenomatosis polyposis coli (APC), and glycogen synthase 
kinase 3 (GSK3) proteins. The role of Wnt/β-catenin signalling in valve formation has 
been shown in various animal models (Gitler et al., 2003, Hurlstone et al., 2003). More 
recently, mutations in the gene encoding for Axin-1 have been linked to BAV disease in 
humans, with no clear mechanistic hypothesis (Wooten et al., 2010). 
35 
 
Selected aforementioned pathways contributing to aortic valve/BAV formation are 
illustrated in Figure 1.4, including the Ca+2/CaM (calcium/calmodulin) regulated 
expression of eNOs and NFATc1, the association of key transcription factors NOTCH1 
and GATA5, and the Wnt/β-catenin pathway. Genes highlighted in purple in this image 
were selected for targeted next-generation sequencing and are discussed in more detail in 
Chapter 7).  
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Figure 1.4 Molecular pathways involved in BAV formation.  
 
Key: AKT, aka Protein Kinase B; APC, adenomatous polyposis coli; AS, argininosuccinate synthetase; AXIN, AXis Inhibitor; Ca, calcium; [Ca2+]I, 
intracellular calcium concentration; CaM, calmodulin; Cav-1, caveolin-1; CsA, cyclosporine A; eNOS, endothelial nitric oxide synthase; FK, tacrolimus; Fzd, 
frizzled; GPCR, G protein coupled receptors; GSK-3, Glyogen synthase kinase-3; HIF-1α , Hypoxia inducible factor 1α ; Hsp-90, Heat shock protein 90; LRP, 
low density lipoprotein receptor related protein; NCID, NOTCH Intracellular Domain; NFATn/c, Nuclear Factor nucleus (n) or cytocol (c) located; NOS, nitric 
oxide synthase; RBP-Jk, Recombination Signal-Binding Protein 1 for J-Kappa; SNO, S-nitrosylation; SRY, sex determining region Y; TCF, T cell factor.  
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1.4 Mechanisms underlying BAV aortopathy 
Aortic dilatation in BAV patients is progressive and may be related to haemodynamic 
abnormalities, secondary to stress exerted on the aortic wall by eccentric turbulent flow 
through the abnormal BAV leaflets, or to genetic abnormalities of the aorta, secondary to 
a common developmental defect affecting the aortic valve and aortic wall (Fedak et al., 
2002). The latter is supported by evidence of histological abnormalities in the BAV aorta, 
commonly known as Erdheim’s cystic medial necrosis, characterised by elastic fibre 
fragmentation, non-inflammatory loss of vascular smooth muscle cells (VSMCs) and 
accumulation of basophilic ground substance within cell-depleted areas of the media 
(Niwa et al., 2001, McKusick, 1972, Parai et al., 1999).  
The proposed culprit lesion in BAV aortopathy is deficiency of a large protein forming 
extracellular microfibril suprastructures, fibrillin-1, leading to detachment of VSMCs 
from elastin and collagen and release of matrix-metalloproteinases (MMPs) (Fedak et al., 
2003). MMPs belong to a family of proteases that possess proteolytic properties and are 
synthetized by a number of cells, including VSMCs, in response to local haemodynamic 
environment and various disease states. MMP-2 (gelatinase A) and MMP-9 (gelatinase 
B) are the most commonly encountered metalloproteinases in the ascending aorta and 
their activity, involving degradation of type IV, elastin, and fibrillar collagens, has been 
shown to be increased in BAV aneurysms compared to aneurysmal tissue from TAV 
patients (LeMaire et al., 2005, Ikonomidis et al., 2007). Expression of MMPs is normally 
kept under tight control predominantly by tissue inhibitors of metalloproteinases 
(TIMPs), with TIMP-1 being the most common in the aorta produced by VSMCs and 
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fibroblasts. The balance of expression of MMPs and TIMPs also appears to be associated 
with aneurysm formation, although several studies have shown conflicting patterns of 
MMP/TIMP expression, possibly due to differences in sites of aortic tissue sampling (El-
Hamamsy and Yacoub, 2009a). 
Medial degeneration of the BAV aortic wall resembles histopathologic changes seen in 
other connective tissue disorders, such as Marfan syndrome, in favour of an inherent 
structural defect of the aortic wall (Niwa et al., 2001). Additional arguments supporting 
the genetic aortopathy theory include the presence of greater degrees of dilatation in 
BAV, both in the absence of valvular disease, compared to age-matched healthy 
individuals, and in the presence of valvular stenosis/regurgitation, compared to TAV 
patients matched for haemodynamic severity of valvular lesions (Girdauskas et al., 
2011a). Moreover, progressive aortic dilation in BAV patients following aortic valve 
replacement and thus, removal of any additive haemodynamic influence, further points to 
a genetic origin of BAV-TAA (Andrus et al., 2003).  
However, recently arising evidence contradicts the single-sided genetic theory of 
aortopathy and highlights the presence of jet eccentricity in stenotic but also, ‘normally’ 
functioning BAVs, causing altered blood flow patterns from a very young age 
(Girdauskas et al., 2011a). As discussed later, this altered haemodynamic environment 
can lead to locally exerted stress with asymmetrical patterns of dilation and 
corresponding histopathologic lesions (i.e., flow-induced vascular remodeling) (Lehoux 
et al., 2002). Moreover, despite the evidence of ongoing aortic dilatation following aortic 
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valve replacement in BAV, there are no comparative reports in the literature showing that 
the TAV aorta behaves differently postoperatively (Andrus et al., 2003). 
1.4.1 Haemodynamic theory 
Intrinsic structural abnormalities of the BAV aortic wall may be augmented by altered 
blood flow patterns secondary to the malformed aortic valve. In vitro cultures of human 
endothelial cells have exhibited the capacity of the latter to respond to different levels of 
wall shear stress (WSS) with downstream alteration of the underlying VSMCs’ 
proliferative, contractile, or synthetic properties (El-Hamamsy and Yacoub, 2009a, 
Topper et al., 1996). Morphological subtypes of BAV have a different natural history 
which may relate to their corresponding haemodynamic effects; anterior-posteriorly 
oriented BAVs are more likely to develop regurgitation, whereas right-left oriented 
BAVs are more prone to stenosis, resulting in different flow patterns in the aorta (Hope et 
al., 2010, Sonoda et al., 2008). Consequently, regurgitant BAVs are thought to increase 
wall tension, due to higher stroke volumes, and correlate with aortic root dilatation 
(Tadros et al., 2009). In contrast, stenotic BAVs generate a high-velocity jet with 
increased longitudinal, rather than radial, stress on the right anterolateral wall of the 
ascending aorta, creating an asymmetric “bulge” in the same region (Tadros et al., 2009). 
The contributory role of haemodynamics has been investigated in aortic tissue specimens 
from patients with stenotic BAVs, exhibiting increased VSMC apoptosis and differences 
in ECM content in the convexity (versus the concavity) of the ascending aorta, where 
wall stress is expected to be higher (Della Corte et al., 2008). The so-called “post-stenotic 
dilatation” theory has also been assessed by four-dimensional (4D) flow magnetic 
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1.4.1.1 Pulmonary arterial hypertension as an aortopathy model  
Pulmonary arterial hypertension (PAH) is defined as a sustained increase of blood 
pressure in the pulmonary circulation to more than 25mmHg at rest or 30mmHg with 
physical exertion (Farber and Loscalzo, 2004).  PAH can be idiopathic or secondary to a 
number of pathologies including left-sided heart disease, lung disease and/or hypoxemia, 
chronic thromboembolic disease, and congenital left-to-right intracardiac shunts. 
Regardless of the primary underlying cause, vascular changes in the pulmonary 
circulation are common and include vasoconstriction, proliferation of smooth muscle and 
endothelial cells, and thrombosis.  
In the setting of congenital heart disease (CHD), PAH develops when incomplete 
separation of the pulmonary and systemic circulations forces blood to flow from the high-
pressure systemic circulation to the low-pressure pulmonary circulation, described as left-
to-right shunting. Eisenmenger syndrome is the extreme manifestation of PAH associated 
with congenital heart defects and consists of pulmonary hypertension in the presence of 
reversed or bidirectional shunting and cyanosis. Shunting may occur at different levels 
and associated defects can be divided into pre-tricuspid, i.e. atrial septal defects (ASDs), 
or post-tricuspid, i.e. non-restrictive ventricular septal defects (VSDs), patent ductus 
arteriosus (PDA) and aortopulmonary windows. 
PAH is primarily considered a disease of the small muscular distal pulmonary arteries. 
However, the large elastic pulmonary arteries are also affected in the setting of PAH and 
CHD, with previous reports of aneurysmal dilatation, atherosclerosis and thrombosis 
(Heath et al., 1960, Broberg et al., 2007, Daliento et al., 2002). As discussed later in 
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Chapter 5, arterial wall remodeling in the setting of PAH can serve as an aortopathy 
model to study medial wall changes in relation to elevated haemodynamic stress. 
Moreover, as inherent abnormalities of the great arteries have been previously reported in 
a variety of CHD lesions (Niwa et al., 2001), similar to those seen in BAV, the 
PAH/CHD model can provide information on the additive contribution of haemodynamic 
stress to intrinsic structural wall defects (Prapa et al., 2013). 
1.4.2 Genetic theory 
The origin of BAV is speculated to be hereditary with familial studies demonstrating the 
occurrence of a BAV in approximately 9% of first-degree relatives of affected individuals 
with an autosomal dominant pattern of inheritance with reduced penetrance (Huntington 
et al., 1997, Fedak et al., 2002). Development of TAA as an isolated feature can also run 
in families following the same pattern of inheritance (Milewicz et al., 1998). 
Interestingly, affected BAV family members may have isolated thoracic aortic dilatation 
or increased aortic stiffness in the absence of BAV, suggesting a common genetic 
background of BAV and TAA as variable manifestations of the same disease (Hiratzka et 
al., 2010, Loscalzo et al., 2007).  
Interestingly, BAV patients exhibit similar degenerative changes in the media of their 
aortic root and pulmonary trunk, with the two segments sharing the same embryologic 
origin of the conotruncus (de Sa et al., 1999). This finding points further to a genetic 
origin of aortopathy in BAV disease but also has clinical implications in surgical 
replacement of the BAV. Ross procedure is a type of aortic valve replacement involving 
excision of the pulmonary valve and a segment of the pulmonary artery with their 
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placement in the aortic position. This procedure is particularly advantageous in young 
patients with BAV requiring valve replacement, as the pulmonary autograft lasts longer 
compared to bioprostheses and does not require anticoagulation, as with mechanical 
valves. However, Ross procedure remains a source of controversy in BAV with evidence 
of poor durability of the pulmonary autograft, due to the above described 
histopathological abnormalities (Takkenberg et al., 2009).  
The specific gene product responsible for development of TAA in BAV disease remains 
elusive and is speculated to be a structural protein or one with a vital role in cardiac 
development. Candidate genes central to the contractile apparatus of the aortic media 
include MYH11 and ACTA2 (Figure 1.6). Mutations in the MYH11 gene, encoding the 
major contractile protein βMHC in VSMCs, have been linked to familial TAA associated 
with PDA and less frequently, BAV (Zhu et al., 2006, Pannu et al., 2007). Similarly, 
mutations in the ACTA2 gene, which encodes α-smooth muscle actin, cause non-
syndromic TAA associated with PDA, BAV and other features of unknown frequency, 
such as livedo reticularis and iris flocculi (Guo et al., 2007, Fatigati and Murphy, 1984). 
Another candidate gene is FN1, encoding for fibronectin-1, a collagen-binding 
glycoprotein interacting with ECM elements leading to microfilament bundle formation 
via a downstream cascade of Ras homolog gene family member (RhoA) and rho kinases 
(ROCKs) (Figure 1.6) (Yoneda et al., 2007). Stress-dependent upregulation of FN1 has 
been previously shown in the BAV ascending aorta (Della Corte et al., 2008) although 
mutations in this gene have not been identified in BAV patients. 
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Additional target genes for BAV aortopathy relate to the synthetic properties of VSMCs 
and have been linked to connective tissue disorders, such as Marfan (MFS) and Loeys-
Dietz (LDS) syndromes. Surprisingly, despite the common finding of fibrillin-1 
deficiency seen in the MFS and BAV aneurysmal aorta, mutations in FBN1 gene 
encoding for this protein are present in MFS but not in BAV patients (Dietz et al., 1991, 
Robinson and Godfrey, 2000).  Recent insights into inherited forms of aortopathy have 
also highlighted the central role of TGFβ signalling in TAA formation with the general 
mechanistic hypothesis of FBN1 deficiency making sequestered TGFβ more accessible to 
activation leading to matrix proteolysis (Carta et al., 2009).  
TGFβ is a multifunctional cytokine, with synthetic and apoptotic properties, that not only 
participates in cardiac valve formation as mentioned above, but also in post-
developmental ECM homeostasis (Goumans et al., 2009, Owens and Wise, 1997, 
Cordenonsi et al., 2003). Its bioavailability is regulated by the large latent complex (LLC) 
which interacts with fibrillin-1 and contains TGFβ in an inactive state (Figure 1.6) (El-
Hamamsy and Yacoub, 2009a, Carta et al., 2009). Once active TGFβ is released in the 
ECM, it binds to its ligand-activated receptors and stimulates signalling via “canonical” 
and “non-canonical” pathways, with shared key terminal evens including MMP-mediated 
proteolysis (Figure 1.6) (Derynck and Zhang, 2003). Canonical signalling relies on a 
Smad-dependent signalling cascade involving nuclear translocation and phosphorylation 
of a family of transcriptional factors (Smads) with subsequent expression of targets, such 
as MMPs. Ligand-activated TGFβ receptors can also stimulate signalling via non-
canonical pathways, including the mitogen-activated protein kinase (MAPK) cascade 
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which cross-talks with the angiotensin converting enzyme (ACE) cascade, as seen in 
Figure 1.6 (Lindsay and Dietz, 2011).  
Increased TGFβ signalling is seen in the dilated aorta of BAV, MFS, and LDS patients 
with the latter testing positive for mutations in the TGFβ receptor type I (TGFBR1) and 
type II (TGFBR2) genes (Gomez et al., 2009, Loeys et al., 2006). However, similar with 
FBN1, despite the common histopathological lesions seen in the BAV and LDS aorta, 
patients with BAV do not carry mutations in TGFBR1 or TGFBR2 gene (Arrington et al., 
2008).  
Other potential genes include type III procollagen (COL3A1) and PLOD1/3 involved in 
collagen metabolism and associated with aneurysm formation in Ehlers-Danlos syndrome 
(Beridze and Frishman, 2012, Takaluoma et al., 2007, Salo et al., 2008) as well as the 
SLC2A10 gene associated with aortic tortuosity syndrome (Figure 1.6) (Coucke et al., 
2006). PLOD1/3 genes encode for lysyl hydroxylase 1 and 3, respectively, which are 
oxygenase enzymes involved in the post-translational modification of pro-collagen in the 
endoplasmic reticulum necessary to the formation and stabilisation of collagen (Figure 
1.6). SLC2A10 gene (also known as GLUT10) encodes the integral membrane protein 
glucose transporter type 10 and is highly expressed in the mitochondria of VSMCs 
protecting cells from oxidative injury (Lee et al., 2010). The genetic cause of syndromic 
and non-syndromic forms of TAA is summarized in Table 1.1 and further discussed in 
Chapter 7 as genetic insights from inherited forms of aortopathy guided our gene 
selection process for next-generation sequencing in BAV. 
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TAA formation in BAV may also be owing to aberrations in genes involved in the 
development of the great vessels and the aortic valve during embryogenesis, such as 
NOTCH1 and endoglin (ENG) (Niessen and Karsan, 2008, Qu et al., 1998). In fact, 
NOTCH1 mutations have been linked to the sporadic BAV-TAA phenotype (McKellar et 
al., 2007), and ENG, a type I membrane glycoprotein interacting with TGFβ receptor and 
BMP singalling cascade (Figure 6.1), may also contribute to TAA formation (Li et al., 
1999, Wooten et al., 2010).  
However, familial studies have exhibited that NOTCH1 mutations are exceedingly rare 
and, although they may represent susceptibility alleles for the BAV-TAA phenotype, 
additional genetic aberrations most likely contribute to its phenotypic expression (Kent et 
al., 2013, McBride et al., 2005). Human tissue studies have also reported reduced eNOs 
expression in the ascending aorta of BAV patients compared to patients with a tri-leaflet 
aortic valve (Aicher et al., 2007). Despite the strong association between eNOs 
deficiency and BAV formation in mice (Lee et al., 2000), BAV patients have not been 
tested for mutations in this gene.  
Figure 1.6 provides an overview of selected molecular pathways involved in TAA 
formation, including canonical and non-canonical TGFβ signalling and its crosstalk with 
the ACE pathway, FN1 gene signalling cascade determining the VSMC synthetic 
phenotype with downstream transcription of contractile protein genes (MYH11 and 
ACTA2), as well as PLOD1/3 and SLC2A10 genes. Genes highlighted in blue underwent 
targeted next-generation sequencing and are further discussed in Chapter 7. Involvement 
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of angiotensin converting enzyme (ACE) gene in TAA formation is discussed under 
“future directions” section of this chapter.  
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Table 1.1 Summary of inherited forms of thoracic aortic aneurysm (TAA), modified from Canadas et al.(Canadas et al., 2010). 
 
Disease Phenotype 
Known mutated 
genes 
Inheritance Pathophysiology 
Syndromic 
Marfan syndrome(Canadas 
et al., 2010) 
Aortic root aneurysm , ectopia lentis, skeletal 
abnormalities, dural ectasia, lung disease  
FBN1 AD 
Fibrillin-1 deficiency and 
increased TGFβ signalling 
Marfan-like syndrome(Loeys 
et al., 2006)  
Overlap with Loeys-Dietz syndrome TGFBR2 AD Increased TGFβ signalling 
Loeys-Dietz syndrome(Loeys 
et al., 2006) 
Aneurysm of aortic root and other vessels, 
aortic tortuosity, hypertelorism, cleft palate or 
abnormal uvula, craniofacial, skeletal and 
cutaneous abnormalities, PDA, ASD 
TGFBR1, 
TGFBR2 
AD Increased TGFβ signalling 
Ehlers-Danlos 
syndrome(Beridze and 
Frishman, 2012) 
Spontaneous arterial, intestinal or uterine 
rupture, characteristic facial appearance, 
translucent skin with easy bruising, 
hypermobile joints 
COL3A1 AD Abnormal type III collagen production 
Arterial tortuosity 
syndrome(Coucke et al., 
2006) 
Tortuosity, stenosis, and dilatation of major 
arteries, joint hypermobility, elongated face, 
hernias 
SLC2A10 AD 
Deficiency of glucose transporter (GLUT10) 
and increased TGFβ signalling 
Turner syndrome(Lin et al., 
1998)  
TAA, short stature, webbed neck, widely 
spaced nipples, gonadal dysfunction, BAV, 
aortic coarctation 
45, X0 - Cystic medial necrosis 
Non-syndromic 
TAAD-PDA(Zhu et al., 2006, 
Pannu et al., 2007) 
TAAD2(Pannu et al., 2005) 
TAAD4(Guo et al., 2007) 
Familial TAA* & 
PDA, BAV 
Cerebral, carotid and popliteal aneurysms 
Levido reticularis, iris floculi, PDA, BAV 
 
MYH11 
TGFBR2 
ACTA2 
AD 
Abnormal smooth muscle βMHC production 
with upregulated IGF-1 and Ang II signalling 
Increased TGFβ signalling 
Abnormal α-smooth muscle actin production 
Bicuspid aortic valve(Tadros 
et al., 2009, Garg et al., 2005) 
TAA, valvular dysfunction NOTCH1 AD 
Fibrillin-1 deficiency, 
increased TGFβ signalling, haemodynamic 
perturbations secondary to the malformed 
valve 
*Selected familial TAA syndromes with known mutated genes. Abbreviations: AD, autosomal dominant; Ang, angiotensin; ASD, atrial septal defect; BAV, bicuspid aortic valve; IGF, 
insulin growth factor; PDA, patent ductus arteriosus; TAAD, thoracic aortic aneurysm and dissection; TGF, transforming growth factor. 
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Figure 1.6 Molecular pathways involved in inherited forms of aortopathy.  
  
Key: ACTA2, smooth muscle alpha actin 2; ACVRL1, activin receptor-like kinase-1; AngII, angiotensin II; BMP, bone morphogenic protein;  CREB, cAMP 
response element-binding protein; ENG, endoglin; ER, endoplasmic reticulum ; FBN1, fibrillin-1; FN1, fibronectin-1; JNK, c-Jun N-terminal kinase; LLC, large 
latent complex; MAPK, mitogen-activated protein kinase (aka ERK); MLCK, myosin light chain kinase; MLCP, myosin light chain phosphatase; MMPs, matrix 
metalloproteinases; NF1, neurofibromin-1; PLOD, 2-oxoglutarate 5-dioxygenase; RhoA, Ras homolog gene family member A; ROCK, Rho-associated protein 
kinase; SLC2A10/GLUT10, solute carrier family 2 member 10; TGF-B, transforming growth factor beta.
 50 
1.5 Future directions in management of BAV aortopathy 
The therapeutic mainstay of TAA continues to be early diagnosis via imaging of the thoracic 
aorta with timely surgical intervention (Hiratzka et al., 2010). Although radiographic screening is 
valuable, many patients who have an increased risk of developing aneurysms in later life may not 
have recognisable enlargement of the aorta at the time of screening even with state-of-the-art 
imaging technologies (Prapa and Ho, 2012). Timely correction of TAA in BAV is fundamental 
and should rely on in depth understanding of the pathogenetic mechanisms implicated in the 
degradation of the aortic wall.  
Appreciation of the genetic component of BAV aortopathy has been recently reflected by the 
American College of Cardiology guidelines on thoracic aortic disease management, with 
lowering of the traditional threshold of 50mm for elective replacement of the aorta to 40mm, 
similar to the cut-off suggested for other connective tissue disorders (Hiratzka et al., 2010). 
However, as our understanding of BAV- TAA pathophysiology increases, novel promising 
therapeutic strategies and risk stratification tools should be gradually translated into clinical 
practice. 
1.5.1 Pharmacological treatment 
Insights into MFS pathophysiology, which has served as the typical aortopathy model in 
inherited TAA disease, have led to emergence of novel pharmacological treatments. Beta 
blockers (b-blockers), a class of drugs interfering with the action of endogenous catecholamines 
epinephrine (adrenaline) and norepinephrine (noradrenaline) on the sympathetic nervous system 
via blockage of b-adrenergic receptors, are used extensively in daily clinical practice for 
treatment of hypertension, arrhythmias, coronary artery disease and heart failure. Prophylactic b-
blockade has been shown to be beneficial in a subset of MFS patients with reduction in rates of 
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aortic root dilatation and improved survival (Shores et al., 1994, Rossi-Foulkes et al., 1999). Its 
therapeutic benefit may be secondary to negative chronotropy and inotropy (reduction of force 
and rate of contraction in the heart) resulting in decreased arterial stress (Milewicz et al., 2005). 
Prophylactic administration of b-blockers in BAV disease is currently based on consensus 
opinion and recommended in patients with aortic dilatation (>40mm) without significant aortic 
regurgitation (Bonow et al., 2006). 
Another antihypertensive drug, the angiotensin II type 1 receptor (AT1) blocker, losartan has 
been shown to improve the aortic phenotype in fibrillin-1 deficient mice (Habashi et al., 2006).  
Angiotensin I-converting enzyme (ACE) is a key component of the renin-angiotensin system 
(RAS) hydrolysing angiotensin I into angiotensin II, a potent vasopressor that stimulates 
aldosterone with salt and water reabsorption (Heeneman et al., 2007). Administration of AT1 
blocker, losartan, has been shown to attenuate the aortic phenotype in both animal models and 
children with MFS (Habashi et al., 2006, Brooke et al., 2008). Following establishment of aortic 
root aneurysm at 7 weeks of age, 6-month treatment with losartan prevented elastic 
fragmentation and reduced TGFβ signalling in the aortic media, compared to a b-blocker 
(propranol) whose beneficial effect was restricted to reduction of aortic root growth rate 
(Habashi et al., 2006).  
The cross-talk between TGFβ and angiotensin II pathways remains poorly understood although it 
has been reported that angiotensin II has the capacity to induce TGFβ1 activity via the AT1 
receptor and can also activate the SMAD signalling cascade in a TGFβ-independent manner via 
the MAPK cascade (Figure 1.6) (Cohn et al., 2007, Zhou et al., 2006, Rodriguez-Vita et al., 
2005). The beneficial effect of angiotensin II blockade has been recently exhibited in a pilot 
study in children with MFS (Brooke et al., 2008) and is further validated by ongoing clinical 
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trials (Lacro et al., 2007). Findings from these studies may also be applicable to BAV patients in 
the future and would necessitate similar clinical trials in BAV patient cohorts. 
Doxycycline, a derivative of tetracycline, acts as a non-specific MMP inhibitor, independent of 
its antimicrobial properties inhibiting bacterial protein synthesis, and has been shown to 
attenuate elastic fragmentation in MFS mouse models (Chung et al., 2008) which may be 
applicable in the treatment of BAV patients with TAA. 
1.5.2 Emerging risk stratification tools in BAV-TAA 
1.5.2.1 Novel imaging 
According to La Place’s law, wall tension increases with aortic radius (Humphrey, 2008). 
However, variables other than aortic diameter, such as aortic elasticity, may allow earlier 
evaluation of abnormal loads in the aortic wall (Baumgartner et al., 2005, Nistri et al., 2008). 
Nistri et al have exhibited abnormal aortic stiffness in BAV patients with absent or mild valvular 
disease and non-aneurysmal aortic dilatation (Nistri et al., 2008). Direct indicators of elevated 
mechanical stress include peak wall stress (PWS) and WSS which can now be measured with use 
of computational modelling methods (Giannakoulas et al., 2009, El-Hamamsy and Yacoub, 
2009a). Both PWS and WSS are known to be reliable markers of the risk of abdominal aortic 
rupture (Venkatasubramaniam et al., 2004, Fillinger et al., 2003) and may also affect TAA 
formation by complex mechanotransduction pathways (Humphrey, 2008, El-Hamamsy and 
Yacoub, 2009a). Moreover, local haemodynamic perturbations secondary to different 
morphological BAV subtypes can now be visualised in vivo by advanced MRI techniques (Hope 
et al., 2010). As quantification of this imaging data becomes increasingly available (Gatehouse et 
al., 2005, Hope et al., 2011), WSS measurements via phase contrast MRI may serve as an 
additional risk stratification tool in BAV disease (Barker et al., 2010).  
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Apart from advanced MRI and computational imaging, molecular imaging of aortic aneurysms 
may also hold a promising future (Buxton, 2012). In vivo molecular imaging has been shown to 
be feasible in examination of aortic valve pathophysiology in hypercholesterolaemic 
apolipoprotein-E deficient mice (Aikawa et al., 2007). Via usage of a panel of near-infrared 
fluorescence imaging agents, key cellular events in early aortic valve disease were captured, 
including endothelial cell and macrophage activation, proteolytic activity, and osteogenesis. 
Similar techniques may be applicable in the future in human aortas, allowing the detection of 
spatiotemporal patters of MMP activity and thus, earlier identification of BAV patients 
predisposed to TAA formation.  
1.5.2.2 Genetic screening 
Targeted sequencing for a panel of inherited aortopathy genes is now suggested for patients with 
TAA with a positive family history and/or associated syndromic clinical features (Hiratzka et al., 
2010). Moreover, screening of first-degree relatives of BAV patients is recommended for the 
presence of BAV and asymptomatic TAA (Hiratzka et al., 2010).  However, genetic screening 
tools specific to BAV disease are currently lacking. This may be owing to the wide phenotypic 
diversity of BAV, which may not only present in association with TAA but can also be part of a 
broader spectrum of abnormalities such as hypolastic left heart syndrome (Laforest and Nemer, 
2012, Hinton, 2012). Recent advances in genetics, such as next-generation sequencing, are vastly 
changing the landscape of clinical genomics and may serve as novel research tools for 
identification of specific susceptibility genes for BAV aortopathy (Ware et al., 2012).  
Over the past decades, Sanger sequencing has served as the gold standard technology for DNA 
sequencing using fluorescently labelled terminating nucleotides and electrophoresis. Despite its 
advantages, sequencing of the whole human genome as part of the human genome project with 
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Sanger sequencing took over 10 years to complete with a cost of US$2.7 billion (Berglund et al., 
2011). Next-generation sequencing technologies developed in the past decade allow massively 
parallel DNA sequencing with a considerably lower cost per sequenced base (Ware et al., 2012). 
These technologies serve not only as research tools but also as diagnostic screening tools for 
cardiovascular conditions, such as inherited cardiomyopathies and arrhythmia syndromes (Meder 
et al., 2011, Herman et al., 2012, Ware et al., 2013). Application of next-generation sequencing 
in BAV could allow low-cost genetic screening of these patients, provided that suitable genes 
predisposing to disease traits are identified.  
1.4 Study aims 
In summary, despite the exponential research in the field of BAV aortopathy, novel risk 
stratification tools for predicting natural history of TAA and guiding the timing of prophylactic 
surgical intervention on the BAV aorta are lacking. The proposed study will use established 
computational, histopathological and genetic methods to explore the following hypotheses:  
1. Asymmetric formation of TAA in BAV disease is related to heterogeneous wall stress 
distribution and varying degrees of histopathological abnormalities at different levels of the 
aorta.  
2. Genetic aberrations underlie the formation of BAV and associated aortopathy. 
The aims of the present study are: 
1. To investigate the role of structural finite-element analysis in BAV aortopathy and assess the 
distribution of mechanical stress and severity of corresponding structural abnormalities in the 
BAV aorta. 
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2. To assess the degree of histological abnormalities and TGFβ signalling in distinct clinical 
phenotypes of BAV-TAA.  
3. To assess the presence of copy-number variation in BAV disease.  
4. To develop a panel of genes for targeted next-generation sequencing in BAV disease. 
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Chapter 2. General methods 
 
Abbreviations 
3D Three-dimensional 
BAV Bicuspid aortic valve 
BAC Bacterial artificial chromosome  
BSA Body surface area 
BRU Biomedical research unit 
CHD Congenital heart disease 
cDNA Complementary DNA 
CGH Comparative genomic hybridization  
CNV Copy number variation 
CMR Cardiac magnetic resonance  
CT Computed tomography 
EVG Elastic Van Gieson 
FEA Finite element analysis  
DAB chromogen 3,3’-diaminobenzidine 
IMS Industrial Methylated Spirits 
KPa Kilopascals 
MRI Magnetic resonance imaging 
NGS Next generation sequencing 
PBS Phosphate buffered saline  
PCR polymerase chain reaction 
PDA Patent arterial duct 
VSMC Vascular smooth muscle cell 
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2.1 Patient Population 
Ethical approval was granted by the Royal Brompton Hospital Research Ethics Committee 
(09/H0708/36) for the whole of this study. All participants were provided with information 
sheets and appropriate written informed consent was obtained. 
2.1.1 Inclusion criteria 
Patients with BAV scheduled to undergo aortic valve replacement and/or ascending aortic 
surgery were included in the study (Chapters 3 and 4). Both adult and paediatric BAV cases 
were included, with appropriate age matching of control samples (Chapter 4). Patients with 
previous known BAV requiring a second operation due to postoperative complications were also 
recruited.  For the control group (Chapter 4), age-matched structurally normal hearts were 
retrieved from patients who had not died from cardiovascular disease, held at the Cardiac 
Morphology Unit and the Department of Histopathology, Royal Brompton Hospital. The latter 
heart biobank was also used in Chapter 5 to study cases with congenital heart disease and 
pulmonary arterial hypertension (detailed methods provided in respective chapter due to distinct 
study population). In Chapter 6, copy number variation data from the Wellcome Trust Control 
Consortium 2 were used as a control group (Bochukova et al., 2010). 
For the genetic studies (Chapters 6 and 7), BAV patients undergoing surgery (previous group) 
were recruited in addition to BAV patients attending the Adult Congenital Heart Disease Unit 
outpatients’ clinic, Royal Brompton Hospital. 
2.1.2 Exclusion Criteria 
The following patients were excluded from this study: 
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1. Patients with clinical features of developmental syndromes, multiple major 
developmental abnormalities or major cytogenetic abnormalities. 
2. Patients fulfilling standard diagnostic criteria for Turner syndrome or connective tissue 
disorders, such as Marfan and Ehlers-Danlos syndromes (Hiratzka et al., 2010). 
3. Patients with inflammatory aortic disease. 
4. Patients with BAV and associated congenital cardiac defects, other than ventricular septal 
defect, coarctation of the aorta and PDA. 
5. Patients unwilling or unable to provide written informed consent. 
2.1.3 Phenotyping 
For patients undergoing surgery, the morphology of the BAV valve (true or functional and 
further sub-types) was assessed at the time of the operation. In the instance of previous aortic 
valve replacement, medical notes and pre-operative imaging (echocardiography or MRI) was 
assessed to delineate the valve morphology.  
Cardiac magnetic resonance (CMR) imaging (Siemens 1.5T) was used for examination of BAV 
morphological subtypes, presence of valvular disease, and aortic diameter measurements in the 
overall study population.  An electronic calculator using aortic diameter and body surface area 
(BSA) was employed for calculation of z-scores (z-value = (measured diameter – predicted 
diameter)/standard deviation of residuals) at selected CMR-standardized aortic sites (aortic sinus, 
sinutubular junction, ascending aorta at level of right pulmonary artery, and ascending aorta 
proximal to the innominate artery) (Kaiser et al., 2008). A clinical cut-off of z-score > 2 standard 
deviations was used to define the presence of dilatation at specified aortic segments (Kim et al., 
2011).  
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For patients participating in the computational modelling study (Chapter 3), computed 
tomography (CT) angiograms were used for aortic diameter measurements and three-
dimensional (3D) reconstruction of their aortas (methods described below). 
Additional individual review of patient echocardiograms (Hewlett Packard Sonos 5500) was 
performed in cases where assessment of BAV morphology from CMR images was 
indeterminate.  
All scans (MRI, CT and echocardiograms) used for assessment of valvular disease and aortic 
diameter measurements were clinically indicated and obtained up to 6 months prior to surgical 
procedure, as part of the diagnostic work-up of BAV patients undergoing surgery.  
2.1.4 BAV patient cohort characteristics 
Overall, a total number of 110 BAV patients were recruited for various aspects of this study with 
an overall mean age of 24,47 years (standard deviation 14,56 years). A selection bias may have 
been inevitably introduced in the study as a significant proportion of patients (37%, table 2.1) 
attended for cardiovascular surgery at the time of recruitment and therefore, may represent the 
more severe spectrum of BAV disease. Equally, 32% of the BAV patient population had initially 
presented at a younger age (<16 years of age, table 2.1) and may potentially harbour a greater 
number of genetic risk factors predisposing to BAV-associated complications compared to the 
remaining study population. However, it was important to include the above sub-cohorts in our 
study, both for collection of surgical tissue samples (Chapters 3 and 4) as well as investigation 
of genetic aberrations in BAV disease (Chapters 6 and 7). 
The majority of recruited patients were morphologically phenotyped via MRI for both aortic 
valve morphology and aortopathy (Table 2.1). The remaining patients were assessed with 
echocardiography, a method also considered to be reliable in the assessment of aortic valve 
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morphology, except in the presence of heavy valve calcification where operative notes were used 
(Chan et al., 1999). In 19% of cases, BAV morphology was not available due to valve 
replacement or valvotomy taking place in early childhood with unavailable imaging and/or 
operative notes. Despite the above limitations, uniform methods of aortopathy assessment were 
used in chapters were correlations between diameter measurements and other features were 
attempted, applying CT in Chapter 3, and MRI in Chapter 4.  
Details of previous operations, cardiovascular risk factors, and BAV-associated CHD lesions in 
recruited patients are given in the respective chapters.   
Table 2.1 Bicuspid aortic valve (BAV) patient cohort characteristics 
BAV patient cohort characteristics  
(n, %) 
Number of recruited patients 
(total n= 110) 
Presentation at early age (<16y) 36 (32) 
At time of recruitment, attending for: 
Surgery 
Regular follow-up 
 
41 (37) 
69 (63) 
BAV morphology phenotyping: 
Magnetic resonance imaging 
Echocardiography 
Operative notes (heavily calcified valve) 
Unavailable 
Aortic measurements: 
Magnetic resonance imaging 
Computed tomography 
Echocardiography 
 
79 (72) 
2 (2) 
8 (7) 
21 (19) 
 
92 (83) 
14 (13) 
4 (4) 
Previous surgery 93 (84) 
Multiple reoperations 36 (32) 
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2.2 Computational modelling 
Methods described below have been previously validated by our group (Prof. XY Xu, 
Department of Chemical Engineering) for three-dimensional reconstructions of thoracic aortic 
aneursyms (Borghi et al., 2006) and subsequent simulation analyses (Cheng et al., 2010) as well 
as by other researchers applying similar computational software to study distribution of 
mechanical stress in thoracic and abdominal aneurysms (Nathan et al., 2011b, Giannoglou et al., 
2006). 
2.2.1 Data acquisition 
All patients underwent CT (Siemens 64) imaging pre-operatively, as part of their routine care. 
Contrast enhanced aortic angiograms obtained from these studies were processed via a 
MATLAB software (Materialise® Mimics® version 14) to build patient-specific 3D models of 
the aortic root and ascending aorta (Cheng et al., 2010).  
2.2.2 Segmentation 
A segmentation technique, based on thresholding and region-growing methods, was employed to 
extract, slice by slice, the contour of the aortic wall. First, a threshold was set for the image 
intensity that represents the entire thoracic aorta. The software created a mask consisting of all 
pixels that fall within the defined range and this was in turn used to build a 3D image. The 
derived images were then cropped to decrease the number of pixels picked up from the 
surrounding chest cavity (Figure 2.1).  
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Figure 2.1 Representation of thresholding, viewed as an CT slice (a) and as a 3D image, before (b) and 
after (c) appropriate cropping. 
 
 
 
 
 
 
 
 
 
 
 
Following creation of a mask representing the thoracic aorta, the geometry was cut down in order 
to isolate the aortic root and ascending aorta (Figure 2.2a-b). Following this, the vessel was 
smoothed to avoid any unexpected high circumferential stress regions during haemodynamic 
simulations from rough surfaces or harsh corners induced by image noise or cardiac motion 
(Redaelli A, 2002). At this point, it was important to smooth the geometry adequately to remove 
any misrepresentations of the vessel but at the same time, not so much so that important 
geometrical features, such as convexity angle or vessel diameter, were altered which would lead 
to errors in simulation results (Figure 2.2c).  
Lastly, as the mask was created based on contrast data outlining the inner lumen of the aorta, the 
outer wall of the vessel had to be created. To that end, the finalized 3D mask was dilated (Figure 
2.2d) applying a uniform wall thickness of 1.5mm. In a similar study, Nathan and colleagues 
applied a uniform thickness of 2mm based on echocardiographic data (Nathan et al., 2011b). 
However, in vivo testing of dilated BAV aortic tissue rings reveal a thinner aortic wall compared 
to normal and TAV subjects, with wall thickness varying between 1.3 to 2.1 mm (Choudhury et 
al., 2009).  
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Figure 2.2 Three-dimensional (3D) aortic models. The complete aortic root and ascending aorta, 
viewed as a CT slice (a) and a 3D image, pre (b) and post (c) smoothing. The created outer wall of the 
aorta is also viewed (d) as a 3D image. 
 
 
 
2.2.3 Discretisation  
The 3D aortic model was imported into a mesh generator (ANSYS ICEM CFD© version 12) and 
broken down into smaller regular elements (termed meshing) in order to obtain a solution from 
haemodynamic simulation (Figure 2.3).  
Figure 2.3 Meshing. The geometry of the aortic root and ascending aorta is viewed, before (a) and after 
meshing (b). The meshed geometry is chopped at the mid level of the sinuses and before the origin of the 
brachiocephalic artery, to create the aortic inlet (c) and outlet (d) respectively.  
 
In patients with aneurysms of the distal ascending aorta, the aortic arch was incorporated into the 
model.  
a. b. c. d. 
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2.3 Aortic tissue sampling 
Intra-operatively, tissue samples were collected from distinct regions of the aortic wall and 
labelled according to their area of origin. Efforts were made to consistently collect tissue from 
the aortic root (level of sinuses of Valsalva) and the ascending aorta (1cm distal to the level of 
sinutubular junction), depending on the type of surgical procedure. In patients undergoing aortic 
valve replacement, the explanted aortic valve leaflets were also harvested. Figure 2.5 provides 
vivid examples of how the collected samples were marked before being further processed. 
Collected specimens were fixed in 10% buffered formalin saline and stored at room temperature 
for subsequent histological and immunohistochemical analyses.  
Figure 2.5 Examples of aortic tissue labelling.  
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2.4 Histology and immunohistochemistry 
2.4.1 Processing of aortic sections 
From fixation in 10% formalin, tissue sections were routinely processed through increasing 
grades of alcohol (70%-100% Industrial Methylated Spirits, IMS) before xylene clearing, 
immersion in paraffin wax for a minimum of 2 hours, and embedment in fresh paraffin wax. 
Serial sections were cut at 6µm using a rotary microtome (RMC Rotary Microtome MT 960) and 
Accu-Edge® low profile disposable blades for histological and immunohistochemical 
examination. For histological assessment, the sections were floated out onto a waterbath at 55°C 
and mounted onto glycerin albumin coated twin frost glass slides. These were then placed for 3 
hours in a section drier before use. Sections at 6µm for immunohistochemical staining were also 
floated out into a 55°C waterbath but mounted onto silane coated twin frost glass slides. 
2.4.2 Histological examination  
 Sister sections of the aorta from each paraffin block were stained with elastic van Gieson 
(EVG), alcian blue, and haematoxylin/eosin stains and examined under light microscopy for 
medial wall abnormalities.  EVG was used for examining elastic fibers (fibrosis and elastic 
fragmentation), alcian blue for basophilic ground substance (cyst-like formations), and 
haematoxylin/eosin for cell nuclei (medionecrosis). Structural defects of the media were 
categorized in 4 distinct grades (0-3) according to the criteria proposed by Schlatmann and 
Becker (Schlatmann and Becker, 1977) adapted from our group (Tan et al., 2005): grade 0 
denoted absence of lesions and grades 1-3 were used according to severity of processes (Figure 
2.6). All sections were examined separately by two observers, with repeat evaluation by a 
blinded third observer in cases of discrepancy. A cumulative histology grading score was 
calculated to assess the severity of medial wall degeneration; points were assigned for each 
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histological feature based on the grade of severity (grade 0 = 0 points, grade 1 = 1 point, grade 2 
= 2 points, grade 3 = 3 points). 
 
 
 
 
 
Figure 2.6 Histological grades of medial elastic 
fragmentation. The range of elastic fragmentation can be 
visualized in a series of ascending aortic tissue biopsies 
(elastic van Gieson stain, magnification x200). Grade 0 is 
seen in a healthy control with parallel distribution of intact 
elastic lamellae (purple); grades 1 and 2 denote mild and 
moderate elastic fragmentation with accumulation of 
ground substance (pink); grade 3 shows severe elastic 
fragmentation with complete loss of elastic lamellae 
involving large areas of the media. 
 
 
 
 
 
 
 
 
2.4.3 Immunohistochemical protocol  
Sections adjacent to the histology stained slides were deparaffinized and then rehydrated in 
descending grades of alcohol.  
1. The endogenous peroxide enzyme activity in the tissue was blocked with a 30% hydrogen 
peroxide solution in methanol (1:10) for 10 minutes at room temperature. This was washed off 
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the sections with phosphate buffered saline (PBS) solution at pH 7.2. The tissues were incubated 
with normal goat serum (Vector, Peterborough) for 10 minutes at room temperature to block 
non-specific binding of the negatively charged primary antibody to non-antigenic positive sites 
in the tissue.  
2. The sections were washed with PBS buffer and specific antigen retrieval methods were 
optimised for anti-pSmad2 (Merck Biosciences) with application of 0.4% pepsin for 20 minutes 
to induce unmasking of the antigenic sites.  
3. Immunohistochemical staining was performed using commercially available pSmad2 (Merck 
Biosciences) diluted with PBS (pH 7.2) at the determined optimal working dilution of 1:15 with 
subsequent incubation (37˚C) of tissues for 2 hours. 
4. Following washing steps using PBS (pH7.2) between each stage, the biotinylated secondary 
antibody (rabbit IgG; Vector) was applied at 37˚C for 15 minutes. An avidin-biotin peroxidase 
complex was then added for 15 minutes at 37˚C using VectorStain Elite ABC (Vector).  
5. The reaction was visualised by the addition of a chromogen 3,3’-diaminobenzidine (DAB) 
with 30% H2O2 for 1-5 minutes and the remaining tissues lightly counterstained with Harris 
Haematoxylin solution for 1.5 minutes before the slides were placed in xylene solution for 15 
minutes. The tissue sections were then cover-slipped using DPX histology mountant.  
Of note, the primary antibody was replaced with rabbit non-immune IgG solution at same 
concentration of the pSmad2 antibody to ensure the specificity of its interaction in tissues. 
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2.4.4 Immunohistochemical grading  
All pSmad2 immunolabelled sections were examined by light microscopy and compared with 
EVG stained sections to determine the discrete zones of the aortic wall. Comparable views were 
observed in antibody labelled slides of the controls.  
A section through the aortic wall from adventitia to intima was viewed at 20x magnification. 
Using an image analysis system (Quantimet 500C QWIN V02.00B; Leica, Cambridge), the 
extent of immunoreaction for the intima, media and adventitia was determined by viewing the 
tissue section and all calls were counted in a measured frame area. Sections were assessed for 
specifically localized staining in the nucleus of VSMCs: positive cells had brown DAB nuclei 
and negative cells had blue Harris Haematoxylin stained nuclei. Data are expressed as the 
percentage of positive pSmad2 nuclei in each aortic wall layer. All slides were reviewed jointly 
by two observers.  
A detailed list of used chemicals and materials (source in brackets) is included below: 
- 3-aminopropyltriethoxy-silane (Sigma-Aldrich)  
- 3,3’-diaminobenzidine chromogen (Sigma-Aldrich) 
- Accu-Edge® low profile disposable blades (RA Lamb) 
- Elite Immunohistochemistry Kit (Vector laboratories) 
- Eppendorf Pipette tips. Volumes 0.1 – 5000μl (VWR) 
- Ethanol (VWR) 
- Glycerin albumin (RA Lamb, East Sussex) 
- Harris Haematoxylin solution (VWR) 
- Hydrogen peroxide [H2O2] (VWR) 
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- Industrial methylated spirits (VWR) 
- Mouse and goat serum (Vector laboratories) 
- Paraffin section waterbath (RA Lamb) 
- Paraffin wax (VWR) 
- Pepsin (Sigma-Aldrich, Dorset) 
- Pipettes – Eppendorf Research. Volume 0.1 – 5000μl (VWR) 
- Phosphate buffered saline tablets (Sigma-Aldrich) 
- pSmad2 Rabbit IgG antibody (Merck) 
- Section Drier (RA Lamb) 
- Super Premium twin frost microscope slides 75 x 25 x 1.0mm (VWR) 
- Tris (hydroxyl) methylamine (Sigma-Aldrich) 
- Winsor Incubator (RA Lamb) 
- Xylene (mixed isomers) (Genta Medical, York) 
- All histological stains sourced from RA Lamb, East Sussex UK and VWR, Leicester, UK 
Haematoxylin & Eosin: containing Harris haematoxylin. 
PAS -alcian blue: containing Periodic Acid, Schiff Reagent and Alcian blue. 
Elastic Van Geison: containing Millers Elastic Haematoxylin and Van Geison. 
2.5 Purification and quantification of DNA 
From each patient, 20 ml of venous blood were collected in EDTA tubes and stored at -80˚ C for 
future DNA extraction. In patients refusing blood sampling, Oragene DNA Self-Collection kits 
were used for storage of 2 ml of saliva in room temperature. 
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An automated DNA purification system (BioRobot EZ1) available at the Cardiovascular 
Biomedical Research Unit (BRU), Royal Brompton Hospital, was used for DNA extraction. The 
EZ1 utilizes silica-magnetic-particle technology for high-throughput DNA extraction. The EZ1 
DNA Blood kit (Qiagen) was used for DNA purification (elution volume of 200 μL) from 350 
μL of whole blood, as per the manufacturer’s standardized protocol. A spectrophotometer 
(NanoDrop™) was used for calculation of concentration (μg/ml) of the extracted DNA by 
measuring the absorbance at 260 nm (A260). Tubes containing DNA were applied to a magnetic 
separator (Qiagen 12-Tube Magnet) for 1 minute and 10 μl of isolated DNA were used for 
quantification, following calibration of the spectrophotometer with distilled water. The purity of 
extracted DNA was determined by calculating the ratio of corrected absorbance at 260 nm to 
corrected absorbance at 280 nm, i.e., (A260 – A320)/(A280 – A320) with an acceptable 
A260/A280 ratio of 1.7–1.9 (Wilfinger et al., 1997).  
The EZ1 DNA Tissue kit (Qiagen) was used for DNA purification from the collected saliva 
samples. Due to lack of a standardized protocol for EZ1 DNA extraction from Oragene saliva 
kits, the following trials were undertaken (data reported for the same sample):  
- 200μL neat sample with no pre-treatment with selected elution volume of 200μL: DNA 
concentration 24μg/ml, A260/A280 2.6. 
- 50μL sample with pre-treatment (140ul buffer G2 and 10ul proteinase K) and selected 
elution volume of 100μL: DNA concentration 16.5μg/ml, A260/A280 2.6. 
- 200μL neat sample with incubation at 50˚C for 2 hours and selected elution volume of 
50μL: DNA concentration 68μg/ml, A260/A280 1.9. 
In view of the maximal DNA yield obtained with saliva incubation at 50˚C, the last out of the 
three protocols was applied for DNA extraction from collected saliva samples.   
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2.6 Statistical analyses 
Data analysis was performed using IBM SPSS Statistics 19.0 (Chapters 3, 4, and 5). 
Continuous variables are expressed as median with range and categorical data as number with 
percentages. Comparisons between groups were performed using the Wilcoxon rank sum test or 
the Fisher exact test accordingly. A two-tailed p value < 0.05 was considered indicative of 
statistical significance. Spearman’s rank correlation coefficients were used to assess the 
relationship between circumferential stress and examined parameters (Chapter 3), between 
pSmad2 signalling and histological features (Chapter 4), and between medial hypertrophy and 
histology grading score (Chapter 5).  
Separate bioinformatic analyses were performed for genetic sequencing results, which are 
detailed in Chapters 6 and 7. 
2.7 Genetic analyses 
Sequencing of DNA samples for copy number variation analyses was performed by collaborators 
at the Wellcome Trust Sanger Institute, Cambridge, and for targeted next-generation sequencing, 
by collaborating team-members of the cardiovascular BRU, Royal Brompton Hospital. The 
following sections summarize the basic principles of the above techniques with a detailed 
description of post-calling data processing and interpretation included in the relevant chapters 
(Chapter 6 and 7). 
2.7.1 Array comparative genomic hybridization 
Until recently, sequencing of the human genome focused on variation at either the chromosomal 
or nucleotide level with reduced knowledge on structural variants of an intermediate size.  Array 
comparative genomic hybridization (CGH) is a technique which allows the identification of 
submicroscopic chromosomal copy number variants (CNVs), ranging from ~1 kb to 3 Mb in 
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size, at the genome wide level (Feuk et al., 2006). The principle of this method relies on 
comparison of copy number variation between a genome of interest and a reference sample.   
DNA fragments of test and reference samples are differentially labelled and competitively 
hybridized to target arrays (eg, BAC clones, cDNAs, oligonucleotides) with extensive coverage 
of the human genome.  Following hybridization of DNA fragments with their respective probes, 
a fluorescence ratio from each probe (test:reference) is used to detect copy number differences 
between the two samples,  with a duplication or deletion in a genomic region expressed by a 
relevant increase or decrease of the relative ratio (Figure 2.7) (Wain et al., 2009). Derived 
intensities are transformed to log2 ratios for further data processing. 
In this study, a variation of the array-CGH approach was applied with usage of hybridization 
intensities derived from spotted oligonucleotides on Affymetrix Genome-Wide Human SNP 
Array 6.0 (Aros, Inc.) (Feuk et al., 2006). DNA samples from BAV patients were run on the 
Affymetrix array and the derived hybridization intensities were compared to genotyping data 
from Wellcome Trust Control Consortium  2  donors assayed on the same platform (Bochukova 
et al., 2010).  
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platform, Life Technologies) amplifies sequencing via fragmentation of genomic DNA followed 
by magnetic bead tagging of each fragment (http://www.chem.agilent.com/Library 
/usermanuals/Public/G753090004_SureSelect_SOLiD5500Multiplexed.pdf). Following bar- 
coding, samples are pooled for emulsion polymerase chain reaction (PCR) and the resulting 
clonally amplified DNA is bound to a glass slide. Then, massively parallel sequencing takes 
place via multiple rounds of hybridization, ligation, and cleavage of dye-labeled oligonucleotide 
probes followed by alignment of DNA sequence to a reference genome for decoding (Metzker, 
2010). Generated reads are de-multiplexed and bioinformatically processed (details in Chapter 
7). 
An additional advantage of NGS techniques is that of whole-exome sequencing, allowing for 
selective sequencing of the coding regions of the human genome. Enrichment of targeted 
genomic regions can be achieved via PCR or hybridization methods (Ware et al., 2012). In this 
study, DNA libraries were constructed using the SureSelectXT Target Enrichment System 
(Figure 2.8) with “custom-made” RNA baits for all exons of 63 genes of interest (design details 
in Chapter 7). Targeted genomic areas were then enriched and barcoded, as described above, 
followed by NGS to screen for sequence variants. 
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Chapter 3. Finite-element analysis 
 
Abbreviations 
3D Three-dimensional 
4D Four-dimensional 
AAA Abdominal aortic aneurysm 
AR Aortic regurgitation 
AS Aortic stenosis 
ASI Aortic size index 
BAV Bicuspid aortic valve 
CT Computed tomography 
FEA Finite element analysis 
HGS Histology grading score 
MFS Marfan syndrome 
MRI Magnetic resonance imaging 
KPa Kilopascal 
TAA Thoracic aortic aneurysm 
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3.1Abstract 
Background: BAV is the commonest inborn heart defect predisposing affected individuals to a 
higher risk of TAA formation and dissection. Although there is a genetic component underlying 
TAA susceptibility, the local haemodynamic environment also plays an important role and is 
currently a critical gap in our understanding of the evolution of BAV-associated disease. We 
have generated the hypothesis that circumferential stress is different between the various aortic 
phenotypes in BAV and that it corresponds to the severity of the structural abnormalities in the 
aortic wall.  
Methods: The 3D geometry of the thoracic aorta was constructed using CT angiography for 
BAV patients about to undergo surgery. The 3D models were broken down into smaller elements 
and circumferential stress, exerted perpendicularly to the aortic wall, was calculated in response 
to applied predefined loads via structural FEA. During surgery, aortic tissue biopsies were 
collected from discrete areas and the degree of medial wall degeneration was correlated to the 
calculated circumferential stress.  
Results: Ten BAV patients (90% male) with a median age of 27 years [2-68] were studied. 
Maximal circumferential stress (KPa) normalised by aortic size index (ASI, cm/m²) was higher 
in the ascending aorta of patients with aortic regurgitation compared to those with aortic stenosis 
(42.6 [32.2-155.3] vs 14.5 [3.7-19.2] KPa; p= 0.025).  Maximal stress in the ascending aorta 
occurred above the left coronary sinus in 80% of patients. A shift in stress location from the 
convex to the concave ascending aorta was observed as the asymmetry of the antero-lateral 
“bulge” increased. A positive correlation between the severity of fibrosis and corresponding 
stress was noticed both in the aortic root (ρ=0.79, p=0.033) and ascending aorta (ρ=0.76, 
p=0.044), with additional associations between stress, cyst-like formations (ρ=0.86, p=0.012) 
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and overall histology grading score (ρ=0.80, p=0.031) at the aortic root level when stress was 
normalised by ASI.  
Conclusion: Our integrated analyses propose a link between radial stress and altered elastic 
component of the aortic media, with varied maximal stress location in distinct BAV aortic 
phenotypes.  Aortic geometry should be taken into consideration in future studies examining the 
haemodynamic theory of BAV aortopathy. 
3.2 Introduction 
BAV is considered as a continuum of an inherent disease process affecting not only the aortic 
valve, causing it to have two instead of three leaflets, but also the aortic root and ascending aorta 
(Tadros et al., 2009). Despite the well recognized aortic dilatation associated with BAV disease, 
the natural history of the affected aortic segments remains largely unknown (Fedak et al., 2002). 
The lifetime likelihood of aortic dissection in BAV may be lower compared to other inborn 
abnormalities (5% versus 40% in MFS), but accounts for a larger number of incidents due to its 
higher prevalence in the general population (0.5 - 2%), comprising the commonest inborn heart 
defect (Tadros et al., 2009, Huntington et al., 1997, Braverman et al., 2005). Maximal aortic 
diameter is an established predictor of aortic dissection and rupture and to date, has been used as 
the single criterion for monitoring TAA formation in BAV disease (Prapa and Ho, 2012). While 
radiographic screening in BAV disease is valuable, many patients at a higher risk of TAA 
formation in later life may not have recognisable aortic enlargement at the time of testing, 
highlighting the need for further risk stratification tools (Chapter 1). 
Considerable research in BAV patients over the past decade has sought to resolve the debate of 
haemodynamic versus genetic abnormalities causing the aorta to dilate. The resulting data have 
not only enhanced our understanding of the disease but also given rise to potential novel tools to 
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assess risk of TAA formation (Girdauskas et al., 2011a). Although genetic screening of BAV 
patients is not routinely available, our appreciation of the genetic aspects of TAA pathogenesis 
has led to the proposal of a lower threshold for elective surgery in BAV disease by the most 
recent American College of Cardiology/American Heart Association guidelines, similar to other 
connective tissue disorders (Girdauskas et al., 2011a, Hiratzka et al., 2010). On the other hand, 
the so-called “post-stenotic dilatation” theory, advocating elevated stress on the convexity of the 
ascending aorta due to disturbed blood flow downstream of a BAV stenotic lesion, has been 
further investigated by 4D magnetic resonance (MR) imaging suggesting disturbed flow patterns 
even in the absence of aortic stenosis (AS) and/or regurgitation (AR) (Girdauskas et al., 2011a, 
Hope et al., 2010).  
The prognostic value of the wealth of structural and functional information currently obtained by 
advanced cardiovascular imaging in BAV disease remains to be seen. Computational modelling 
offers the advantage of rigorous utilization of the above data in the field of arterial biomechanics, 
allowing for validation of clinically relevant hypotheses (Giannakoulas et al., 2009). In fact, peak 
mechanical stress calculated by FEA has been shown to be superior to maximal aortic diameter 
for prediction of aortic dissection in patients with abdominal aortic aneurysms (Fillinger et al., 
2003). The application of a similar model to study the effect of mechanical stress on TAA 
formation on the basis of geometrical features of the vessel wall would be particularly 
advantageous in the setting of BAV disease. The aim of this study was to address this critical gap 
in our understanding of BAV aortic “mechanical homeostasis”, by utilization of pre-operative 
imaging combined with computational modelling to assess the distribution of mechanical stress 
and severity of corresponding structural abnormalities in the BAV aorta.  
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3.3 Methods 
3.3.1 Summary 
Informed consent was obtained from patients with BAV planning to undergo surgery at the 
Royal Brompton Hospital. Patients with developmental syndromes, major cytogenetic 
abnormalities and connective tissue disorders, such as MFS, were excluded from the study. 
Imaging data obtained preoperatively via CT angiography were used to study the distribution of 
mechanical stress in the proximal aorta, applying computational modelling methods. During the 
operation, aortic tissue samples were collected from discrete areas of the aortic root and 
ascending aorta and histological analyses were performed. A detailed description of methods is 
included in Chapter 2. 
For each patient, maximal circumferential stress was reported at the level of the aortic root and 
ascending aorta. In addition, mean circumferential stress was calculated in areas of the aortic 
wall corresponding to the sites of tissue sampling during surgery (Figure 3.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 82 
Figure 3.1 Circumferential stress measurements. The result of finite element analysis as derived by 
ANSYS ICEM CFD© version 12 software can be viewed. The colour-coded three-dimensional map 
depicting the distribution of circumferential (Von Mises) stress (Pa) was reviewed and for each patient, 
maximal stress (red arrow) was reported at the level of the aortic root and ascending aorta. In addition, 
mean stress (green arrow) was calculated in areas of the aortic wall corresponding to the sites of tissue 
sampling during surgery. In this particular case, as the patient underwent aortic valve replacement, a 
single biopsy was collected from the anterior proximal aorta. 
 
3.3.2 Technical difficulties over course of the study 
When this study was initially designed, as it was the first of its kind involving integrated 
histological and computational modelling analyses, we used differential degrees of medial wall 
degeneration between the convexity and concavity of the ascending aorta in BAV patients with 
aortic regurgitation (2.5 versus 1.7 grades with a population standard deviation of 0.6) for our 
power calculations (Cotrufo et al., 2005). In order to detect a difference of 0.8 grades between 
areas of high and low mechanical stress (paired analyses) at a significance level of 0.01 and a 
power of 90%, we would need to recruit 12 patients. A total of at 15 patients was set as a target 
to adjust for technical difficulties in the harvesting, processing and analysis of tissue samples. 
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As mentioned in Chapter 2, all preoperative imaging scans were clinically indicated and 
obtained up to 6 months prior to surgical procedure, comprising a part of the diagnostic work-up 
of BAV patients undergoing surgery. Preoperative magnetic resonance imaging (MRI) is 
increasingly employed in BAV patients as it provides accurate aortic diameter measurements as 
well as functional data related to valvular disease and left ventricular function. In contrast, 
computed tomography (CT) angiograms are considered to be the gold standard for three-
dimensional (3D) reconstructions of the aorta but subject patients to significant radiation 
exposure and are usually performed preoperatively when more detailed aortic anatomy is 
required for surgical planning or CT coronary angiography is performed simultaneously to assess 
for presence of coronary artery disease (Rengier et al., 2013).  
In order to increase the number of recruited patients for this study, it was initially decided to use 
preoperatively obtained MRI angiograms for 3D reconstructions. However, their use would 
mandate an MRI slice thickness of <2mm (Rengier et al., 2013) with greater slice thicknesses 
leading to potential loss of important geometrical features and subsequent errors in 
computational modelling simulations. The above limitation was confirmed in a pilot study 
employing a “standard” 5mm slice thickness MRI angiogram for 3D reconstruction of the aorta, 
which was felt to be suboptimal (Figure 3.2). Unfortunately, the lower slice thickness parameter 
is rarely set outside research context limiting the use of clinically indicated preoperatively 
obtained MRI scans of BAV patients. As a result, it was decided to restrict our applied 
methodology to use of preoperative CT angiograms for all of our 3D reconstructions. 
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Figure 3.2 Pilot three-dimentional (3D) reconstruction employing magnetic resonance imaging 
(MRI). The complete structural analysis of a patient undergoing the Ross procedure for severe aortic 
stenosis can be seen with colour coded mechanical stress distribution in the anterolateral (a), posterior (b) 
and medial (c) wall of the aortic root and ascending aorta. As visualised in the images, 3-D reconstruction 
with use of 5mm slice thickness MRI, leads to poor depiction of geometrical features of the vessel wall 
and may result in significant simulation errors.  
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3.4 Results 
3.4.1 Patient characteristics 
Patient characteristics are summarized in Table 3.1. A total of 10 BAV patients planning to 
undergo surgery were recruited. Median age was 27 years [2-68], 90% of participants were male. 
The majority of patients had aortic valve disease (90%); three had AS and six had AR. A single 
68y old patient had systemic hypertension (patient #10) treated with a calcium-channel blocker 
with none of the remaining patients having any cardiovascular disease risk factors (diabetes, 
hypertension, smoking) or being on any cardiovascular medication. Two patients (#4 and #9 had 
repaired coarctation of the aorta) and a single patient (patient #6) had a spontaneously closed 
ventricular septal defect. None of the remaining patients had any BAV-associated congenital 
heart defects, as outlined in the inclusion criteria in Chapter 2.  
Biopsies were collected from multiple areas of the aortic wall, depending on the type of surgical 
procedure, with recording of the exact site of tissue collection. 
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Table 3.1 Patient characteristics 
 
Abbreviations: Ao, aortic; ARR, aortic root replacement; Asc, ascending; AVR, aortic valve replacement; BAV, bicuspid aortic valve; BSA, 
body surface area; Pt, patient; R-L, fusion of right and left coronary leaflets; R-N, fusion of right and non-coronary leaflets; VSARR, valve 
sparing aortic root replacement. 
Pt     Sex Age 
(y) 
BAV 
type 
              BAV  
  Disease          Degree 
Ao 
Root 
(cm) 
Asc Ao 
(cm)    BSA Surgical procedure 
     Aortic samples 
    Root      Asc Ao 
1. M 2 True AS Severe 1.4 2.3 0.59 Ross + + 
2. M 14 R-N AR Moderate 2.8 5.6 1.66 Ao root & arch replacement + + 
3. M 22 True AS Severe 3.1 2.9 1.78 Ross + + 
4. M 24 True - - 6.4 1.7 2.07 VSARR + - 
5. M 26 NA AR Moderate 6.6 3.9 1.91 ARR + - 
6. F 28 R-N AR Severe 4.0 5.4 1.74 Bentall + + 
7. M 29 R-L AR Severe 3.4 2.6 2.08 AVR - + 
8. M 34 R-N AR Severe 3.8 5.2 1.84 AVR 
& Asc Ao replacement - + 
9. M 37 True AR Mild 6.3 3.0 2.09 VSARR + - 
10. M 68 R-L AS Severe 3.2 3.2 2.05 AVR - + 
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3.4.2 Maximal Mechanical Stress 
Overall, three aortic phenotypes, related to BAV disease, were analysed (Figure 3.3). Within 
the 3 aortopathy groups, there were no significant differences in absolute or normalised 
maximal stress in the ascending aorta compared to the aortic root (Figure 3.3).  
Figure 3.3 Analyzed BAV aortic phenotypes and corresponding maximal stress values. Ao root, 
aortic root; asc ao, ascending aorta; ASI, aortic size index; max, maximal. Aortic images created by 
artist for purpose of thesis chapter. 
 
Aortic phenotype 
Mild dilatation 
(n=3) 
Asc Ao aneurysm 
(n=4) 
Ao Root aneurysm 
(n=3) 
p value* 
Ao Root 
Max Stress (kPa) 
24.8 (4.4-75.5) 66.1 (12.2-154.3) 77.9 (67.3-120.4) 
0.445 
Asc Ao 
Max Stress (kPa) 
31.3 (5.8-47.6) 130.7(56.6-523.6) 46.4 (41.5-46.4) 
Ao Root 
Max Stress/ASI 
14.2 (2.8-46.3) 28.7 (5.9-91.3) 25.2 (19.4-40.0) 
0.114 
Asc Ao 
Max Stress/ASI 
19.2 (3.7-38.1) 47.1 (14.5-155.3) 32.2 (20.3-56.6) 
* Paired analysis in overall population. Separate paired analysis within the 3 aortopathy groups did not reveal any 
significant differences in neither absolute nor normalized maximal stress in ao root versus asc ao.  
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Table 3.2 Maximal circumferential stress (in all subjects sub-divided by BAV morphology 
and disease). A single subject was not included in the first part of the table as BAV 
morphology was not available in this case (patient #5, table 3.1).  
Abbreviations: Ao, aortic; AR, aortic regurgitation; AS, aortic stenosis; Asc, ascending; ASI, aortic 
size index; BAV, bicuspid aortic valve; R-L, fusion of right and left coronary leaflets; R-N, fusion of 
right and non-coronary leaflets. 
 
Similarly, no differences in stress values were noticed between different morphological 
subtypes of BAV (Table 3.2). The normalised maximal stress in the ascending aorta was 
higher in patients with AR compared to those with AS (42.6 [32.2-155.3] vs. 14.5 [3.7-19.2] 
KPa; p= 0.025, Table 3.2).  Absolute values of maximal stress did not correlate with 
maximum diameters, both at the level of the root (ρ= 0.23, p=0.511) and the ascending aorta 
(ρ= 0.44, p=0.199). Similarly, no correlation was found between maximal stress and 
Stress BAV Groups 
Maximal Stress (KPa) 
location 
 
Aortic root  
normalised for  
root ASI  
 
Ascending aorta 
normalised for  
asc ao ASI 
 
True 
(n=4) 
 
19.4 (6.3-40.0) 
 
 
 
20.3 (14.5-56.6) 
BAV Subtypes 
R-L 
(n=2) 
 
24.6 (2.8-46.3) 
 
 
 
20.9 (3.7-38.1) 
 
R-N 
(n=3)  
 
51.0 (5.9-91.3) 
 
 
 
51.6 (42.5-155.3) 
 
p 
value*¹ 
 
0.580 
 
 
 
0.139 
Maximal Stress (KPa) 
location 
 
Aortic root 
normalised for  
root ASI  
 
Ascending aorta 
normalised for  
asc ao ASI  
 
AR 
(n=6) 
 
46.3 (5.9-91.3) 
 
 
 
42.6 (32.2-155.3) 
BAV Disease 
AS 
(n=3) 
 
6.3 (2.8-14.2) 
 
 
 
14.5 (3.7-19.2) 
 
None 
 (n=1) 
 
25.2 
 
 
 
95.0 
 
p 
value*² 
 
0.101 
 
 
 
0.025 
*¹ Kruskall-Wallis test for comparisons between 3 groups 
*² Mann-Whitney test for comparisons between 2 groups (AR versus AS) 
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maximum ASI in the aortic root (ρ= 0.24, p=0.489) and the ascending aorta (ρ= 0.57, 
p=0.08).  
The regional distribution of maximal stress was investigated. Patient-specific 3D wall stress 
distributions with absolute values of maximal stress are depicted in Figure 3.4 and Table 3.3, 
respectively. In the majority of patients (8/10, 80%), maximal stress was located on the 
concave aspect of the ascending aorta above the left coronary sinus. In a single patient (1/10, 
10%), maximal stress occurred on the convex aspect of the ascending aorta above the right 
coronary sinus and in another patient (1/10, 10%), it was located on the anterior aspect of the 
ascending aorta.  
Table 3.3 Absolute values of maximal stress and aortic radius measurements. Patient 
numbers correspond to table 3.1 and figure 3.4.  
Pt Diameter (cm) Z score ASI (cm/m²) Max Stress (KPa) 
1.    Root 
 Asc Ao 
1.4 
2.3 
-.66 
4.99 
2.37 
3.90 
14.94 
56.59 
2.    Root 
       Asc Ao 
2.8 
5.6 
1.02 
16.72 
1.69 
3.37 
154.35 
523.57 
3.    Root 
       Asc Ao 
3.1 
2.9 
1.93 
2.78 
1.74 
1.63 
24.80 
31.35 
4.    Root 
       Asc Ao 
6.4 
1.7 
14.94 
-4.21 
3.09 
.82 
77.91 
46.41 
5.    Root 
       Asc Ao 
6.6 
3.9 
16.23 
7.35 
3.46 
2.04 
67.30 
41.53 
6.    Root 
       Asc Ao 
4.0 
5.4 
5.81 
15.43 
2.30 
3.10 
117.36 
160.15 
7.    Root 
       Asc Ao 
3.4 
2.6 
2.30 
0.25 
1.63 
1.25 
75.55 
47.66 
8.    Root 
       Asc Ao 
3.8 
5.2 
4.69 
14.11 
2.07 
2.38 
12.26 
101.30 
9.    Root 
       Asc Ao 
6.3 
3.0 
14.46 
2.24 
3.01 
1.44 
120.41 
46.41 
10.  Root 
       Asc Ao 
3.2 
3.2 
1.54 
3.35 
1.56 
1.56 
4.44 
5.78 
         Abbreviations: Ao, aortic; Asc, ascending; ASI, aortic size index; Max, maximal; Pt, patient. 
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3.4.3 Histological abnormalities 
The vast majority of BAV patients had severe medial wall abnormalities (≥ grade 2) 
involving their ascending aorta, including elastic fragmentation (85%), fibrosis (28%) and 
cyst-like formations (42%). Medionecrosis was rarely seen and was found to be mild (grade 
1) in 14% of samples. In the aortic root, severe elastic fragmentation was present in 28% of 
samples, fibrosis in 42%, cyst-like formations in 42% and medionecrosis in none (Figure 
3.5). The median histology grading score (HGS) was 4.5 [3-7] in the ascending aorta and 3.5 
[2-5] in the aortic root. No significant differences in HGS were noticed between aortic 
phenotypes or BAV morphological subtypes. When subdivided by aortic valve disease, 
patients with AR had a significantly higher HGS compared to those with AS (6 [5-7] vs. 3.5 
[3-4]; p=0.029) in their ascending aorta.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Percentage of severe medial wall abnormalities (≥ grade 2) in collected tissue 
biopsies. The right-sided panel illustrates the presence of elastic fragmentation (a), fibrosis (b), and 
cyst-like formations (c, black arrows) on microscopy (x200 magnification, a and b, elastic van 
Gieson; c, alcian blue stain). 
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3.4.4 Integrated analyses 
The degree of medial wall abnormalities was correlated to the mean mechanical stress in the 
corresponding areas of the aortic wall (Figure 3.6). In the aortic root samples, the normalised 
mechanical stress correlated with the severity of fibrosis (ρ= 0.85, p=0.015), cyst-like 
formations (ρ= 0.86, p=0.012), and overall HGS (ρ= 0.80, p=0.031). In the ascending aorta, a 
positive correlation was noticed between normalised mechanical stress and fibrosis (ρ= 0.76, 
p=0.044). When absolute values of mechanical stress were used, a positive correlation was 
noticed between stress and fibrosis, both in the aortic root (ρ= 0.79, p=0.033) and the 
ascending aorta (ρ= 0.76, p=0.044). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 Representative overview of correlations between the degrees of medial wall 
abnormalities and mean circumferential stress in the corresponding areas of aortic wall tissue 
biopsies. Three aortic phenotypes can be seen in descending order (mild dilatation, ascending aortic 
aneurysm, aortic root aneurysm) with examples of corresponding degrees of elastic fragmentation 
(x200, elastic van Gieson stain).  
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3.5 Discussion 
This study demonstrates that mechanical stress distribution differs between BAV aortic 
phenotypes, with maximal stress located in the concave aspect of the ascending aorta in the 
majority of cases. Combined biomechanical and histological analyses exhibited a strong 
positive correlation between the degree of fibrosis and mechanical stress, both in the aortic 
root and the ascending aorta. When mechanical stress was normalised to ASI, additional 
positive correlations were noticed between stress, cyst-like formations, and overall histology 
grading score at the level of the aortic root.  
3.5.1 Maximal mechanical stress 
To date, the distribution of mechanical stress in the BAV aorta has been investigated by a 
single group; Nathan and colleagues compared equal numbers of BAV and TAV adult 
patients (n=20) and reported increased 99th percentile wall stress in the ascending aorta of 
BAV patients, regardless of aortic diameter (Nathan et al., 2011b). Similarly to our findings, 
the authors reported no differences in 99th percentile wall stress between different BAV 
morphological subtypes (Nathan et al., 2011b) albeit higher normalised maximal stress was 
noticed in our BAV subjects with AR compared to those with AS, which reached statistical 
significance at the level of the ascending aorta (Table 3.2). Direct comparisons of reported 
stress values with our findings in BAV subjects are not possible due to the different 
intraluminal applied pressure, despite similar material properties of the vessel wall 
(Giannakoulas et al., 2005).  However, differences in location of stress may be more 
important than actual values, especially in the instance of higher stress in the convexity of the 
ascending aorta where type A dissections typically occur (Nathan et al., 2011b). Nathan et al. 
reported maximal stress above the left coronary sinus in 50%, above the right coronary sinus 
in 45%, and in the distal ascending aorta in 5% of BAV cases whereas in the majority of 
TAV aortas (65%), maximal stress was located above the left coronary sinus (Nathan et al., 
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2011b). In our study, maximal stress occurred in the concavity of the ascending aorta (above 
the left coronary sinus) in the vast majority (90%) of BAV patients. This suggests that stress 
patterns in our subjects are geometry-driven as most of them had similar geometrical features 
with a “bulge” in the anterolateral portion of the ascending aorta characteristic of BAV 
disease (Figure 3.4).   
Despite differences in pathophysiology and location, virtual models of abdominal aortic 
aneurysms (AAA) can be used to partly explain the location of mechanical stresses in the 
ascending aorta. Previous studies have investigated the effect of bulge shape asymmetry in 
AAA biomechanics and reported changes in the location of maximal stress in relation to the 
altered shape of the aneurysm sac. Both static (Vorp et al., 1998) and fluid-structure 
interaction analyses (Scotti et al., 2005), have reported a shift in location of circumferential 
stress in AAA sac from the distal ends of the anterior wall to the midsection of the posterior 
wall as asymmetry increases, which may be explained by the increasing curvature of the sac 
allowing accelerated flow in the opposite (posterior) area (Figure 3.7) (Scotti et al., 2005). 
Similarly, it may be that mechanical stress distribution in the ascending aorta shifts from the 
distal ends of the bulge in the anterolateral wall (including the area above the right coronary 
sinus) to the posterior-medial wall as asymmetry of the bulge increases. Although theoretical 
aneurysm models are outside the scope of this study, the stress patterns of the aneurysms in 
our BAV subjects would support this theory (Figure 3.4). As the bulge asymmetry increases 
from patient 6 (with dilatation extending to the sinutubular junction) to patient 2 and patient 8 
(with a prominent anterolateral bulge proximally), the location of maximal circumferential 
stress shifts from the anterior aorta (patient 6) to the medial wall (patient 2) and finally, the 
area above the left coronary sinus (patient 8). Due to the more uniform dilatation noted in 
BAV cases with aortic root dilatation, interpretation of stress distribution in this area would 
need to follow different theoretical models of spherical aneurysms exhibiting maximum 
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circumferential stress near the junction of the aneurysm, as seen in patients 4 and 9 in our 
study (Stringfellow et al., 1987).  
Figure 3.7 Computational modelling in abdominal aortic aneurysm (AAA). Both static (A) and 
fluid-structure interaction analyses (B) have reported a shift in location of circumferential stress 
(N/cm2) in the AAA sac from the distal ends of the anterior wall to the midsection of the posterior 
wall as asymmetry (expressed by the β parameter) increases. Both images depict AAA virtual models 
of increasing sac asymmetry and uniform wall thickness; A. is adjusted by Vorp et al. and shows 
anterior (left column) and posterior views (right column) of Von Mises stress (Vorp et al., 1998) and 
B. is adjusted by Scotti et al. and shows anterior/left lateral views of displacement (left column) and 
Von Mises stress (right column) (Scotti et al., 2005). 
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3.5.2 Integrated analyses 
This study also investigated associations between histological abnormalities and 
corresponding stress in the BAV aorta, although the prognostic value of the former remains 
elusive (Prapa and Ho, 2012). In fact, the presence of structural wall abnormalities in BAV 
disease may not precipitate aortic dissection in isolation but make the aorta susceptible to 
such an event. External factors, such as acute exertion and emotion, can trigger the onset of 
aortic dissection in a genetically “weakened” aorta with aneurysm rupture occurring when the 
developing mechanical stress exceeds the tensile strength of the aortic wall (Elefteriades and 
Farkas, 2010, Vorp et al., 1998). However, it remains unclear whether structural changes in 
the BAV aorta are purely inherent or the result of external haemodynamic factors, including 
increased mechanical stresses as the diameter enlarges (Schlatmann and Becker, 1977).  
Okamoto et al. studied the influence of histological structural changes in the ascending aorta 
of BAV and MFS patients on wall stress and distensibility by fitting in vivo elastic tissue 
properties into a cylindrical mathematical model of the aorta (Okamoto et al., 2003). The 
authors reported reduced distensibility of the ascending aorta in BAV patients with greater 
degrees of elastic fragmentation. However, no differences in mean circumferential stress 
were noticed in their studied groups, although the frequency of severe fibrosis and 
medionecrosis was lower in their tissue samples compared to other studies (Schlatmann and 
Becker, 1977). By examining the effect of patient-specific aortic geometry (rather than elastic 
properties) on circumferential stress, we report a positive correlation between increased stress 
and severity of fibrosis, both in the aortic root and the ascending aorta. Arterial remodelling 
in response to increased radial stress has been studied extensively in patients with systemic 
hypertension, exhibiting altered contribution of elastic components of the media (fracture of 
elastic lamellae and increased collagen turnover) leading to dilatation, increased wall 
thickness and stiffness of the vessels (Humphrey, 2008). Similarly, in congenital heart 
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disease, whereby the great arteries are “inherently” abnormal, severe fibrosis with increased 
elastin/collagen ratio has been described by our group in the pulmonary artery of patients 
exposed to long-standing elevated pulmonary arterial pressures (Chapter 5) (Prapa et al., 
2013).  
When stress was normalised for ASI, a stronger correlation with fibrosis was noticed in the 
aortic root with additional associations between stress, cyst-like formations and overall HGS 
at the same level. Cyst-like formations in the media have been described as the only potential 
histological abnormality distinguishing the dissecting aorta from normotensive and 
hypertensive controls (Manley, 1964). It has been previously proposed that the root dilatation 
phenotype accompanied by varying degrees of aortic insufficiency may represent the 
predominantly genetic form of BAV disease (Girdauskas et al., 2011a), as it would be less 
influenced by altered haemodynamic factors compared to the ascending aorta which is 
subjected to eccentric blood-flow patterns and focally elevated WSS, even in the absence of 
AS (Hope et al., 2010). However, in our study, the degree of histological abnormalities in the 
root was not greater compared to that of the ascending aorta, although when subdivided by 
aortic valve disease, patients with pure AR had a significantly higher HGS in their ascending 
aorta, in agreement with previous findings (Roberts et al., 2011). It is, therefore, possible that 
mechanical (rather than shear) stress has a greater pathophysiologic effect on aortic root 
dilatation, especially in view of the fact that the majority of our BAV subjects had regurgitant 
valves subjecting the aorta to higher stroke volumes rather than stenotic valves causing 
eccentric jet lesions in the distal ascending aorta with potentially corresponding asymmetric 
structural abnormalities (Tadros et al., 2009, Della Corte et al., 2008).  
3.5.3 Limitations 
This study has several limitations in relation to vessel wall properties incorporated into the 
finite-element analyses. Firstly, the arterial wall was assumed to have uniform elastic 
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properties in all subjects with properties of an isotropic linearly-elastic material. Although 
similar wall characteristics have been applied in equivalent studies in BAV disease (Nathan 
et al., 2011b), a more accurate method would be that of mechanical testing of our collected 
tissue biopsies and incorporation of in vivo elastic properties into our model. Another 
assumption is that of uniform wall thickness in all of our subjects; Scotti and colleagues 
studied the effect of differential wall thickness in AAA models and showed that uniform 
thickness may underestimate peak stress by an average of 9.4% when applying quasi-static 
computational conditions (Scotti et al., 2005). However, in vivo examination of BAV 
aneurysmal aortic tissue rings failed to exhibit significant variations in regional wall 
thickness (Choudhury et al., 2009). Finally, an important limitation is that of the applied 
computational method per se, as our model did not take into consideration the effect of 3D 
time-varying blood flow, allowing calculation of WSS, which may have an important 
haemodynamic effect especially in stenotic BAV disease (Girdauskas et al., 2011a). Although 
fluid-structure interaction analysis would reflect more accurately the in vivo haemodynamic 
conditions, it would also require a significantly greater amount of workload with an estimated 
23-fold increase in computational costs, restricting its current role as a readily accessible risk 
stratification tool for clinicians (Scotti et al., 2005). Analyses are also limited by the lack of 
controls, restricted numbers, and varying age of our subjects which may impose additional 
effects on the elastic properties of their aortic walls. Aortic geometry has been previously 
reported to be an established contributing factor to aneurysm expansion and rupture potential, 
regardless of the heterogeneity of the wall (Scotti et al., 2005). Despite its limitations, this 
study is the first of its kind to assess the effect of patient-specific aortic geometry on 
circumferential stress and corresponding histological abnormalities in a typical group of BAV 
patients who would be expected to present to a Congenital Heart Disease Unit.  
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3.6 Conclusions 
This study employs patient-specific 3D aortic models combined with structural finite-element 
analysis to study the effect of geometrical features of BAV aortic phenotypes on 
circumferential stress and corresponding histological abnormalities. Overall, maximal stress 
occurred above the left coronary sinus in the majority of patients with maximal stress location 
shifting from the convex to the concave aspect of the vessel wall as asymmetry of the 
anterolateral bulge increased. Future sequential static computational analyses in enlarging or 
dissected BAV aortas will be able to validate the prognostic value of maximal mechanical 
stress, as has been carried out in AAA disease (Fillinger et al., 2003). Our integrated analyses 
propose a link between radial stress and altered elastic component of the BAV aortic media, 
which may be competitive or synergistic to that of shear stress assessed by fluid-structure 
interaction analyses or 4D MR imaging (Cheng et al., 2010, Hope et al., 2010). As more 
advanced tools are becoming available to clinicians, it would be safe to assume that we are 
moving away from the “aortic diameter criterion” and closer to individualized risk 
stratification and management of BAV disease.  
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Chapter 4. BAV aortic phenotypes  
 
Abbreviations 
ACE Angiotensin converting enzyme 
AR Aortic regurgitation 
ARB Angiotensin receptor blocker 
AS Aortic stenosis 
AVR Aortic valve replacement  
BAV Bicuspid aortic valve 
CMR Cardiac magnetic resonance 
CNC Cardiac neural crest 
ECM Extracellular matrix  
FBN1 Fibrillin-1 
LDS Loeys Dietz syndrome 
MMP Matrix metalloproteinase 
pSmad2 Phosphorylated Smad2 
TGFβ Transforming growth factor-beta 
TGFBR Transforming growth factor-beta receptor 
VSMC Vascular smooth muscle cell 
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4.1 Abstract 
Background: TGFβ signalling plays a central role in vascular remodelling and aneurysm 
formation. A hypothesis of lineage-specific capacity in TGFβ responsiveness has recently 
emerged which may explain the different patterns of aortopathy in BAV disease. To that end, 
we aimed to assess the degree of histological abnormalities and TGFβ activation in the 
mesoderm-derived aortic root and ectoderm-derived ascending aorta of BAV patients. 
Methods: Aortic tissues from BAV patients and controls sampled at the level of sinuses of 
Valsalva and distal ascending aorta were examined via light microscopy for histological 
abnormalities and nuclear phosphorylated Smad2 (pSmad2) signalling, a marker of TGFβ 
activation. A detailed histology grading score was used to assess the severity of medial wall 
abnormalities. Immunohistochemical data was expressed as the percentage of positive 
pSmad2 nuclei in each aortic wall layer. 
 Results: Aortic specimens collected during surgery from 18 BAV patients (median age 22.5 
[2–39]) were compared to 12 age-matched controls. Paired analysis in BAV patients reported 
a higher cumulative histology grading score in the ascending aorta compared to the root (5.5, 
[2-9] versus 4, [2-7]; p=0.004), which was persistently greater in patients with regurgitant 
valve disease (6, [2-9] versus 4, [2-6]; p=0.026), and in patients with aortic root dilatation (6, 
[3-9] versus 4, [2-6]; p=0.029). At immunohistochemistry, pSmad2 signalling was 
significantly higher in the BAV media compared to controls, both in the aortic root (38.7 [14-
61] versus 10.7 (2-36), p<0.001) and in the ascending aorta (40.3 [4-54] versus 7.9 [3-46], 
p=0.001). Medial pSmad2 activation did not differ significantly between the ascending aorta 
and root of BAV patients, with or without respective aortic dilatation. In the overall 
population, a positive correlation was noticed between the degree of pSmad2 signalling in the 
media and the severity of medial wall abnormalities, both in the aortic root (ρ=0.57; p=0.001) 
and the ascending aorta (ρ=0.6; p<0.001). 
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Conclusion: The dilated aortic root phenotype may represent the primarily genetic form of 
BAV disease as patients with either root dilatation and/or predominant regurgitant valve 
disease had greater levels of medial wall degeneration in their ascending aorta. Enhanced 
TGFβ signalling appears to play a key role in BAV aortopathy. The presence of increased 
pSmad2 activation in non-dilated BAV aortic segments points to a genetic trigger, with no 
differences in signalling between the mesoderm-derived root and the ectoderm-derived 
ascending aorta.  
4.2 Introduction 
The heterogeneous nature of BAV disease has been increasingly recognized over the past 
decades, with extensive research focusing on discrete clinical phenotypes and their respective 
pathophysiology (Tadros et al., 2009, Girdauskas et al., 2011a). As seen in Chapter 3, 
different patterns of BAV aortopathy include typical asymmetric enlargement at the 
convexity of the ascending aorta, and isolated aortic root dilatation (Della Corte et al., 2007, 
Bauer et al., 2006, Cotrufo and Della Corte, 2009, Nistri et al., 1999). These phenotypes may 
be secondary to haemodynamic stress-induced vascular remodelling although our integrated 
analyses in Chapter 3 suggested that genetic factors may be equally operative (Robicsek et 
al., 2004, Hope et al., 2010, Hinton, 2012). Irrespective of potential underlying mechanisms, 
the end-result of medial wall degeneration in the BAV ascending aorta has been established 
whereas, to date, no surgical reports have focused on the histopathology of the aortic root in 
the same setting (Girdauskas et al., 2011a, Fedak et al., 2003).  
The central role of increased TGFβ signalling in inherited aortopathy has recently emerged 
(Lindsay and Dietz, 2011, El-Hamamsy and Yacoub, 2009a). TGFβ is a multifunctional 
cytokine, with synthetic and apoptotic properties, that participates in extracellular matrix 
(ECM) homeostasis (Goumans et al., 2009, Owens and Wise, 1997, Cordenonsi et al., 2003). 
Its bioavailability is partially regulated by fibrillin-1 which interacts with the large latent 
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Enhanced TGFβ signalling, as assessed by nuclear phosphorylated Smad2 (pSmad2) 
accummulation, has been reported in syndromic and non-syndromic ascending aortic 
aneurysms, including patients with BAV (Gomez et al., 2009). A hypothesis of lineage-
specific capacity in TGFβ responsiveness has been recently proposed (Lindsay and Dietz, 
2011). The proximal ascending aorta is a mosaic of VSMCs derived from the cardiogenic 
mesoderm (second heart field) and the ectodermal cardiac neural crest (CNC), whereas the 
VSMCs in the aortic root are purely of mesoderm origin (Figure 4.2a) (Lindsay and Dietz, 
2011). Based on experiments on the aorta of chick embryos, ectodermal VSMCs respond to 
TGFβ stimulation with increased DNA synthesis whereas mesodermal VSMCs show little 
activation with growth-inhibition (Topouzis and Majesky, 1996). Thus, in patients with BAV 
it can be hypothesized that the aortic root, which lies on the boundary of the CNC 
developmental field, would respond differentially to primary insults, such as genetic or 
haemodynamic aberrations, compared to the neighbouring ascending aorta. The aim of this 
study was to assess the degree of histological abnormalities and TGFβ signalling in aortic 
segments of distinct embryologic origin, which may explain the occurrence of diverse clinical 
phenotypes in BAV disease.  
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Figure 4.2 Developmental field boundaries in the thoracic ascending aorta (A). Binary nuclear 
pSmad2 activation (B). Two cell populations of either strong (brown nuclei) or absent (blue nuclei) 
pSmad2 signalling can be observed in the ascending aortic media of a patient with bicuspid aortic 
valve (x200 magnification).  
 
4.3 Methods  
4.3.1 Aortic specimens 
Informed consent was obtained from BAV patients planned to undergo surgery at the Royal 
Brompton Hospital, London. During the operation, tissue specimens (4mm x 2mm) were 
collected from the aortic root (within the sinuses) and the distal ascending aorta (>1cm above 
the sinutubular junction). Preoperative CMR imaging (Siemens 1.5T) was used for 
examination of BAV morphological subtypes, presence of valvular disease, and aortic 
diameter measurements.  An electronic calculator was employed for calculation of z-scores at 
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the presented CMR-standardized aortic sites (aortic sinus and ascending aorta at the level of 
the right pulmonary artery) (Kaiser et al., 2008).  
For the control group, age-matched structurally normal hearts were retrieved from patients 
who had not died from cardiovascular disease, held at the Cardiac Morphology Unit and the 
Department of Histopathology of the Royal Brompton Hospital. Coronary sinus and 
ascending aortic sections were obtained from the controls and compared to the surgical tissue 
samples from BAV patients. 
Chapter 2 includes a detailed description of histological and immunohistochemical analyses. 
Figure 4.2b provides an example of image analysis application (Chapter 2) to assess pSmad2 
immunolabeled frame areas of the media.  
4.4 Results 
4.4.1 Patient characteristics 
Aortic tissue specimens from 18 BAV patients (22.5 years, [2-39]) were compared to 12 
controls (27.5 years [6-41]). Three paediatric cases (age < 16 years) were included in each 
group. Thirteen out of the 18 BAV patients underwent targeted sequencing for a number of 
genes related to inherited aortopathy and BAV disease (results included in Table 4.6 under 
discussion, detailed description in Chapter 7). The majority of BAV patients (67%) were 
male and underwent aortic root replacement (50%). All BAV patients had valvular disease 
with predominant AR in 67% (Table 4.1). Standardized z-scores were used for assessment of 
aortic diameters in BAV subjects due to their wide age range. In the aortic root, median z-
score was 4.91, [-1.14–9.94], with normal diameter (-2 ≤ z < 2) in 6 (33%), mild dilation (2 ≤ 
z < 4) in 1 (6%), and marked dilatation (z ≥ 4) in 11 (61%) patients.  Median z-score in the 
ascending aorta was 7.14, [1.19–16.72], with normal diameter in 2 (12%), mild dilation in 3 
(17%), and marked dilatation in 13 (72%) patients. 
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As this was a relatively young population of BAV patients, none of the recruited subjects had 
any acquired cardiovascular disease risk factors or was on any anti-hypertensive 
pharmacological treatment, including ACE-inhibitors and angiotensin receptor blockers 
(ARBs) that might have affected the degree of pSmad2 signalling. 
Table 4.1. Patient characteristics. CoA, coarctation of the aorta; CVD, cardiovascular 
disease; L-N, fusion of left and non-coronary leaflets; PDA, patent arterial duct; R-L, fusion 
of right and left-coronary leaflets; R-N, fusion of right and non-coronary leaflets; VSD, 
ventricular septal defect. 
Patient characteristics (n=18) 
Age (y) 22.5 (2–39) 
Male gender (n, %) 12 (66.7) 
BAV type (n, %) 
True 
R-N 
R-L 
L-N 
Not available 
 
6 (33.3) 
5 (27.8) 
4 (22.2) 
1 (5.6) 
2 (11.1) 
Predominant BAV disease (n, %) 
Aortic regurgitation 
Aortic stenosis 
 
12 (66.7) 
6 (33.3) 
Type of operation (n, %) 
Ross 
Root replacement 
Bentall 
 
7 (38.8) 
9 (50) 
2 (11.2) 
Z score (median, range) 
Aortic root 
Ascending aorta 
 
4.91 (-1.14–9.94) 
7.14 (1.19–16.72) 
CVD risk factors (n, %) 
Hypertension 
Diabetes 
Smoking 
Other CHD lesions (n, %) 
VSD 
CoA 
PDA 
 
0 (0) 
0 (0) 
0 (0) 
 
2 (11.1) 
0 (0) 
1 (5.5) 
 
4.4.2 Histological findings 
Severe medial wall abnormalities (≥ grade 2) were present in the aorta of BAV patients 
(Table 4.2). Paired analyses revealed significantly greater elastic fragmentation (12, 66.7% 
versus 6, 33.3%; p=0.034) and fibrosis (11, 61.1% versus 4, 22.2%, p=0.02) in the ascending 
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aorta compared to the aortic root of BAV subjects. Cyst-like formations occurred with similar 
frequency in the ascending aorta and root (8, 44.4% versus 10, 55.6%; p=0.48) whereas 
medionecrosis was absent in both segments.  The overall histology grading score was greater 
in BAV patients compared to controls, both in the root (p<0.001)  and in the ascending 
aorta (p<0.001; Table 4.2). Paired analysis in BAV patients reported a higher cumulative 
histology grading score in the ascending aorta compared to the root (5.5, [2-9] versus 4, [2-7]; 
p=0.004).  
Table 4.2 Histological abnormalities in examined aortic specimens. 
Variable 
      Control (n=12) 
Root          Ascending   
                aorta 
           BAV (n=18) 
Root          Ascending   
                Aorta 
P value* 
Histological Abnormalities  
(≥ grade 2), n (%) 
Elastic Fragmentation 
Fibrosis 
Medionecrosis 
Cyst-like formations 
 
 
0 (0) 
2 (16.7) 
0 (0) 
0( 0) 
 
 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
 
 
6 (33.3) 
4 (22.2) 
0 (0) 
10 (55.6) 
 
 
12 (66.7) 
11 (61.1) 
0 (0) 
8 (44.4) 
 
 
0.034 
0.02 
1 
0.48 
Histology grading score, 
median (range) 
1 (0-3) 1 (0-1) 4 (2-7) 5.5 (2-9) 0.004 
* Aortic root versus ascending aorta in BAV patients (paired analysis) 
 
No differences in histology grading score were noticed when BAV patients were subdivided 
by morphological subtypes.  Paired analysis revealed a significantly higher histology score in 
the ascending aorta compared to the root (6, [2-9] versus 4, [2-6]; p=0.026) of BAV patients 
with regurgitant valve disease. No other histological differences were noticed between 
regurgitant and stenotic BAVs (Table 4.4).  Overall, BAV patients with either ascending 
aortic or root dilatation (z-score ≥ 2) had greater medial wall degeneration in their ascending 
aorta compared to the root (paired analysis, Table 4.5). Similarly, comparison between BAV 
patients without and with aortic root dilatation, revealed significantly greater histology scores 
in the ascending aorta of the latter (4, [2-6] versus 6, [3-9]; p=0.029). 
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4.4.3 Immunohistochemical findings 
Immohistochemical staining for pSmad2 was significantly greater in all three aortic wall 
layers of BAV patients compared to controls (Table 4.3, Figure 4.5). The cumulative pSmad2 
staining was higher in the aortic root (38.1, [17-58] versus 12.1, [2-29]; p<0.001) and the 
ascending aorta (40.3, [8-49] versus 8.2, [4-37]; p<0.001) of BAV patients compared to 
controls (Table 4.3). Within BAV patients, there were no significant differences in pSmad2 
signalling between the ascending aorta and the aortic root, both as a cumulative total 
percentage and in any of the separate aortic wall layers (Table 4.3). 
Table 4.3 Percentage of pSmad2 signalling in patients and controls. 
 
Morphological subtypes of BAV did not differ in levels of pSmad2 activation. Patients with 
regurgitant BAV disease had higher pSmad2 signalling in the media of the ascending aorta 
compared to those with stenotic valvular disease (44.6, [24-54] versus 18.1, [4-38]; p=0.001, 
Table 4.4). In contrast, paired analyses revealed that patients with stenotic BAVs had greater 
pSmad2 activation in the aortic root compared to the ascending aortic media (35.4, [30-61] 
versus 18.1, [4-38]; p=0.046, Table 4.4). No differences in pSmad2 activation in the media 
were noticed between patients with or without aortic dilation (z-score < 2) in either the root 
or the ascending aorta (Table 4.5). Patients without aortic root dilatation had greater pSmad2 
pSmad2% BAV (n=18) Control (n=12) p value 
Aortic root 
Intima 38.2 (6-79) 11.5 (2-19) 0.001 
Media 38.7 (14-61) 10.7 (2-36) <0.001 
Adventitia 39.9 (25-59) 7.6 (2-15) <0.001 
Total 38.1 (17-58) 12.1 (2-29) <0.001 
Ascending Aorta 
Intima 30.5 (8-54) 7.6 (6-17) <0.001 
Media 40.3 (4-54) 7.9 (3-46) 0.001 
Adventitia 43.9 (10-74) 10.2 (4-19) <0.001 
Total 40.3 (8-49) 8.2 (4-37) <0.001 
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signalling in the adventitia of their ascending aorta compared to those with root dilatation 
(55.8, [22-74] versus  29.1, [10-60]; p=0.039, Table 4.5). Paired analysis in BAV patients 
with aortic roots of normal diameters reported higher pSmad2 activation in the intima of the 
aortic root compared to the ascending aorta (41.4, [22-73] versus 22.8, [8-41]; p=0.046, Table 
4.5).  
In the overall population, a positive correlation was noticed between the percentage of 
pSmad2 signalling in the media and the degree of medial wall abnormalities, both in the 
aortic root (ρ=0.57; p=0.001) and the ascending aorta (ρ=0.6; p<0.001, Figure 4.3). When the 
grading score was broken down to its histological features, positive correlations were 
observed between pSmad2 activation in the ascending aortic media and the respective degree 
of elastic fragmentation (ρ=0.49; p=0.006), fibrosis (ρ=0.39; p=0.033), and cyst-like 
formations (ρ=0.59; p=0.001). In the aortic root, positive associations were noticed between 
pSmad2 signalling in the media and the levels of elastic fragmentation (ρ=0.38; p=0.036) and 
cyst-like formations (ρ=0.64; p<0.001) in the same area. 
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Table 4.4 Histological and immunohistochemical findings divided by aortic valvular disease.  
Variable Controls (n=12) Regurgitant BAV (n=12) Stenotic BAV (n=6) P value* 
Intima pSmad2% 
Aortic root 
Ascending aorta 
 
11.5 (2-19) 
7.6 (6-17) 
 
31.1 (6-73) 
34.9 (8-54) 
 
43.5 (8-79) 
23 (10-45) 
 
0.38 
0.43 
Media pSmad2% 
Aortic root 
Ascending aorta 
 
10.7 (2-36) 
11.8 (3-46) 
 
39.2 (14-58) 
44.6 (24-54) 
 
35.4 (30-61) † 
18.1 (4-38) 
 
0.96 
0.001 
Adventitia pSmad2% 
Aortic root 
Ascending aorta 
 
7.6 (2-15) 
10.2 (4-19) 
 
39.8 (25-59) 
48.8 (10-74) 
 
36.9 (25-53) 
22.5 (15-61) 
 
0.75 
0.49 
Total pSmad2% 
Aortic root 
Ascending aorta 
 
10.8 (2-29) 
8.2 (4-37) 
 
38.1 (17-58) 
43 (21-49) 
 
37.2 (30-52) † 
21 (8-41) 
 
0.89 
0.003 
Histology grading score 
Aortic root 
Ascending aorta 
 
 
1 (0-3) 
1 (0-1) 
 
 
   4 (2-6) † 
6 (2-9) 
 
 
3 (2-7) 
4 (4-6) 
 
 
0.39 
0.55 
* Regurgitant versus stenotic BAV; †P <0.05, aortic root versus ascending aorta (Wilcoxon signed-rank test). 
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Table 4.5 Histological and immunohistochemical findings divided by absence (z-score < 2) or presence (z-score ≥ 2) of aortic dilatation. 
Variable 
Aortic root 
 Z < 2 (n=6) 
Aortic root  
Z ≥ 2 (n=12) 
P value*¹ 
Ascending aorta 
Z < 2 (n=2) 
Ascending  aorta 
Z ≥ 2 (n=16) 
P value*² 
Intima pSmad2% 
Aortic root 
Ascending aorta 
 
  41.4 (22-73) † 
22.8 (8-41) 
 
25.2 (6-79) 
33.6 (10-54) 
 
0.26 
0.30 
 
40.5 (8-73) 
32 (23-41) 
 
38 (6-79) 
30.6 (8-54) 
 
0.89 
0.78 
Media pSmad2% 
Aortic root 
Ascending aorta 
 
36.5 (30-52) 
41.4 (18-47) 
 
40.2 (14-61) 
39 (4-54) 
 
0.57 
0.77 
 
34.9 (31-38) 
24.3 (4-44) 
 
39.3 (14-61) 
40.3 (14-54) 
 
0.48 
0.39 
Adventitia pSmad2% 
Aortic root 
Ascending aorta 
 
37.6 (34-55) 
55.8 (22-74) 
 
39.3 (25-59) 
29.1 (10-60) 
 
0.92 
0.039 
 
36.4 (36-37) 
34.9 (21-48) 
 
39.9 (25-29) 
44.4 (10-74) 
 
0.39 
0.57 
Total pSmad2% 
Aortic root 
Ascending aorta 
 
38.6 (32-46) 
41.7 (19-45) 
 
36.8 (17-58) 
34.9 (8-49) 
 
0.92 
0.77 
 
34.8 (30-39) 
26.2 (8-45) 
 
38.1 (17-58) 
40.3 (19-49) 
 
0.67 
0.57 
Histology grading score 
Aortic root 
Ascending aorta 
 
2.5 (2-5) 
4 (2-6) 
 
  4 (2-7) † 
6 (3-9) 
 
0.12 
0.029 
 
4.5 (4-5) 
5 (4-6) 
 
 3.5 (2-7)† 
5.5 (2-9) 
 
0.39 
0.94 
*¹ Z score < 2 versus Z > 2 in the aortic root; *² Z score < 2 versus Z > 2 in the ascending aorta; †P <0.05, aortic root versus ascending aorta 
(paired analysis) 
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Figure 4.3 Correlation between medial pSmad2 signalling and histology grading score. The cumulative histology grading score for medial wall 
abnormalities in the aortic root (A) and the ascending aorta (B) correlated positively with the respective degree of pSmad2 signalling in the overall 
population. 
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Figure 4.5 Representative overview of medial wall abnormalities and pSmad2 signalling in adjacent serial sections of the aortic root and the 
ascending aorta. The initrarily aligned and sparser elastic lamellae (purple, marked with arrows) of the healthy aortic root media can be seen in the elastic 
van Gieson (EVG) stained-sections. Immunolabelling for pSmad2 was uniformly distributed in the media of BAV patients and located in the proximity of 
mucoid degeneration areas (pale blue; corresponding alcian blue-stained sections, marked with asterisks). x200 magnification in all sections. 
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4.5 Discussion 
This study demonstrates that severe structural abnormalities are present in the media of the 
aortic root and the ascending aorta of BAV patients, with an overall greater histology grading 
score in the ascending aortic segment, even in the presence of aortic root dilatation. Enhanced 
nuclear pSmad2 signaling was observed in the VSMCs of all aortic wall layers of BAV 
patients, with the presence of two distinct populations with either strong or absent 
immunostaining in both studied aortic segments.  In the overall population, a positive 
correlation was noticed between the degree of medial pSmad2 activation and corresponding 
histology grading score in the aortic root and the ascending aorta, respectively.  
4.5.1 The dilated root phenotype 
Despite the existence of extensive literature on histological abnormalities of the dilated 
ascending aorta of BAV patients, the often affected aortic root in the same cohort has rarely 
been investigated (Girdauskas et al., 2011a). Aneurysms of the sinuses of Valsalva are 
infrequent and can be acquired or congenital, with concomitant valve abnormalities found in 
approximately 10% of patients (Ott, 2006).  The relative paucity of the aneurysmal aortic root 
may also account for the lack of information on the morphology of the healthy sinuses 
(Iliopoulos et al., 2013). As illustrated by our histological findings and in agreement with a 
recent communication, the “bulge-shaped” non-pathologic sinuses have a more complex 
medial microstructure with arbitrarily aligned and sparser elastic lamellae compared to the 
bordering ascending aorta with coherent circumferential alignment of its elastic components 
(Figure 4.5) (Iliopoulos et al., 2013). This observation is of particular importance to future 
histological studies addressing the aneurysmal aortic root which mandates consideration of 
the less symmetric morphology of the healthy sinuses.  
The “aortic root phenotype” has been increasingly recognized in BAV disease with up to 
15% of affected patients presenting at a young age with predominant dilatation at the level of 
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the sinuses and various degrees of accompanying aortic valve annular dilatation with aortic 
insufficiency (Della Corte et al., 2007). Flow-induced changes secondary to BAV 
morphological variations may account for the observed different risks of aortic dilatation; 
fusion of the coronary leaflets has been linked to aortic root enlargement at a younger age 
whereas fusion of the right and non-coronary leaflets correlated with increased aortic arch 
dimensions (Schaefer et al., 2008, Schaefer et al., 2007, Russo et al., 2008). In this study, no 
histological differences were noticed between diverse BAV morphological subtypes. 
However, a greater histology grading score was observed in the ascending aorta compared to 
the root of patients with regurgitant BAV disease (Table 4.4). Similarly, BAV patients with 
root dilatation had greater degrees of medial wall degeneration in their ascending aorta 
compared to those without (Table 4.5). The above findings are in agreement with Roberts et 
al. who reported a much greater likelihood of significant elastic fragmentation in the 
ascending aorta of BAV patients with pure AR (Roberts et al., 2011).  These observations 
would support the application of a lower threshold for surgical replacement of the BAV 
dilated ascending aorta in the instance of concomitant aortic root dilatation and/or 
predominant regurgitant valve disease (Roberts et al., 2011).  
The genetic origin of BAV aortopathy has been supported by evidence of progressive 
ascending aortic dilatation following isolated aortic valve replacement (AVR), and thus 
removal of any additive haemodynamic factors secondary to the malformed valve 
(Girdauskas et al., 2011a). In contrast, incremental enlargement of the sinuses of Valsalva has 
rarely been reported following AVR (Park et al., 2011). In this study, when only BAV 
patients with present aortic root or ascending aortic dilatation (z-score ≥ 2) were considered, 
paired analyses reported a consistently higher histology grading score in the ascending aorta 
compared to the root of both groups (Table 4.5). Thus, this finding could explain the lower 
observed rates of aortic root dilatation in BAV disease and may advocate a more judicious 
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approach to prophylactic aortic root replacement in the presence of moderately dilated 
sinuses of Valsalva (Park et al., 2011).  
4.5.2 TGFβ signalling 
The culprit lesion in BAV aortic wall disease remains unknown although recent evidence 
point to a shared activation of the TGFβ/Smad pathway in TAAs of diverse aetiology, with 
the common end-result of medial wall degeneration (Milewicz et al., 2008, Gomez et al., 
2009). High levels of pSmad2 activation have been observed in the aneurysmal ascending 
aorta of patients with syndromic TAA, such as MFS and LDS syndrome, and other non-
syndromic forms including BAV and degenerative disease (Gomez et al., 2009, Maleszewski 
et al., 2009).  Gomez et al. reported an average 46% nuclear pSmad2 staining in the media of 
the dilated ascending aorta of 15 BAV patients compared to our 40% in 16 BAV subjects 
with a respective z-score ≥ 2 (Table 4.5) (Gomez et al., 2009). Notably, the not-previously 
investigated aortic root and non-dilated ascending aorta were also examined in our study with 
significantly higher pSmad2 activation in BAV patients compared to controls (Tables 4.3, 
4.5). Similarly to previous findings, pSmad2 immunolabelling was uniformly distributed in 
the media and located in the proximity of mucoid degeneration areas (Figure 4.5) (Gomez et 
al., 2009, Maleszewski et al., 2009). Overall, a positive correlation was noticed between the 
percentage of pSmad2 signalling in the media and the degree of medial wall abnormalities, 
both in the aortic root and the ascending aorta, which was in agreement with Gomez et al. 
who reported a similar association between the cumulative medial pSmad2 activation and 
elastic fragmentation in the aneurysmal ascending aortic wall of different aetiologies (Figure 
4.4) (Gomez et al., 2009).  
Despite the above associations, the exact sequence of mechanisms leading to medial wall 
degeneration downstream TGFβ signalling remains elusive (Figure 4.1). The general 
mechanistic hypothesis in MFS is that fibrillin-1 (FBN1) deficiency, secondary to FBN1 gene 
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mutations, makes sequestered TGFβ more accessible to activation with subsequent matrix 
proteolysis via release of MMP-2 and -9 (El-Hamamsy and Yacoub, 2009a, Carta et al., 
2009). The paradox of amplified TGFβ signalling in LDS patients with TGFBR1 or TGFBR2 
mutations is less well understood with potential mechanisms including activation of 
SMAD2/3 in response to TGFβ1 by other signalling mediators without direct interaction with 
TGFβ receptors (Jones et al., 2009, Gomez et al., 2009). Preliminary genetic sequencing in 
13 out of 18 BAV subjects participating in this study revealed novel variants in the NOTCH1 
gene, which has been linked to calcified BAV disease and associated aneurysm formation 
(Table 4.6) (Garg et al., 2005). Despite the reported absence of FBN1 gene mutations in 
isolated BAV disease in the literature, a reduction in fibrillin-1 expression in the extracellular 
matrix of dilated BAV aortas has been described and in fact, two of our studied subjects 
tested positive for FBN1 mutations which merit further investigation (Laforest and Nemer, 
2012, Nataatmadja et al., 2003). None of our sequenced patients tested positive for mutations 
in TGFBR1 or TGFBR2 genes, although a single patient had a mutation in the gene encoding 
for TGFβ1. Finally, all genetically tested patients carried a SMAD3 known common variant, 
albeit mutations in this gene have been linked to aortic aneurysms with early-onset 
osteoarthritis (van de Laar et al., 2011). Next-generation sequencing results are discussed in 
more detail in Chapter 7. 
Table 4.6 Next-generation sequencing results (selected genes) in BAV patients. AA; 
amino-acid, * mutations in the same individual. 
BAV  
subjects (n) 
Gene AA change Clinical significance 
13/13 SMAD3 Tyr85Cys Common variant 
3/13 NOTCH1 
Ser2170Asn* 
Asn197Lys 
Arg1761Gln 
Novel (putative benign) 
Novel (probably damaging) 
Novel (possibly damaging) 
2/13 FBN1 
Val670Met 
Pro809Leu* 
Probable-pathogenic 
Novel (probably damaging) 
1/13 TGFB1 Leu8Met Novel (probably damaging)  
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Another potential mechanism underlying increased TGFβ signalling in aortopathy relates to 
the embryologic origin of VSMCs in neighbouring thoracic aortic segments and their 
differential TGFβ responsiveness (Figure 4.2a) (Topouzis and Majesky, 1996, Lindsay and 
Dietz, 2011). It is hypothesized that VSMCs in the aortic root and neighbouring ascending 
aorta respond differentially to primary insults, such as FBN1 deficiency or loss of function 
mutations of TGFBR1 and TGFBR2, with the more “vulnerable” mesodermal cells in the 
root loosing TGFβ feedback inhibition and the more “tolerant” ectodermal cells in the 
ascending aorta responding to compensatory mechanisms of increased TGFβ ligand 
expression (Lindsay and Dietz, 2011). The binary status of nuclear pSmad2 signalling, with 
either strong or absent activity in VSMCs of the media, as shown in the aortic root of a LDS 
patient by Lindsay et al. and in BAV disease by our study, would favour this theory (Figure 
4.2b) (Lindsay and Dietz, 2011). However, we were unable to detect any significant 
differences across all aortic wall layers in the degree of pSmad2 immuno-labelling between 
the BAV aortic root and ascending aorta (Table 4.1).  
Overall, the initial trigger for increased TGFβ signalling in the BAV aorta remains to be 
identified, although the presence of equally increased pSmad2 activation in dilated and non-
dilated aortic segments points to a genetic substrate (Table 4.5). VSMCs have also been 
shown to be responsive to haemodynamic perturbations with downstream alteration of their 
proliferative, contractile, or synthetic properties, including TGFβ1 expression induced by 
increased shear stress (El-Hamamsy and Yacoub, 2009a, Topper et al., 1996, Ohno et al., 
1995). However, unexpected findings were revealed upon examination of the haemodynamic 
influence on pSmad2 activation; patients with regurgitant BAV disease had increased 
signalling in their ascending aorta whereas paired analyses revealed higher signals in the 
aortic root of patients with stenotic BAV disease (Table 4.4). If haemodynamic alterations 
were indeed in operation, the opposite effect would be expected, as regurgitant BAVs are 
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thought to increase wall tension, due to higher stroke volumes, and correlate with aortic root 
dilatation whereas stenotic BAVs generate a high-velocity jet imposing increased 
longitudinal stress on the ascending aorta (Tadros et al., 2009).  
4.5.3 Limitations 
This study is limited by the small number of tissue samples and longer formalin-fixation of 
control samples (stored at the biobank of the Cardiac Morphology Unit, Royal Brompton 
Hospital) which may have affected our immunohistochemical analyses. However, it is the 
first study of its kind including histology of both the aortic root and ascending aortic 
segments with uniform application of optimized pSmad2 antibody concentration in all 
studied tissue samples. Genetic testing was available in a subset of BAV patients and merits 
further validation. Immunostaining for TGFβ1 and potential co-localization with pSmad2 
activation was not performed, albeit outside the scope of this study which was to provide 
preliminary data on the aortic root phenotype in BAV disease. Sub-group analyses in BAV 
patients with and without aortic dilatation may have been underpowered due to the limited 
number of patients in the non-dilated groups. Interquartile range of z-scores could have been 
used to sub-divide our population as an alternative method. However, it was decided to use 
the cut-off z score of greater or less than 2, for clinically relevant interpretation of data.  
4.6 Conclusions 
Patients with BAV have marked histological abnormalities in both their aortic root and 
ascending aorta. The dilated aortic root phenotype may represent the primarily genetic form 
of BAV disease as patients with either root dilatation and/or predominant regurgitant valve 
disease had greater levels of medial wall degeneration in their ascending aorta. In contrast, 
structural abnormalities in the aortic root per se were lower compared to these seen in the 
ascending aorta, even in the presence of root dilatation, and may advocate a more judicious 
approach to prophylactic aortic root replacement in this cohort. Increased nuclear pSmad2 
 121 
signalling was observed in the BAV aorta and did not differ significantly between the 
mesoderm-derived root and the ectoderm-derived ascending aorta. The presence of enhanced 
pSmad2 activation in non-dilated BAV aortic segments points to a genetic trigger whereas 
any haemodynamic influence secondary to valvular disease appears less operative. It was 
thus, decided to further investigate the genetic basis of BAV disease and associated 
aortopathy with application of state-of-the-art genetic sequencing tools (Chapters 6 and 7). 
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Chapter 5. PAH model of aortopathy  
 
Abbreviations 
Ao Aortic 
ASD Atrial septal defect 
ASO arterial switch operation  
BAV Bicuspid aortic valve 
CHD Congenital heart disease 
ES Eisenmenger syndrome 
HGS Histology grading score 
LPA Left pulmonary artery 
LV Left ventricular 
MFS Marfan syndrome 
PAH Pulmonary arterial hypertension 
PDA Patent arterial duct 
PT Pulmonary trunk 
PT/Ao MT Pulmonary trunk-to-aortic media thickness 
RPA Right pulmonary artery 
STJ Sinutubular junction 
TAA Thoracic aortic aneurysm 
TGA Transposition of the great arteries 
TOF Tetralogy of Fallot 
VSD Ventricular septal defect 
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5.2 Abstract 
Background: Pulmonary arterial hypertension (PAH) is considered primarily a disease of the 
distal pulmonary arteries but also affects the larger proximal pulmonary arteries causing them 
to become aneurysmal. With this study, we aimed to examine arterial wall remodelling in 
PAH associated with CHD, which can serve as an aortopathy model for medial wall changes 
in relation to elevated haemodynamic stress.  
Methods: Tissue samples from the great arteries (pulmonary trunk and aorta) of 10 formalin-
fixed human hearts from patients with PAH/CHD were examined via light microscopy and 
compared to age-matched healthy controls. A detailed histology grading score was used to 
assess the severity of medial wall abnormalities. 
Results: Significant medial wall abnormalities (grade ≥ 2) were present in the pulmonary 
trunk (PT), including fibrosis (80%), and atypical elastic pattern (80%). Cyst-like formations 
were present in less than one third of patients and were severe in a single case leading to wall 
rupture. The cumulative PT histology grading score was significantly higher in PAH/CHD 
cases compared to controls (p<0.0001) and correlated positively with larger vessel diameter 
(ρ=0.812, p<0.0001) and greater degrees of medial wall hypertrophy (ρ=0.749, p<0.0001). 
Significant medial wall abnormalities were also found in the aorta of PAH/CHD patients, 
including fibrosis (60%), elastic fragmentation (10%), and medionecrosis (10%).  
Conclusion: Chronic PAH in association with CHD results in marked medial wall 
abnormalities in the large pulmonary arteries. Structural defects also existed in the aorta of 
PAH/CHD patients, suggestive of inherent abnormalities of the great arterial walls which are 
further enhanced in the PT due to elevated intravascular pressures.  
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5.3 Introduction 
As seen in Chapters 3 & 4, medial wall abnormalities are found at different segments of the 
BAV aorta and their asymmetrical patterns of dilatation may be owing to haemodynamic 
vascular remodelling on the background of an inherent structural weakness. Histological 
abnormalities underlying TAA formation and dissection have been described as early as the 
1930s with the term “cystic medial necrosis” established by Erdheim, although later disputed 
(Niwa et al., 2001, Erdheim, 1930). MFS has served as the typical aortopathy model in 
inherited TAA disease since the discovery of causative fibrillin-1 mutations by Dietz and 
colleagues in 1991 (Dietz et al., 1991). As thoracic aortic complications in patients with 
congenital heart disease (CHD) became increasingly recognised, research focus broadened 
from connective tissue disorders to a wide array of inborn heart defects. In fact, medial wall 
abnormalities, similar to those seen in MFS and BAV, have been described in a wider range 
of disparate congenital heart defects, including coarctation of the aorta, Tetralogy of Fallot 
(TOF), complete transposition of the great arteries (TGA), atrial septal defect (ASD) and 
ventricular septal defect (VSD) (Niwa et al., 2001).  
The above abnormalities can affect both the proximal aorta and pulmonary trunks of CHD 
patients and are thought to be associated with or account for progressive vessel wall dilatation 
with aneurysm formation and rupture. Approximately 10% of adults with CHD develop PAH 
of variable severity, with Eisenmenger syndrome representing its extreme manifestation 
(Diller and Gatzoulis, 2007). Apart from the distal small muscular pulmonary arteries, the 
pulmonary trunk and its large elastic branches are also affected in this setting, with previous 
reports of aneurysmal dilatation, atherosclerosis and thrombosis (Heath et al., 1960, Daliento 
et al., 2002, Broberg et al., 2007). It remains unknown whether structural defects of the 
pulmonary trunk wall is purely the result of distal pulmonary vascular disease and PAH or 
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whether there is an additional contribution from the above described intrinsic abnormalities 
associated with the underlying cardiac defect (Botney, 1999, Prapa et al., 2013). 
Normally, morphological changes in the elastic pulmonary artery take place after birth and 
relate to the imposed intravascular pressures. Due to the presence of pulmonary hypertension 
in the healthy foetus, the media of the pulmonary trunk resembles that of the aorta during the 
first six months of life, with long, parallel and uniform elastic lamellae (Heath and Edwards, 
1960). By the second year, pressures in the pulmonary artery fall and the media acquires its 
normal “adult” configuration with short fragmented fibrils and sparser elastic tissue. In 
patients with CHD associated with pulmonary hypertension, the pulmonary trunk may retain 
its “aortic” configuration or undergo transition to its “adult” elastic pattern, depending on 
whether the hypertension dates from birth or develops later in life (Heath and Edwards, 
1960). 
Aneurysms of the hypertensive pulmonary trunk have been described in a number of CHD 
lesions, including PDA, ASD, VSD, and TGA with nonrestrictive VSD (Niwa et al., 2001, 
Veldtman et al., 2003). The aim of this study was to assess the histological features of the 
large elastic pulmonary arteries and aorta in adult patients with PAH/CHD, with an aim to 
apply this knowledge to an ‘aortopathy’ model for haemodynamically-induced vascular 
remodelling in the setting of BAV, as investigated in Chapter 3.  
5.4 Methods 
5.4.1 Tissue specimens 
Heart specimens from adult PAH/CHD patients, who died between 1975 and 1999, were 
retrieved from our cardiac morphology archive (Royal Brompton Hospital, London, UK) of 
formalin-fixed hearts. For the control group, age-matched structurally normal hearts were 
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retrieved from subjects who were not known to have suffered from any congenital heart 
abnormality and had not died from a cardiovascular cause.  
5.4.2 Macroscopic analysis 
Circumference measurements of the luminal surface of the pulmonary trunk (PT) and aorta 
were made 5mm above the sinutubular junction (STJ) with additional measurements of the 
internal circumference of the right and left main pulmonary artery (RPA and LPA), just 
above the PT bifurcation. All diameter measurements were indexed to the length of the left 
ventricle (LV), defined as the left atrioventricular junction to left ventricular apex distance, to 
account for differences in age/patient size and presence of a rudimentary morphological right 
ventricle in 3 patients with congenital heart defects.  
5.4.3 Microscopic analysis 
Full thickness sections of the PT and aorta were dissected 5mm distally to the STJ. RPA and 
LPA sections were obtained directly above the bifurcation level. Chapter 2 provides a 
detailed description of histological analyses undertaken for examination of the aorta. The 
same methods were used for examination of the elastic pulmonary arteries (PT, RPA and 
LPA) which were also assessed for medionecrosis, fibrosis, and cystic-like formations, 
applying histological criteria adopted for the pulmonary artery (grades 0-3) (Bedard et al., 
2009, de Sa et al., 1999).  
As described above, by the second year of life the healthy PT looses its resemblance to the 
aorta and acquires its adult pattern with short fragmented fibrils and sparser elastic tissue. 
The media also becomes thinner with a pulmonary trunk-to-aortic media thickness (PT/Ao 
MT) ratio of 0.4 to 0.7 (Heath et al., 1959). In this study, the PT elastic tissue configuration 
was examined using the Heath classification and the PT/Ao MT ratio was calculated (Heath 
and Edwards, 1960). Due to these physiological morphologic adaptations of the PT, an 
‘inversed’ score was used to evaluate the severity of elastic fragmentation in the pulmonary 
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arteries compared to that of the aorta. Thus, specimens with the normal pulmonary pattern of 
short, overlapping and fragmented lamellae were graded as 0 whereas those with complete 
absence of elastic fragmentation resembling the ‘aortic’ phenotype (Heath and Edwards, 
1960), were classified as grade 3 atypical elastic pattern (Figure 5.1c).  
The elastic components of the PT and aortic media were also examined using elastic van 
Gieson stain and colour image analysis (Quantimet 500C QWIN V02.00B, Leica, 
Cambridge, UK) (Salih et al., 2004). Following identification of populations of elastic fibres 
crossing the midline of a frame area (20x magnification), the percentage of elastin and 
collagen exhibiting staining for each population was measured. For each examined tissue 
specimen, the mean elastin/collagen ratio was calculated by obtaining a percentage of elastin 
and collagen in 5 frame areas. 
5.4.4 Histology grading scores 
As detailed in Chapter 2, a histology grading score (HGS) was calculated to assess the 
severity of medial wall abnormalities in the great arteries (Tan et al., 2005). In the case of the 
pulmonary arteries, the HGS included the ‘atypical elastic pattern’ (grades 0 to 3) described 
above to report the severity of elastic fragmentation. 
5.5 Results 
Tissue specimens were collected from 10 formalin-fixed hearts from adult PAH/CHD 
patients (29.5 years, [22 years-83 years]) and compared to 10 healthy controls (44.5 years, 
[19years-70 years]). Patient clinical characteristics are summarised in Table 5.1. None of the 
CHD patients had undergone surgery apart from the 24-year-old female with situs inversus 
and ASD who underwent atrial partition with mitral valve repair at the age of 19 years. 
Branch pulmonary arteries were not available in the control hearts and the LPA was not 
available in a single PAH/CHD patient. 
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Table 5.1 Patient characteristics. Abbreviations: ASD, atrial septal defect; CFH, congestive 
heart failure; DILV, double inlet left ventricle; LPA, left pulmonary artery; MV, mitral valve; 
PDA, patent ductus arteriosus; PAH, pulmonary arterial hypertension; TGA, transposition of 
the great arteries; TV, tricuspid valve; VSD, ventricular septal defect; SCD, sudden cardiac 
death 
Age deceased Gender Mode of death CHD Lung histology 
22y male CHF 
TV atresia, ASD, 
VSD 
Medial/intimal 
hyperplasia 
24y female SCD 
Situs inversus, 
ASD, cleft MV 
Medial/intimal 
hyperplasia 
29y male SCD DILV, VSD, PDA 
Dilated plexiform 
lesions 
29y female CHF VSD, PDA 
Dilated plexiform 
lesions 
29y female Non-cardiac ASD, VSD, PDA 
Dilated plexiform 
lesions 
30y male CHF DILV, TGA, VSD 
Mild hypertensive 
changes 
35y male SCD PDA 
Medial/intimal 
hyperplasia 
55y female CHF PDA 
Dilated plexiform 
lesions 
59y female CHF ASD 
Mild hypertensive 
changes 
83y female CHF ASD 
Consistent with 
PAH but no 
dilatation/plexiform 
lesions 
 
5.5.1 Pulmonary trunk 
The PT/LV index of PAH/CHD patients (median 1.33, [0.94-2.07]) was significantly higher 
compared to controls (0.75, [0.57- 0.92]; p <0.0001). The majority of PAH/CHD patients had 
severe medial wall abnormalities (≥ grade 2) in their PT, including fibrosis (80%) and 
atypical elastic pattern (80%) (Figure 5.2). Only a single case (10%) had medionecrosis and 
cyst-like formations, which were both of mild degree (grade 1). The PT elastic tissue 
configuration was abnormal in all PAH/CHD patients: 8 (80%) had transitional and 2 (20%) 
had aortic configuration (Figure 5.1c). The PT/Ao MT ratio was significantly higher in 
PAH/CHD (1.0, [0.5-1.8]) compared to controls (0.5, [0.4 to 0.7]; p<0.0001). The cumulative 
HGS for PT medial wall abnormalities was significantly higher in PAH/CHD (6, [4 to 7]) 
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compared to controls (3, [2 to 3]; p<0.0001) (Figure 5.3).  Overall, the cumulative PT HGS 
correlated positively with the degree of medial hypertrophy (PT/Ao MT ratio) (ρ=0.749, p 
<0.0001) as well as PT diameter (PT/LV index) (ρ=0.812, p <0.0001) (Figure 5.4).  
5.5.2 Main pulmonary artery branches 
The median diameter of the LPA and RPA at bifurcation level was 2.5cm [1.4-3.1] and 2.1cm 
[1.6-3.5], respectively. Significant medial wall abnormalities (grade ≥ 2) were present in the 
pulmonary artery branches of the majority of patients, including fibrosis (60%, right; 44%, 
left), atypical elastic pattern (90%, right; 100%, left), medionecrosis (20%, right; 22%, left) 
and cyst-like formations (11%, left branch only) (Figure 5.2). All patients had abnormal 
elastic tissue configuration, which was transitional in 90% and aortic in 10% of the RPA 
branches, and transitional in 88% and aortic in 11% of the LPA branches. The cumulative 
HGS was similar in the branches and PT of PAH/CHD patients (PT 6, [4 to 7]) versus LPA 
(5, [4-8]; p=0.72 and RPA (6, [4-7]; p=0.56). 
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5.5.4 Elastic components of the media 
The median elastin/collagen ratio was significantly higher in PAH/CHD patients compared to 
controls (0.78 [0.38-1.64] versus 0.46 [0.38-1.64]; p=0.009). Advanced age correlated with 
lower elastin/collagen ratio in the overall study population (ρ=-0.587, p=0.006) (Figure 5.1b).  
 
 
 
Figure 5.2 Histological changes in the great arteries. Histological changes in the media (≥ grade 2) 
and intima of the pulmonary trunk, right and left pulmonary arteries (RPA, LPA) (A) and aorta (B). 
Significant fibrosis with diffuse intimal thickening were common findings in the pulmonary arteries 
(C*1) whereas cyst-like formations were rarely seen (C*2). Elastic van Gieson (C*1) and alcian blue 
(C*2) stain, magnification x200. 
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Figure 5.3 Histology grading scores (HGS) for the great arteries.  The cumulative HGS for medial 
wall abnormalities in the pulmonary trunk (A) and aorta (B) was significantly higher in PAH/CHD 
cases versus controls.  
 
5.6 Discussion 
In patients with PAH/CHD, histological abnormalities are not restricted in the small muscular 
pulmonary arteries but are also present in the pulmonary trunk and its large elastic branches. 
Commonly encountered histological findings included fibrosis and atypical elastic pattern 
whereas cyst-like formations and medionecrosis were rarely seen, which together with the 
aortic phenotype of the media, may explain the low incidence of dissection of aneurysmal 
PTs in PAH/CHD (Tredal et al., 1974). Structural abnormalities were also found in the aorta 
of PAH/CHD patients, suggestive of inherent abnormalities of the great arterial walls.  
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Figure 5.4 Correlation between PT HGS, vessel diameter and medial hypertrophy.  The 
cumulative histology grading score (HGS) for medial wall abnormalities of the pulmonary trunk (PT) 
correlated positively with the degree of medial wall thickness (A) and larger vessel diameter (B). LV, 
left ventricle.  Patients are depicted in red triangles and controls in blue dots. 
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5.5.1 Medial wall abnormalities in the elastic pulmonary arteries 
Significant abnormalities (grade ≥ 2) were present in the majority of the elastic PAs of 
PAH/CHD patients (Tredal et al., 1974, Niwa et al., 2001). Fibrosis was the predominant 
described histological feature in the media, with atypical architecture of the elastic lamellae 
similar to that of the aorta. Similarly, fibrotic changes were present in the BAV aorta 
(Chapter 3) which correlated strongly with the degree of mechanical stress exerted to the 
aortic wall. Haemodynamic data were incomplete in this data set and thus, correlations 
between stress and histological changes in the hypertensive PT could not be made in analogy 
to the BAV aorta.  However, the significant volume and pressure overload of the pulmonary 
circulation in the setting of PAH may equally account for these changes. 
Arterial wall remodelling in response to increased radial stress has been studied in patients 
with systemic hypertension with findings of altered contribution of the elastic components of 
the media (elastic lamellae fracture and increased collagen turnover) and dilatation of the 
vessel wall dilatation with hypertrophy and increased stiffness (Humphrey, 2008).  In this 
study, a greater elastin/collagen ratio was noticed in the PAH-CHD cases compared to 
controls, with an abundance of collagen as age increased in the overall population (Figure 
5.1b). The close correlation between the above medial changes, vessel size and medial 
hypertrophy (Figure 5.4), supports the pathophysiological link between the severity of PAH 
and the structural abnormalities (Prapa et al., 2013).  
Conversely, cyst-like formations were present in less than one third of PAH patients and only 
in a single case (24y female with situs inversus and atrial septal defect, Table 5.1) were they 
significant (grade 2) and resulted in recurrent wall rupture of the left pulmonary artery, which 
was proven fatal. Medial cyst-like formations have been described as the only potential 
histological feature differentiating the dissecting aorta from normotensive and hypertensive 
controls (Manley, 1964). It has been previously suggested that the relatively low rate of 
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dissection and pulmonary artery rupture in PAH/CHD may be due to the rarity of cyst-like 
formations as an underlying histological feature (Tredal et al., 1974). In patients with BAV, 
cyst-like formations are more frequently found (Chapters 3 and 4) and may reflect a 
proteolytic process which renders the arterial wall susceptible to dissection and rupture. 
5.5.2 Determinants of aortopathy in CHD lesions 
Interestingly, a higher cumulative histology grading score was noted not only in the PT but 
also in the aorta of PAH/CHD cases compared to controls. Inherent abnormalities of the great 
arteries have been previously reported in normotensive subjects with a variety of CHD 
lesions and may reflect the paradigm of BAV disease affecting both of the great vessels, 
possibly due to perturbations in their common embryologic origin, the conotruncus  
(Chapter 1) (Niwa et al., 2001). Similar to the haemodynamic theory of aortopathy in BAV 
disease, the above findings raise the possibility of elevated intravascular pressures further 
enhancing intrinsic structural defects of the pulmonary trunk in the setting of PAH.   
Medial wall abnormalities also exist in the normotensive dilated pulmonary trunk of patients 
with pulmonary valve stenosis, either isolated or as part of TOF (Niwa et al., 2001, Veldtman 
et al., 2003, Bedard et al., 2009). It is postulated that in utero haemodynamic perturbations 
secondary to the malformed pulmonary valve contribute to degeneration of the pulmonary 
artery media, similar to the so-called “post-stenotic” dilatation in BAV disease. Importantly, 
changes in the media of the TOF pulmonary trunk persist even after reparative surgery, 
suggestive of irreversible remodelling of the vessel wall (Bedard et al., 2009) resembling the 
progressive aortic dilation seen in BAV patients following aortic valve replacement (Andrus 
et al., 2003).  
5.5.2 Clinical implications of PT wall abnormalities 
Regardless of the origin of structural abnormalities in the pulmonary artery, their existence 
may have important implications in surgical planning and late post-operative complications. 
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An exemplary case is that of arterial switch operation (ASO) for anatomical repair of 
complete transposition of the great arteries. Medial wall abnormalities are present in the 
pulmonary trunk (neoaorta) leading to development of neoaortic root dilation and aortic 
regurgitation in 16% of patients approximately 5 years following ASO (Losay et al., 2001). 
Similarly, pulmonary valve auto-transplantation (Ross procedure) remains controversial in 
young patients with BAV in need of aortic valve replacement with histological abnormalities 
of the pulmonary root potentially accounting for postoperative pulmonary autograft dilation 
(Chapter 1) (de Sa et al., 1999).   
The histological changes detected in this study are also likely to affect the compliance of the 
proximal pulmonary arteries and have a negative impact on pulmonary perfusion and right 
ventricular function. The healthy PT wall is intrinsically more compliant compared to that of 
the aorta, due to the greater wall thickness of the latter and differences in the medial structure 
(Harris et al., 1965). In PAH, several studies have illustrated reduced extensibility of the PT 
which has been attributed to altered distribution of medial elastic components (Zuckerman et 
al., 1991, Reuben, 1971, Jarmakani et al., 1971). Pulmonary arterial stiffness has a key role in 
the vicious circle of vascular remodelling in PAH, with elastance of the pulmonary 
circulation comprising an essential component of afterload maintenance via adequacy of the 
right ventricular - pulmonary arterial coupling (Wang and Chesler, 2012).  
Narrowing of the distal pulmonary arteries in PAH increases mean pulmonary arterial 
pressure leading to exertion of enhanced circumferential stress to the proximal large 
pulmonary vessels with distension and hypertrophy of the arterial wall (Figure 5.1a). The 
above changes contribute to proximal vascular stiffening which, in turn, results in increased 
downstream flow pulsatility and damage of the microvascular pulmonary endothelium 
(Bedard et al., 2009). Current therapies for PAH are primarily focused on remodelling of the 
small muscular pulmonary arteries (Diller and Gatzoulis, 2007). In view of the significant 
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potential impact of PT stiffness on both the right ventricle and distal vasculature, the large 
elastic pulmonary arteries consist emerging novel therapeutic targets in PAH/CHD. 
5.6 Study limitations  
This study is restricted by the small number of tissue specimens and lack of PT branches in 
control subjects. Indexed PT and aortic diameters could not be compared directly to 
normograms due to the shrinkage of arterial tissue secondary to formalin fixation. However, 
all studied specimens were prepared and stored in similar methods and any changes in 
diameter should be uniform. Despite sufficient clinical information on all CHD subjects, 
haemodynamic data were incomplete and hence not included in the analyses.  
5.7 Conclusion 
Patients with PAH/CHD have marked histological lesions in their proximal elastic pulmonary 
arteries, which correlated positively with increased vessel wall diameter and thickness. 
Fibrosis with atypical architecture of the elastic components of the media were predominant 
features and may constitute novel therapeutic targets in PAH. Structural wall abnormalities 
also existed in the aorta of PAH/CHD patients, suggestive of inherent abnormalities of the 
great arterial walls which are further enhanced in the PT due to elevated intravascular 
pressures. The following chapters (chapter 6 & 7) investigate further the genetic component 
of the aforementioned histological abnormalities contributing to aortopathy in CHD lesions 
and particularly, BAV disease.  
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Chapter 6. Copy number variation 
 
 
Abbreviations 
ACE Angiotensin converting enzyme 
ALP Alkaline phosphatase 
AS Aortic stenosis 
AT1 Angiotensin II receptor type 
AVR Aortic valve replacement 
BAV Bicuspid aortic valve 
CHD Congenital heart disease 
CNV Copy number variation 
CNVE Copy number variation event 
CGH Comparative genomic hybridization 
CNS Central nervous system  
DDR Deletion-to-duplication ratio 
FBN1 Fibrillin-1 
GABA gamma-aminobutyric acid  
HLHS Hypoplastic left heart syndrome 
LOD score Logarithm (base 10) of odds 
LVOTO Left ventricular outflow tract obstruction  
MAD Median absolute deviation 
MFS Marfan syndrome 
QC Quality control 
RAS Renin-angiotensin system 
R-L Fusion of right- and left-coronary leaflets 
SAC Sum of auto-correlation  
TAA Thoracic aortic aneurysm 
TGFβ Transforming growth factor beta 
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6.1 Abstract 
Background: BAV disease encompasses a spectrum of left-sided cardiac lesions with a 
strong, yet not fully elucidated, genetic component. Recent evidence points to the presence of 
chromosomal copy number variants (CNVs) as a cause for inherited and sporadic structural 
heart disease.  In this study, we hypothesized that BAV patients exhibit rare, clinically 
significant CNVs that are not present in healthy controls. 
Methods: Genomic DNA from 94 BAV patients (mean age 35 ± 13years) was hybridized to 
the Affymetrix 6.0 array for CGH and the frequency of identified CNVs was compared to a 
data-set from the Wellcome Trust Control Consortium 2 containing 5,919 genotyped donors 
of European ancestry. 
Results: Post CNV-calling quality control and filtering gave rise to 4,842 CNVs (81.2% 
deletions) with a median size of 23.2kb in 93 BAV patients (single case excluded) and 
341,194 CNVs (78.7% deletions) with a median size of 23.6kb in 5,919 controls. When 
CNVs where clustered into events (CNVEs), a significantly greater incidence of rare 
(frequency < 1%) and large (100-200kb) deletions was detected in sporadic BAV cases 
compared to controls. However, none of the recurrent rare events survived multiple test 
correction for identification of likely pathogenic CNVs. Individual review of CNV calls 
encompassing genes with BAV functional relatedness revealed a 20kb heterozygous deletion 
on chromosome 17 in a single patient, overlapping with more than 2/3 of the ACE gene. 
Additional CNVs encompassing genes expressed in the heart included a recurrent duplication 
on chromosome 2 overlapping ALPPL2 and a single deletion on chromosome X located 1kb 
upstream of GABRE. 
Conclusion: Patients with BAV disease harbour a significantly greater number of rare, large 
deletions compared to controls, although these are unlikely to be clinically significant. 
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Identified CNVs encompassed several genes including ACE, a key element of the 
angiotensin-aldosterone system contributing to vascular function and disease. Future studies 
in larger BAV cohorts and families are needed to assess the role of structural genomic 
variants in this complex disease.  
 
6.2 Introduction 
As discussed in Chapter 1, BAV appears to be a complex heterogeneous trait with a strong 
genetic component; not only is it considered to be a disease of the entire aortic root and 
ascending aorta but also, a part of a broader spectrum of left-sided cardiac malformations 
(Tadros et al., 2009, Hinton et al., 2009). This phenotypic diversity along with the additive 
influence of haemodynamic factors may account for the lack of firm conclusions on the 
genetic basis of BAV disease (Girdauskas et al., 2011a). To date, the majority of investigators 
have adopted a candidate gene approach, focusing mainly on genes encoding proteins of vital 
importance for the conservation of the structural integrity of the aortic wall (FBN1, ACTA2, 
TGFβ) and genes encoding products involved in cardiac development (NKX2.5, UFD1L) 
(Laforest and Nemer, 2012, Guo et al., 2007, Girdauskas et al., 2011b, Majumdar et al., 2006, 
Mohamed et al., 2005, Arrington et al., 2008). Other authors have performed linkage studies 
in affected kindreds, leading to identification of genetically relevant loci (5q, 13q, 18q) and 
mapped genes (NOTCH1 on 9q) (Martin et al., 2007, Garg et al., 2005).   
Array-CGH is a technique which allows the identification of submicroscopic chromosomal 
CNVs at the genome wide level, the resolution of which is platform-specific (Chapter 2). 
The utilisation of this technique has revealed the overlap of CNVs with genes and the 
association of CNVs with levels of gene expression and specific clinical phenotypes (Aitman 
et al., 2006, Fanciulli et al., 2007). Structural genomic variants have also been reported in 
patients with CHD and additional birth malformations, although BAV disease has not been 
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examined in isolation (Thienpont et al., 2007, Richards et al., 2008, Greenway et al., 2009). 
These findings imply that CNVs may account for a significant component of human 
phenotypic variation, including structural heart disease, and can lead to identification of novel 
disease related genes and loci. The aim of this study was to examine the presence of CNVs in 
BAV disease in comparison to a well-characterised large control cohort from the Wellcome 
Trust Control Consortium, Sanger Institute, Cambridge, UK. 
6.3 Methods 
6.3.1 Patient recruitment 
Patient recruitment and phenotypic assessment is described in Chapter 2. Blood samples 
were collected from the majority of patients with alternative collection of saliva from 
participants who refused blood sampling. For the control group, data from the Wellcome 
Trust Control Consortium 2 containing 5,919 genotyped donors of European ancestry were 
used (Bochukova et al., 2010). 
Methods of DNA extraction and purification are included in Chapter 2. 
6.3.2 CNV discovery 
Following DNA extraction, samples were stored at -20˚C and sent to the Wellcome Trust 
Sanger Institute, Cambridge, UK for further quality testing and genotyping. DNA samples 
were run on Affymetrix Genome-Wide Human SNP Array 6.0 (Aros, Inc.), and compared to 
genotyping data from Wellcome Trust Control Consortium 2 donors assayed on the same 
platform. CNVs were discovered separately for cases and controls. 
6.4 Results 
6.4.1 Patient characteristics 
A summary of patient characteristics is included in Table 5.1. The majority of patients were 
male (68%) and had functional BAVs with predominant R-L type (34%). Mean age was 35 
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years; all patients were adults with the exception of a single paediatric case. All genotyped 
BAV patients were isolated cases apart from the 2 year-old child whose father also had a 
BAV and was included in the analyses.  
6.4.2 CNV calling 
Pre-calling sample quality control (QC) 
Raw intensities were regenerated and normalized across samples typed on the same plate 
from .CEL files using Affymetrix Power Tools. Intensities were transformed to log2 ratio 
using the plate median as the reference. A number of statistics, including median and median 
absolute deviation (MAD), were calculated from the log2 ratio for each sample and samples 
with MAD greater than 0.3 were removed (details in following sections). 
CNV calling and QC 
CNVs were called plate by plate using Birdseye from Birdsuite version 1.5.3, which 
generates a LOD score for each call that measures its likelihood of being in the called copy 
number state. A number of summary statistics was produced and parameters checked 
included the LOD score, the size of the call, the number of probes supporting the calling, and 
local probe density for the quality of the calls (Figure 5.1). The following criteria were set to 
filter CNV calls:  
i) LOD score ≥ 10 
ii) Size ≥ 1kb 
iii) Number of probes ≥ 5 
iv) Probe density ≥ 1 per 10kb  
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Table 6.1 Patient characteristics. 
BAV population (n) 94 
Sex (male n, %)  64 (68) 
Age (years, mean) 35 (13) 
BAV subtype (n, %) 
True 
Right-left 
Right-non 
Left-non 
Not known 
 
22 (23) 
32 (34) 
17 (18) 
2 (2) 
21 (23) 
Moderate- severe AVD (n, %) 
Aortic regurgitation 
Aortic stenosis 
 
46 (49) 
50 (53) 
Concomitant lesions (n, %) 
Thoracic aortic dilatation/aneurysm 
Coarctation of the aorta 
Ventricular septal defect  
Patent arterial duct 
 
52 (55) 
28 (30) 
14 (15) 
5 (5) 
Other (n, %) 
Family history of CHD 
Previous endocarditis 
Previous cardiac surgery (n, %) 
Aortic valve replacement 
Ross 
Root replacement 
Bentall 
CVD risk factors (n, %) 
Hypertension 
Diabetes 
Smoking 
 
30 (32) 
3 (3) 
72 (76) 
26 (27) 
18 (19) 
13 (13) 
15 (16) 
 
2 (2) 
2 (2) 
1 (1) 
Abbreviations: AVD, aortic valve disease; CHD, congenital heart disease; 
CVD, cardiovascular disease 
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Figure 6.3 Distribution of deletion-to-duplication ratio. Each dot represents a BAV sample with 
colour representing the level of sum of auto-correlation (SAC). The solid blue line represents the 
median of log2 deletion-to-duplication ratio and the dashed blue lines represent four times the median 
absolute deviation (MAD) of the residuals away from the fitted line. Dots encircled by red (two 
samples can be visualized in this graph) were cases falling outside the blue dashed lines’ region to be 
removed. 
 
 
Following individual review of CNV calls generated by the above three BAV samples, two of 
these were manually re-included in the final analyses (Figure 6.4) and a single case was 
excluded for technical reasons, as outlined above.  
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Figure 6.4 Example of array data from BAV samples with excessive CNV calls. Log2 ratios of 
two samples (red line) in identical genomic regions of chromosome 1; other samples in the same 
genotyping plate are depicted in grey. Following individual visualisation of the total CNVs from these 
samples, it was decided to re-include them in the final analyses due to their overlap with CNVs from 
the remaining BAV samples. 
 
In the end, this process gave rise to 4,842 CNVs (81.2% deletions) with a median size of 
23.2kb in 93 BAV cases and 341,194 CNVs (78.7% deletions) with a median size of 23.6kb 
in 5,919 controls. 
Merging CNV calls 
A clustering-like algorithm was used to merge CNV calls with extensive overlap into CNV 
events (CNVEs). These variables are likely to be identical with any slight differences in 
location owing to technical fluctuations in the precision of CNV discovery.  The CNV calls 
among BAV cases were clustered into 869 CNVEs with a median size of 32.4kb; 704 of them 
overlapped reciprocally >50% with control CNVEs. 
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6.4.3 CNV Burden Analysis 
We tested the hypothesis that BAV patients exhibit a greater burden of rare (<1% frequency) 
and large (>500kb) CNVs compared to controls. Statistical significance was established by 
10,000 rounds of permutation. Since we observed differences in the distribution of noise 
between samples and controls, we performed a conditioned permutation to control for this 
effect (Tables 6.2 and 6.3, calculated p values according to two conditions: level of noise and 
total number of calls per sample). 
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Table 6.2 Global CNV burden analysis: CNV event (CNVE) type and frequency (annotated CNVs size 100-200kb). Presented p values 
conditioned for level of noise expressed by median absolute deviation (MAD, p1) and for total number of calls per sample (NCPS, p2). 
 
CNVEs  
Type 
CNVEs 
Frequency Case rate Control rate 
Case/control 
ratio 
p1 
(MAD) 
 
p2 
(NCPS) 
Losses and gains Single occurrence 0.2795 0.1645 1.6989 0.0108 0.0046 
Losses Single occurrence 0.1612 0.0658 2.4478 0.0025 0.0021 
Gains Single occurrence 0.118 0.0986 1.1987 0.235 0.146 
Losses and gains 2 - 6 occurrences 0.2150 0.1861 1.1550 0.252 0.157 
Losses 2 - 6 occurrences 0.1075 0.0851 1.2628 0.159 0.107 
Gains 2 - 6 occurrences 0.1075 0.1010 1.0643 0.399 0.311 
Losses and gains 7 - 60 occurrences 0.3763 0.4941 0.7615 0.920 0.785 
Losses 7 - 60 occurrences 0.2043 0.2042 1.0002 0.387 0.213 
Gains 7 - 60 occurrences 0.1720 0.2899 0.5934 0.976 0.953 
Losses and gains All <1% 0.8709 0.8449 1.0308 0.326 0.117 
Losses All <1% 0.4731 0.3552 1.3316 0.021 0.0054 
Gains All <1% 0.3978 0.4896 0.8125 0.866 0.729 
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Table 6.3 Global CNV burden analysis: CNV event (CNVE) type and size (annotated CNVs frequency <1%). Presented p values 
conditioned for level of noise expressed by median absolute deviation (MAD, p1) and for total number of calls per sample (NCPS, p2). 
 
 
CNVEs  
Type 
CNVEs 
Size (kb) Case rate Control rate 
Case/control 
ratio 
p1 
(MAD) 
 
p2 
(NCPS) 
Losses and gains 100-200 0.8709 0.8449 1.0308 0.326 0.117 
Losses 100-200 0.4731 0.3552 1.3316 0.021 0.0054 
Gains 100-200 0.3978 0.4896 0.8125 0.866 0.729 
Losses and gains 200-500 0.4408 0.5507 0.8004 0.923 0.797 
Losses 200-500 0.1720 0.1833 0.9385 0.493 0.417 
Gains 200-500 0.2688 0.3674 0.7315 0.946 0.857 
Losses and gains >500 0.1290 0.1905 0.6770 0.907 0.859 
Losses >500 0.0322 0.0471 0.6843 0.639 0.628 
Gains >500 0.0967 0.1434 0.6746 0.863 0.807 
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6.4.4 Identification of likely pathogenic CNVs 
We performed the Fisher's exact test to examine CNVs that are rare (<1%) in the pooled 
population of cases and controls, but are specific or enriched in cases. The frequency of a 
CNV for this test was defined as the number of individuals that carry CNV calls 
overlapping more than 50% of the CNV in question since we were more interested in the 
affected genomic region rather than whether the CNVs correspond to a single mutation 
event. Overall, we observed 162 deletion CNVEs and 81 duplication CNVEs with a p-
value < 0.05. However, (1) only two “dropped” duplications on chromosome 17 (Figure 
5.5) survived multiple test corrections, (2) the vast majority of CNVEs were just 
singleton case CNVs not found in controls, and (3) some identified CNVEs could be 
under-called common CNVs or “false association” at the border of common CNVs, such 
as in the case of the “dropped” duplications. Other information, such as functional 
relatedness due to overlap of CNVEs with genes of interest, would be needed in order to 
support the argument that the failure of an association signal to survive multiple test 
correction was not just a random fluctuation of test statistics among a large number of 
tests. Individual review of the top eight recurrent CNV calls in BAV cases (Tables 6.4 
and 6.5) revealed a single duplication on chromosome 2 overlapping alkaline phosphatase 
placental-like 2 (ALPPL2, ENSG00000163286) gene which has been shown to be 
expressed in human heart tissue, as discussed later (Figure 6.6). 
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Figure 6.5 “Dropped” duplication on chromosome 17. Due to the close clustering of CNVs 
calls in controls, many “normal” calls in the BAV cases may have been accounted as duplications 
whereas we would expect to see a clear separation of calls in order to interpret the significance of 
the duplication. Depicted log2 ratios correspond to number of copies; ratio > 1 indicates 
duplication and ratio < 1 indicates deletion. 
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Table 6.4 Rare recurrent deletions in BAV cases. 
Chromosome Start End 
Size 
(bp) 
Case 
(n) 
Control 
(n) 
Odd  
ratio P 
18 56267422 56272211 4790 3 23 8.535547 0.007201 
3 7880524 7888516 7993 2 7 18.52006 0.007941 
6 57018293 57060589 42297 2 7 18.52006 0.007941 
1 1.51E+08 1.51E+08 14833 3 24 8.178987 0.008012 
5 98795643 98842659 47017 3 24 8.178987 0.008012 
1 1.51E+08 1.51E+08 6439 3 25 7.85109 0.008874 
3 1.94E+08 1.94E+08 2431 4 50 5.272772 0.009409 
3 1.27E+08 1.27E+08 22940 2 10 12.96779 0.014126 
 
 
Table 6.5 Rare recurrent duplications in BAV cases. 
Chromosome Start End 
Size 
(bp) 
Case 
(n) 
Control 
(n) 
Odd  
ratio P 
17 18296117 18353283 57167 23 18 106.9256 2.01E-32 
17 18254555 18450883 196329 17 4 328.1796 2.04E-28 
22 19872615 20247323 374709 4 19 13.93484 0.000379 
1 2.07E+08 2.07E+08 6052 2 4 32.38166 0.00341 
7 57599484 57741524 142041 2 5 25.92692 0.004727 
7 57621147 57671281 50135 2 7 18.52006 0.007941 
22 20038030 20264568 226539 4 51 5.167407 0.010029 
2 2.33E+08 2.33E+08 79810 2 9 14.41078 0.01189 
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underwent aortic valve and hemi-root replacement (pre-operative aortic diameters of 
50mm at the level of the root, 38mm at the sinutubular junction, and 47mm at the 
proximal ascending aorta, Figure 6.7). There was no known family history of CHD. 
 
Table 6.6. Investigated genes of interest associated with BAV disease and TAA 
formation.  
Ensebl Gene ID Gene Gene name Chromosome 
ENSG00000163221 S100A12 S100 calcium binding protein A12 1 
ENSG00000177000 MTHFR methylenetetrahydrofolate reductase 1 
ENSG00000136634 IL10 Interleukin 10 1 
ENSG00000060718 COL11A21 Collagen type XI 1 
ENSG00000083444 PLOD1 lysyl hydroxylase 1 1 
ENSG00000168542 COL3A1 Collagen alpha-1 (III) 2 
ENSG00000115414 FN1 Fibronectin-1 2 
ENSG00000084674 APOB Apolipoprotein B 2 
ENSG00000163513 TGFBR2 TGF- b receptor type 2 3 
ENSG00000163884 KLF15 Kruppel-like factor 15 3 
ENSG00000160791 CCR5 chemokine receptor 5 3 
ENSG00000183072 NKX2.5 NK2 transcription factor related 5 
ENSG00000113083 LOX lysyl oxidase 5 
ENSG00000152661 GJA1 gap junction protein, alpha 1 6 
ENSG00000091831 ESR1 Estrogen receptor alpha 6 
ENSG00000118523 CTGF connective tissue growth factor 6 
ENSG00000049540 ELN Elastin 7 
ENSG00000164867 NOS3/eNOS Nitric oxide synthase 3 7 
ENSG00000106366 PAI1/SERPINE1 serpin peptidase inhibitor 7 
ENSG00000146648 EGFR epidermal growth factor receptor 7 
ENSG00000164692 COL1A2 Collagen type II 7 
ENSG00000106397 PLOD3 lysyl hydroxylase 3 7 
ENSG00000148400 NOTCH1 NOTCH1 9 
ENSG00000106799 TGFBR1 TGF- b receptor type 1 9 
ENSG00000106991 ENG endoglin 9 
ENSG00000107796 ACTA2 alpha smooth muscle actin 10 
ENSG00000035403 VCL vinculin 10 
ENSG00000172638 EFEMP2 
EGF containing fibulin-like extracellular 
matrix protein 2 11 
ENSG00000166341 DSCHS1 Dachsous 1 11 
ENSG00000139567 ACVRL1 activin receptor-like kinase-1 12 
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ENSG00000179295 PTPN11 Protein-tyrosine phosphatase 12 
ENSG00000111424 VDR Vitamin D receptor 12 
ENSG00000187498 COL4A1 Collagen alpha-1(IV) 13 
ENSG00000100644 HIF1A hypoxia inducible factor 1, alpha subunit 14 
ENSG00000119630 PGF placental growth factor 14 
ENSG00000072110 ACTN1 Alpha-actinin-1 14 
ENSG00000134001 EIF2S1 eukaryotic translation initiation factor 2 14 
ENSG00000166147 FBN1 Fibrillin-1 15 
ENSG00000166949 SMAD3 SMAD family member 3 15 
ENSG00000133392 MYH11 smooth muscle myosin, heavy chain 11 16 
ENSG00000103197 TSC2 tuberin 16 
ENSG00000103126 AXIN1 Axin-1 16 
ENSG00000185615 PDIA2 
protein disulfide isomerase family A, member 
2 16 
ENSG00000125398 SOX9 SRY-box 9 17 
ENSG00000123700 KCNJ2 
potassium inwardly-rectifying channel, 
subfamily J, member 2 17 
ENSG00000196712 NF1 Neurofibromin-1 17 
ENSG00000171298 GAA lysosomal alpha-glucosidase 17 
ENSG00000159640 ACE angiotensin I converting enzyme 17 
ENSG00000108821 COL1A1 Collagen Type I 17 
ENSG00000131196 NFATc1 
Nuclear factor of activated T-cells, calcineurin-
dependant-1 18 
ENSG00000127528 KLF2 Kruppel-like factor 2 19 
ENSG00000130203 APOE Apolipoprotein E 19 
ENSG00000105329 TGFB1 TGF-beta 1 19 
ENSG00000130700 GATA5 GATA binding protein 5 20 
ENSG00000101384 JAG1 JAGGED1 20 
ENSG00000197496 SLC2A10 glucose transporter type 10 20 
ENSG00000100985 MMP9 matrix metallopeptidase 9 20 
ENSG00000070010 UFD1L ubiquitin fusion degradation 1 like 22 
ENSG00000188153 COL4A5 Collagen alpha -5 (IV) X 
ENSG00000196924 FLNA Filamen-A X 
ENSG00000184634 MED12 mediator complex subunit 12 X 
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6.4.6 CNV calling for X chromosome  
None of the identified rare CNVs on the X chromosome encompassed novel or selected 
genes of interest (Table 6.6). Tests were performed both separately and in combination, 
for males and females (Table 6.7). The only interesting finding was that of a 6kb 
heterozygous deletion (chr X: 150895188-150901132) in a single patient that was not 
present in controls; the patient was a 32 year-old female with a functional BAV and a 
history of AVR for severe AS. At the time of recruitment, she had normal aortic 
diameters with no other lesions and a negative family history for CHD. The deletion was 
just 1kb upstream of GABRE (ENSG00000102287), a gene coding a subunit of a chloride 
channel mediating synaptic transmission that is also expressed in the heart (to a lesser 
extent). 
6.4.7 Supplementary data 
CNV analyses were additionally performed in a single family and three trios following 
recruitment of consenting first-degree family members of BAV cases included in this 
study (pedigrees depicted in Figure 6.8). All family members were echocardiographically 
screened for heart disease with no detected abnormalities expect from a dilated thoracic 
ascending aorta in family #1 (Figure 6.8). Similar analyses applying the aforementioned 
methods did not detect any likely pathogenic CNVs harbouring genes of interest in the 
index cases or their family members.  
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Figure 6.8 Family pedigrees.  Family trees are depicted for four bicuspid aortic valve (BAV) 
patients (index cases marked with arrows) and their first-degree family members. Circle depicts 
female and square, male patients with blue colour denoting cases with BAV and white colour, 
cases with tricuspid aortic valve (TAV). The horizontal line connecting the diagonal lines in 
family #4 denotes monozygotic twins. Abbreviations: R-L, right- and left-coronary; R-N, right- 
and non-coronary; TAA, thoracic aortic aneurysm. 
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Table 6.7 Rare deletions and duplications on the X chromosome (combined results for male and female BAV patients). Abbreviations: Chr, 
chromosome; Del, deletion; Dup, duplication; Inf, infinite.  
Chr Start End 
Size 
(bp) 
Del. 
Cases 
(n) 
Del. 
Controls 
(n) 
Dup. 
Cases 
(n) 
Dup. 
Controls 
(n) 
Del. 
Odds 
ratio 
Del. 
p value 
Dup. 
Odds 
ratio 
Dup. 
p value 
X 1.44E+08 1.44E+08 99291 1 0 0 2 Inf 1.77E-02 0 1.00E+00 
X 1.49E+08 1.49E+08 23465 1 0 0 0 Inf 1.77E-02 0 1.00E+00 
X 1.51E+08 1.51E+08 5945 1 0 0 0 Inf 1.77E-02 0 1.00E+00 
X 88352266 88386448 34183 0 0 4 22 0 1.00E+00 10.47 1.03E-03 
X 91195197 91241279 46083 0 0 3 17 0 1.00E+00 10.06 4.94E-03 
X 91215681 91241279 25599 0 0 3 24 0 1.00E+00 7.11 1.16E-02 
X 2778567 2825538 46972 0 4 1 0 0 1.00E+00 Inf 1.77E-02 
X 57165332 57178738 13407 0 0 1 0 0 1.00E+00 Inf 1.77E-02 
X 70451051 70504174 53124 0 0 1 0 0 1.00E+00 Inf 1.77E-02 
X 89415789 89459641 43853 0 0 1 0 0 1.00E+00 Inf 1.77E-02 
X 89578305 89876837 298533 0 0 1 0 0 1.00E+00 Inf 1.77E-02 
X 1.14E+08 1.14E+08 22556 0 0 1 0 0 1.00E+00 Inf 1.77E-02 
X 1.46E+08 1.46E+08 35491 0 1 1 0 0 1.00E+00 Inf 1.77E-02 
X 1.49E+08 1.49E+08 367046 0 0 1 0 0 1.00E+00 Inf 1.77E-02 
X 91455945 91472313 16369 0 0 1 1 0 1.00E+00 55.74 3.52E-02 
X 1.52E+08 1.52E+08 376649 0 2 1 1 0 1.00E+00 55.74 3.52E-02 
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6.5 Discussion  
This study demonstrates a significantly greater incidence of rare (< 1% frequency) and large 
(100-200kb) deletions in BAV patients compared to controls (Tables 6.2 & 6.3, Figure 6.9). 
However, none of the recurrent rare events survived multiple test correction for identification 
of likely pathogenic CNVs. Individual review of CNV calls encompassing genes with 
functional relatedness to BAV disease revealed a 20kb heterozygous deletion on chromosome 
17 in a single patient, overlapping with more than 2/3 of the ACE gene (Figure 6.7a). 
Additional CNVs encompassing genes which are expressed in the heart to a lesser extent 
included a recurrent duplication on chromosome 2 overlapping ALPPL2 and a single deletion 
on chromosome X located 1kb upstream of GABRE. 
6.5.1 CNVs in CHD 
Recent studies in patients with CHD have illustrated the presence of clinically significant 
CNVs as a cause for both inherited and sporadic structural heart disease (Greenway et al., 
2009, Thienpont et al., 2007). Greenway et al. reported de novo CNVs at 10 loci accounting 
for at least 10% of non-syndromic sporadic cases of Tetralogy of Fallot whereas Thienpont 
and colleagues described chromosomal imbalances in patients with a variety of CHD lesions 
with additional phenotypic features suggestive of chromosomal aberrations (Greenway et al., 
2009, Thienpont et al., 2007). Both authors identified CNVs encompassing genes known to 
cause CHD, such as NKX2.5 and NOTCH1. In a different study including children with CHD 
and concomitant birth defects, a duplication of chromosome 2q33 was reported in a single 
BAV case with coarctation, developmental delay, and dysmorphic facies (Richards et al., 
2008). Interestingly, chromosome 2q duplications have been previously linked to birth 
malformations (Bird and Mascarello, 2001) and despite the lack of syndromic features in all 
of our cases, two BAV patients had duplications overlapping ALPPL2 gene located on 
chromosome 2q37 (Figure 6.6). 
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Figure 6.9 Overall distribution of rare autosomal deletions and duplications in BAV cases and controls.   
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ALPPL2 belongs to the closely related family of alkaline phosphatase (ALP) genes, encodes 
for the placental ALP-like enzyme of the testis and thymus, and has been shown to be 
expressed in the heart (to a lesser extent) with no reported involvement in cardiac 
development(Knoll et al., 1988, Martin et al., 1987). 
There is mounting evidence suggesting that BAV is part of a larger spectrum of cardiac 
malformations, including aortic valve stenosis, aortic coarctation, and hypoplastic left heart 
syndrome (HLHS), collectively known as left ventricular outflow tract obstruction (LVOTO) 
(Loffredo et al., 2004, Lewin et al., 2004, Hinton et al., 2009). Hitz et al. examined a large 
number of families segregating left-sided CHD lesions, including BAV, and reported a 
number of de novo and inherited CNVs contributing to 10% of their cases (Hitz et al., 2012). 
Identified chromosomal regions encompassed genes known to act in valvulogenesis 
pathways, such as CTHRC1 and MFAP4 (Hitz et al., 2012). The additional contribution of 
CTHRC1 over-expression to calcific AS was suggestive of developmental gene defects 
leading to both early and adult onset valvular disease (Hitz et al., 2012, Bosse et al., 2009). In 
our study, ACE was the only gene with similar functional relatedness to BAV disease 
(O'Brien et al., 2002, Nishimoto et al., 2002), overlapping with a large heterozygous deletion 
in a single BAV case (Figure 6.7a). 
6.5.2 ACE gene 
Angiotensin I-converting enzyme, encoded by the ACE gene, is a key component of the 
renin-angiotensin system (RAS) hydrolysing angiotensin I into angiotensin II, a potent 
vasopressor that stimulates aldosterone (Heeneman et al., 2007). Recently, the RAS system 
has been suggested to play a key role in TAA formation with evidence of increased 
expression of ACE in the aneurysmal aortic wall (Heeneman et al., 2007, Nishimoto et al., 
2002) and direct action of aldosterone and angiotensin II on VSMCs with transcription of 
genes involved in vascular fibrosis, inflammation, and calcification (Jaffe and Mendelsohn, 
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2005). Administration of AT1 blocker, losartan, has been shown to attenuate the aortic 
phenotype in both animal models and children with MFS (Habashi et al., 2006, Brooke et al., 
2008). Thus, in our BAV patient carrying the heterozygous ACE deletion, a “protective” 
rather than “damaging” effect on the aorta would be expected provided that gene 
haploinsufficiency results in reduced angiotensin II levels. In contrast, histological 
examination of collected tissue specimens revealed severe fibrosis and elastic fragmentation 
in the concave and convex aspects of the aneurysmal ascending aorta (Figure 6.7b). 
The functional effect of a single ACE allele has only been investigated in animal models so 
far, with step-wise reduction of ACE plasma activity by 25% in heterozygous mice (ACE +/-) 
and 70% in homozygous mice (ACE -/-) (Alexiou et al., 2005).  ACE haploinsufficiency did 
not have a significant effect on angiotensin II, with similar plasma and heart tissue levels in 
heterozygous and wild type mice (Alexiou et al., 2005). Interestingly, human studies have 
linked a polymorphism involving the insertion (I) or deletion (D) of a 287bp DNA sequence 
in intron 16 of the ACE gene to aneurysm formation, with DD carriers having higher plasma 
and heart tissue ACE levels and increased predisposition to TAA formation, including 
patients with a BAV (Danser et al., 1995, Foffa et al., 2012). Therefore, it is possible that the 
quantitative level of ACE gene function does not influence angiotensin II activity, which can 
also be activated in an ACE-independent manner, or changes in ACE activity are attenuated 
by compensatory mechanisms (Uehara et al., 2013, Alexiou et al., 2005).  
The presence of a single copy number of ACE may also impact earlier developmental 
processes. Similar to the observations by Hitz et al. who reported CNVs overlapping genes 
expressed during cardiac development (Hitz et al., 2012), ACE gene expression is present in 
the aortic valve and ascending aorta of wild-type mice during embryogenesis (Figure 6.9). 
Angiotensin II receptors are also widely expressed in the fetal tissue and have been shown to 
contribute to early embryologic development of the heart (Burrell et al., 2001). Interestingly, 
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expression of ACE and angiotensin II has also been exhibited in later onset severe calcific 
aortic stenosis, similar to the one seen in our BAV proband carrying the ACE deletion 
(O'Brien et al., 2002). The impact of reduced ACE expression on cardiac development can be 
examined by the fetopathy of ACE-inhibitors administered during human pregnancy. In utero 
exposure to these agents over the second and third trimesters of pregnancy has been 
associated with a number of conditions including oligohydramnios, hypocalvaria, 
abnormalities of the urinary tract and renal vascular system, renal failure, and death (Briggs, 
2002, Tabacova et al., 2003, Pryde et al., 1993). Earlier exposure to ACE-inhibitors during 
the first trimester has been linked to a number of cardiovascular malformations, including 
atrial septal defect, patent ductus arteriosus, ventricular septal defect, and pulmonary stenosis 
(Cooper et al., 2006). The presence of a BAV was not mentioned in the aforementioned large 
epidemiological study, although it is a phenotype that can potentially be overlooked in the 
presence of other major cardiovascular defects. 
Figure 6.9 The expression of ACE gene in the embryonic mouse heart. In situ hybridization for 
ACE gene expression performed on sagittal sections of a wild-type E14.5 mouse heart (a, b). Strong 
expression can be seen in the endothelium of the ascending aorta (asterisks) in both sections, with 
additional expression in the pulmonary valve (arrow), and aortic valve (arrowhead) seen in b. Source 
of pictures: www.eurexpress.org. 
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6.5.3 X- chromosome linkage theory 
This study also investigated the suggested BAV linkage to X-chromosome, due to the 
disease’s male predominance and its association with Turner syndrome (Tadros et al., 2009). 
Turner syndrome is characterized by complete or partial absence of one X chromosome in 
female patients, leading to early ovarian failure and a higher incidence of congenital cardiac 
malformations, including BAV, aortic valve disease, and coarctation of the aorta 
(Prandstraller et al., 1999). The 45X karyotype is associated with complex and more severe 
CHD, whereas the BAV phenotype is more frequent in X-structural abnormalities (X-rings 
and Xp monosomy) (Prandstraller et al., 1999, Sachdev et al., 2008). In our non-syndromic 
BAV probands, there was an absence of likely pathogenic CNVs located on the X 
chromosome.  This was in agreement with a previous family-based heritability study that 
failed to identify BAV X-linkage (Martin et al., 2007).  
When rare CNVs on the X-chromosome were examined for overlapping genes (Table 6.6), a 
6kb heterozygous deletion 1kb upstream GABRE gene was reported in a female BAV patient 
that was absent in controls. GABRE gene, mapped to chromosome Xq28, encodes a subunit 
of the gamma-aminobutyric acid (GABA) receptor which mediates synaptic transmission in 
the central nervous system (CNS) (Wilke et al., 1997). An alternative GABA subunit, with up 
to 45% amino-acid sequence overlap with CNS subunits, has been shown to be expressed in 
the electrical conduction system of the human heart (Garret et al., 1997). Notably, despite the 
unknown role of GABRE gene in valve formation, another gene involved in electrical 
conduction has been linked to BAV disease. Mutations in KCNJ2, encoding the inward-
rectifying potassium current Kir2.1, have been reported in BAV patients with Andersen 
syndrome, characterized by periodic paralysis, ventricular arrhythmias, and dysmorphic 
features (Plaster et al., 2001). Animal studies have shown that the function of inward-
rectifying potassium current Kir2.1 is not restricted to excitable tissue, thus leading to 
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speculation of an important role of ion channels in organ development through signalling 
pathways (Plaster et al., 2001, Karschin and Karschin, 1997).  
6.5.4 Limitations 
This study is limited by the restricted number of BAV patients who had heterogeneous 
phenotypes and variable family history of CHD. The absence of adequate parental samples is 
an additional limiting factor; the small number of recruited family members did not allow the 
undertaking of an alternative method of “trio” analysis involving screening of probands and 
their unaffected parents for detection of CNVs (Greenway et al., 2009). Our preliminary 
results merit further validation through expression studies for proof of causation. Future 
analyses with larger cohorts will be needed to investigate the potential clinical significance of 
identified rare and large CNVs which did not survive multiple statistical test correction.  
6.6 Conclusion 
This study demonstrates that patients with BAV disease harbour a significantly greater 
number of rare, large deletions compared to controls, although unlikely to be clinically 
significant. Individual review of CNV calls overlapping genes with BAV functional 
relatedness revealed a 20kb heterozygous deletion in a single patient overlapping ACE gene, 
a key element of the angiotensin-aldosterone system contributing to vascular function and 
disease. Mutations in the ACE gene were further investigated via next-generation sequencing 
in the same BAV patient cohort (Chapter 7). Additional CNVs of interest included a 
recurrent duplication encompassing ALPPL2 and a single deletion 1kb of GABRE, with no 
known involvement of the latter genes in cardiac development although found to be 
expressed in the heart. The functional effects of the above CNVs merit further validation in 
conjunction with genetic analyses in larger BAV cohorts.  
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Chapter 7. Next-generation sequencing  
 
Abbreviations 
 
AAA Abdominal aortic aneurysm 
AS Aortic stenosis 
AVR Aortic valve replacement 
BAV Bicuspid aortic valve 
BRU Biomedical research unit 
CHD Congenital heart disease 
CoA Coarctation of the aorta 
ECM Extracellular matrix 
HLHS Hypoplastic left heart syndrome 
MAF Minor allele frequency 
NGS Next generation sequencing 
PDA Patent arterial duct 
R-L Fusion of right- and left-coronary leaflets 
SNP Single nucleotide polymorphism 
TAA Thoracic aortic aneurysm 
TGFβ Transforming growth factor beta 
UTR Prime untranslated region 
VSD Ventricular septal defect 
VSMC Vascular smooth muscle cell 
 
Abbreviated gene names are included in Table 7.1 
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7.1 Abstract 
Background: BAV is a complex multifactorial disease encompassing a wide spectrum of 
phenotypic manifestations and associated genetic aberrations. Recent advances in genomics 
with the advent of cutting-edge NGS techniques, allow comprehensive genetic 
characterization of BAV patients in a timely and cost-efficient manner.  
Methods: Genomic DNA from 94 BAV patients was used to construct DNA libraries 
(SureSelectXT Target Enrichment System for SOLiD 4) followed by NGS (SOLiD 5500 
platform) of 63 genes of interest, known to be associated with BAV phenotypic traits.  
Results: A total of 157 likely pathogenic variants were identified in 62 (66%) BAV cases, 
out of which 41 (44%) carried mutations in more than one genes. Previously reported variants 
were identified in NOTCH1, COL3A1, and APOE genes with additional discovery of a large 
number of novel variants, which are predicted to be harmful, in genes related to BAV 
formation, aortopathy, calcific aortic stenosis, and hypoplastic left heart syndrome. Sanger 
sequencing will be performed to confirm novel mutations in prioritized genes of interest.   
Conclusion: Application of NGS techniques in BAV allows comprehensive assessment of a 
wide array of targeted genes and provides preliminary evidence on the polygenic nature of 
this complex heterogeneous trait.  
 
7.2 Introduction 
The effect of haemodynamic stress on the BAV aorta (Chapter 3) along with presence of 
CNVs in BAV patients encompassing a number of genes (Chapter 6) reinforced current 
views in the literature on the multifactorial nature of BAV disease (Laforest and Nemer, 
2012, Hinton, 2012). In this chapter, recently available cutting-edge genomic techniques at 
the Royal Brompton Hospital campus (Cardiovascular BRU) were utilized to further 
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investigate the genetic basis of BAV disease via targeted NGS of a wide array of associated 
genes of interest.  
Introduction of NGS technologies is currently changing the landscape of clinical genomics, 
with a dramatic increase in throughput at a constantly reducing cost (Ware et al., 2012). 
Targeted NGS is an especially attractive technique allowing selective sequencing of the 
coding regions of the human genome as opposed to costly, and occasionally unnecessary 
whole-genome sequencing (Biesecker, 2010, Choi et al., 2009). This approach has been 
applied successfully for research and diagnostics in several cardiovascular conditions, 
including inherited cardiomyopathies and arrhythmia syndromes (Meder et al., 2011, Herman 
et al., 2012, Ware et al., 2013). Application of this technique in BAV disease is particularly 
beneficial, in view of the wide spectrum of observed phenotypic manifestations with a large 
number of associated genetic aberrations (Hinton, 2012). The aim of this study was to create 
a library of genomic regions associated with various BAV phenotypic traits which, following 
further validation, may serve as a future clinical diagnostic tool for risk stratification in this 
population. 
7.3 Methods 
7.3.1 Sample collection 
A total of 94 BAV patient samples were sequenced (cohort described in CNV study, Chapter 
6). DNA extraction and purification methods are described in detail in Chapter 2. 
7.3.2 Next-generation sequencing 
Assay Design 
General principles of targeted NGS are described in Chapter 2. For the design of the 
sequence capture array, current literature was reviewed and 63 genes of interest were selected 
(Table 7.1). In addition to genes known to be associated with syndromic and sporadic BAV 
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disease, a number of genes related to inherited forms of aortopathy, aneurysm formation, AS, 
and valve formation were also included in the library (subpanels in Table 7.1). Gene 
sequences were retrieved from a reference database (http://www.ensembl.org) and RNA baits 
were designed for all exons of Ensembl transcripts of the selected genes, using Agilent’s 
eArray platform (https://earray.chem.agilent.com/earray). The final microarray design 
included UTRs and flanking exon/intron boundaries (+/-100 bp) with a total number of 
16,216 unique 120 mer RNA baits covering a target region of 479,673bp. Applied standard 
eArray parameters to generate RNA baits included tiling frequency = 5x, bait length = 120, 
standard repeats = off, avoid overlap = 20, and layout strategy = centred.  
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Table 7.1 Summary of sequenced genes. Genes harboring likely pathogenic variants (post NGS): * isolated cases; ‡ recurrent or multiple.  
Ensebl Gene ID Gene Chromosome Function/signalling pathways Human phenotype Reference 
Extracellular matrix proteins  
ENSG00000166147 FBN1 (Fibrillin-1) ‡  15 Tissue elasticity, TGFβ  MFS, BAV Ao- increased expression  (Dietz et al., 1991, Gomez et al., 2009) 
ENSG00000115414 FN1 (Fibronectin-1) ‡ 2 Marker of VSMC synthetic phenotype  
 Increased expression in convexity of 
Asc ao in stenotic BAV 
(Della Corte et al., 
2008) 
ENSG00000049540 ELN (Elastin) ‡ 7 Tissue elasticity 
Williams-Beuren syndrome; BAV with 
supravalvular AS 
(Szabo et al., 2006, Li 
et al., 1998) 
ENSG00000168542 
COL3A1  
(Collagen alpha-1 III) ‡ 
2 Collagen metabolism 
EDS, type 4; frequent arterial dissection 
with infrequent aneurysm 
(Liu et al., 1997, 
Superti-Furga et al., 
1988) 
ENSG00000188153 
COL4A5  
(Collagen alpha-5 IV) 
X Collagen metabolism 
X-linked  Alport syndrome; Asc ao & 
abdominal aneurysm 
(Kashtan et al., 2010) 
ENSG00000187498 
COL4A1  
(Collagen alpha-1IV) ‡ 
13 Collagen metabolism 
Hereditary angiopathy,nephropathy, 
aneurysms and muscle cramps 
(Plaisier et al., 2007, 
Poschl et al., 2004) 
ENSG00000083444 
PLOD1  
(lysyl hydroxylase 1) ‡ 
1 Collagen metabolism EDS type 6, rare aneurysm (Wenstrup et al., 1989, Takaluoma et al., 2007) 
ENSG00000106397 
PLOD3  
(lysyl hydroxylase 3) ‡ 
7 Collagen metabolism 
Bone fragility, arterial rupture and 
deafness 
(Salo et al., 2008, 
Ruotsalainen et al., 
2006) 
ENSG00000113083 LOX (lysyl oxidase) ‡ 5 Collagen metabolism, TGFβ Unknown, Ao aneurysm in KO mice (Maki et al., 2002) 
ENSG00000172638 EFEMP2 (fibulin-4) * 11 
Elastic fiber formation, connective tissue 
development 
Cutis laxa with Asc ao aneurysm and  
arterial tortuosity  
(Dasouki et al., 2007, 
Huang et al., 2010) 
Transcription factors  
ENSG00000130700 
GATA5 (GATA binding 
protein 5) ‡ 
20 
Cardiac development 
(aortic valve) 
Unknown, BAV in 25% of KO mice (Laforest et al., 2011) 
ENSG00000125398 SOX9 (SRY-box 9) * 17 Chondrogenesis 
Unknown, calcific valvular disease in 
KO mice 
(Peacock et al., 2010) 
ENSG00000131196 
NFATc1 (Nuclear factor of 
activated T-cells calcineurin-
dependant1) ‡ 
18 
                 Cardiac development 
(endocardial cushion growth & remodelling) 
Unknown (de la Pompa et al., 1998) 
ENSG00000183072 
NKX2.5 (NK2 transcription 
factor related) ‡ 
5 
Cardiac development  
(cardiac homeobox gene) 
BAV-TAA, ASD, VSD, TOF, Ebstein's, 
DORV 
(Biben et al., 2000, 
Schott et al., 1998, 
Majumdar et al., 2006, 
Wang et al., 2011) 
ENSG00000070010 
UFD1L (ubiquitin fusion 
degradation 1 like) 
22 
Cardiac development  
(cardiac outflow tract) 
BAV-TAA, DGS/VCFS (conotruncal 
cardiac defects) 
(Mohamed et al., 2005) 
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Transmembrane proteins 
ENSG00000148400 NOTCH1‡ 9 
Cardiac development 
(cardiac outflow tract) 
BAV, calcific aortic stenosis, VSD, 
TOF, mitral stenosis 
(Garg et al., 2005, 
Niessen and Karsan, 
2008) 
ENSG00000106799 
TGFBR1 
(TGFβ receptor type 1) 
9 Connective tissue degradation, TGFβ 
MFS-type 2, LDS, BAV Ao- increased 
expression 
(Loeys et al., 2006, 
Gomez et al., 2009) 
ENSG00000163513 
TGFBR2 
(TGFβ receptor type 1) 
3 Connective tissue degradation, TGFβ 
MFS-type 2, LDS, BAV Ao- increased 
expression 
(Loeys et al., 2006, 
Gomez et al., 2009) 
ENSG00000106991 ENG (endoglin) ‡ 9 
Cardiac development (aortic valve formation), 
TGFβ superfamily 
BAV (Wooten et al., 2010) 
ENSG00000101384 JAG1 (JAGGED1) * 20 
Cardiac development  
(aortic valve formation)  
Allagile syndrome; BAV with 
characteristic facies, jaundice & skeletal 
abnormalities 
(McElhinney et al., 
2002) 
ENSG00000123700 KCNJ2 17 
Excitable myocardial tissue (inward-rectifying 
potassium current Kir2.1) 
Andersen syndrome; BAV with periodic 
paralysis, ventricular arrhythmias & 
dysmorphic features 
(Andelfinger et al., 
2002) 
ENSG00000152661 GJA1 (connexin-43) 6 
Connexin gap junction- development of 
normal cardiac architecture and ventricular 
conduction 
Hypoplastic left heart syndrome (Yu et al., 2004) 
ENSG00000139567 
ACVRL1 (activin receptor-
like kinase-1) 
12 TGFβ superfamily 
Hereditary haemorrahagic 
telangiectasia, arterial aneurysms 
(Andersen et al., 2010, 
Oh et al., 2000) 
ENSG00000197496 
SLC2A10 (glucose 
transporter type 10) 
20 Glucose homeostasis Arterial tortuosity syndrome (Coucke et al., 2006) 
Cytoplasmic proteins 
ENSG00000166949 
SMAD3 (SMAD family 
member 3) 
15 Connective tissue degradation, TGFβ 
LDS, aortic aneurysm with 
osteoarthritis 
(van de Laar et al., 
2011) 
ENSG00000107796 
ACTA2 (alpha smooth 
muscle actin) 
10 Vascular contractility, TGFβ 
Familial aortic aneurysm; BAV with 
livedo reticularis 
(Guo et al., 2007) 
ENSG00000133392 
MYH11 (smooth muscle 
myosin, heavy chain 11) ‡ 
16 Vascular contractility, angiotensin II 
Familial aortic aneurysm with patent 
ductus arteriosus 
(Zhu et al., 2006, 
Pannu et al., 2007) 
ENSG00000196924 FLNA (Filamin-A) ‡ X Actin cytoskeleton, TGFβ  
Periventricular nodular heterotopia with 
EDS, Asc ao aneurysm and valvular 
dystrophy 
(Sheen et al., 2005, 
Feng et al., 2006) 
ENSG00000196712 NF1 (Neurofibromin-1) ‡ 17 Ras-MEK-ERK 
Neurofibromatosis, arterial aneurysm 
and stenosis 
(Friedman et al., 2002) 
ENSG00000179295 
PTPN11 (Protein-tyrosine 
phosphatase 2C) 
12 Ras-MEK-ERK 
Noonan syndrome, coronary artery 
aneurysm and rare Asc ao aneurysm 
(Purnell et al., 2005, 
Araki et al., 2004, 
Iwasaki et al., 2009) 
ENSG00000103197 TSC2 (tuberin) ‡ 16 Tumour suppression, mammalian target of Tuberous sclerosis, diffuse (Cao et al., 2010) 
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rapamycin (mTOR) thoracoabdominal aneurysm 
ENSG00000163221 
S100A12 (S100 calcium 
binding protein A12) 
1 Interleukin-6, TGFβ 
Increased expression in MYH11-
mutation aneurysm 
(Hofmann Bowman et 
al., 2010) 
ENSG00000164867 
NOS3/eNOS (endothelial 
nitric oxide synthase) * 
7 
Cardiac development, stress-induced vascular 
remodelling 
Abdominal aortic aneurysm, BAV in 
KO mice 
(Atli et al., 2010, 
Fernandez et al., 2009) 
ENSG00000103126 AXIN1 (Axin-1) ‡ 16 
Cardiac development 
(cardiac valve, outflow tract), Wnt  
BAV (Wooten et al., 2010) 
ENSG00000185615 PDIA2 ‡ 16 
Protein disulfide isomerase family A, member 
2 
BAV (Wooten et al., 2010) 
ENSG00000171298 GAA ‡ 17 Lysosomal alpha-glucosidase 
Acid maltase deficiency, intracranial 
aneurysm, lysosomal accumulation in 
heart and aorta of KO mice 
(Raben et al., 1998) 
Nuclear protein 
ENSG00000127528 
KLF2 (Kruppel-like 
 factor 2)  
19 Unknown 
Unknown, Ao aneurysm and dissection 
in KO mice 
(Kuo et al., 1997) 
ENSG00000163884 
KLF15 (Kruppel-like factor 
15) * 
3 
Inhibition of VSMC proliferation and 
migration, thrombospondin-2, p53, TGFβ 
Unknown, Ao aneurysm and 
cardiomyopathy in KO mice 
(Haldar et al., 2010, Lu 
et al., 2010) 
ENSG00000184634 
MED12 (mediator complex 
subunit 12) ‡ 
X WNT-β-catenin, WNT-PCP 
Lujan–Fryns syndrome with ao root 
dilation 
(Schwartz et al., 2007, 
Rocha et al., 2010) 
Vascular endothelial growth factor (VEGF) pathway members 
ENSG00000100644 
HIF1A (hypoxia inducible 
factor 1, alpha subunit) ‡ 
14 Proangiogenic transcriptional factor, VEGF  
Hypoplastic lef heart syndrome with 
BAV 
(Hinton et al., 2009) 
ENSG00000119630 
PGF 
 (placental growth factor) 
14 Embryogenesis (angiogenesis), VEGF  
Hypoplastic lef heart syndrome with 
BAV, atherosclerosis 
(Hinton et al., 2009) 
ENSG00000072110 
ACTN1 (Alpha- 
actinin-1) ‡ 
14 Cardiac development (cardiac valve), VEGF  
Hypoplastic lef heart syndrome with 
BAV 
(Hinton et al., 2009) 
ENSG00000134001 EIF2S1 14 
Eukaryotic translation initiation factor 2, 
subunit 1 alpha, VEGF  
Hypoplastic lef heart syndrome with 
BAV 
(Hinton et al., 2009) 
ENSG00000035403 VCL (vinculin) * 10 Cytoskeletal protein, VEGF  
Hypoplastic lef heart syndrome, dilated 
cardiomyopathy 
(Hinton et al., 2009) 
Enzymes regulating nitric oxide generation 
ENSG00000153904    DDAH1* 1 dimethylarginine dimethylaminohydrolase 1 Type II diabetes (Abhary et al., 2010) 
ENSG00000213722 DDAH2 6 dimethylarginine dimethylaminohydrolase 2 Type II diabetes (Abhary et al., 2010) 
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Associated with abdominal aortic aneurysm (AAA) 
ENSG00000100985 
MMP9 (matrix 
metallopeptidase 9) ‡ 
20 Connective tissue degradation, TGFβ 
BAV-TAA with autoimmune disease 
(case report), AAA 
(Foffa et al., 2009) 
ENSG00000159640 
ACE (angiotensin I 
converting enzyme) ‡ 
17 Connective tissue degradation, angiotensin II 
BAV-TAA, AAA, left ventricular 
hypertrophy 
(Foffa et al., 2009, 
Foffa et al., 2012) 
ENSG00000177000 
MTHFR (methylene-
tetrahydrofolate  
reductase * 
1 Connective tissue degradation 
BAV-TAA with autoimmune disease 
(case report), AAA, coronary artery 
disease 
(Foffa et al., 2009) 
ENSG00000106366 
PAI1/SERPINE1 (serpin 
peptidase inhibitor) * 
7 Connective tissue degradation 
BAV-TAA with autoimmune disease 
(case report), AAA, coronary artery 
disease 
(Foffa et al., 2009) 
Associated with aortic stenosis 
ENSG00000130203 
APOE  
(apolipoprotein E) ‡ 
19 
Catabolism of triglyceride-rich lipoprotein 
constituents 
Aortic stenosis-BAV (case report), 
atherosclerosis, Alzheimer’s 
(Saravanan and Kadir, 
2009) 
ENSG00000084674 
APOB  
(apolipoprotein B) ‡ 
2 
Primary apolipoproteins of chylomicrons & 
low-density lipoproteins 
Calcific aortic stenosis, atherosclerosis (Anger et al., 2006) 
ENSG00000111424 
VDR  
(Vitamin D receptor) * 
12 Transcription factor, mineral metabolism 
Calcific aortic stenosis, type II vitamin 
D-resistant rickets 
(Ortlepp et al., 2001) 
ENSG00000091831 
ESR1  
(Estrogen receptor alpha) 
6 Transcription factor 
Calcific aortic stenosis, cancer, 
osteoporosis 
(Anger et al., 2006) 
ENSG00000136634 IL10 (Interleukin 10) 1 Anti-inflammatory cytokine 
Calcific aortic stenosis, HIV-1 
infection, rheumatoid arthritis 
(Ortlepp et al., 2004) 
ENSG00000160791 
CCR5  
(chemokine receptor 5) ‡ 
3 
Transmembrane protein, anti-inflammatory 
properties  
Calcific aortic stenosis, HIV-1 infection (Ortlepp et al., 2004) 
ENSG00000118523 
CTGF (connective tissue 
growth factor) ‡ 
6 Chondrocyte proliferation 
Calcific aortic stenosis, systemic 
sclerosis 
(Ortlepp et al., 2004) 
ENSG00000146648 
EGFR (epidermal growth 
factor receptor) 
7 Transmembrane protein, cell proliferation Calcific aortic stenosis, lung cancer (Anger et al., 2006) 
Associated with mitral valve prolapse (MVP) 
ENSG00000105329 TGFB1 (TGF-beta1) ‡ 19 Connective tissue degradation, TGFβ 
MVP, increased expression in LDS 
aorta 
(Lindsay et al., 2012, 
Hagler et al., 2013) 
ENSG00000108821 
COL1A1  
(Collagen Type I) ‡ 
17 Collagen metabolism MVP, EDS, osteogenesis imperfecta 
(Sykes et al., 1990, De 
Paepe, 1998, Malfait et 
al., 2007) 
ENSG00000164692 
COL1A2  
(Collagen type II) ‡ 
7 Collagen metabolism MVP, osteogenesis imperfecta (Sykes et al., 1990, De Paepe, 1998) 
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ENSG00000060718 
COL11A1 
(Collagen type XI) ‡ 
1 Collagen metabolism 
MVP, EDS, Stickler syndrome, 
Marshall syndrome 
(Griffith et al., 1998, 
Khalifa et al., 2012) 
ENSG00000166341 DCHS1 (Dachsous 1) ‡ 11 
Cadherin family member, expressed in 
fibroblasts 
MVP, zebrafish model - no valve 
(personal communication to S.Cook) 
(Freed et al., 2003) 
 
Abbreviations: AAA, abdominal aortic aneurysm; Ao, aorta; AS, aortic stenosis; Asc Ao, ascending aortic; ASD, atrial septal defect; BAV, bicuspid aortic valve; 
DGS/VCFS, DiGeorge syndrome/Velo-cardio-facial syndrome; DORV, double outlet right ventricle; EDS, Ehlers Danlos syndrome; KO, knock-out; LDS, Loyes Dietz 
syndrome; MFS, Marfan syndrome; MVP, mitral valve prolapse; TAA, thoracic aortic aneurysm; TOF, Tetralogy of Fallot; VSD, ventricular septal defect. 
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Library preparation and sequencing 
Targeted exons and adjacent introns were enriched and barcoded, followed by next-
generation sequencing to screen for sequence variants. First, 3μg of genomic DNA was 
sheared using the Covaris S2 system and libraries constructed using the SureSelectXT 
Target Enrichment System for SOLiD 4.  Libraries were multiplexed and 32 samples 
pooled per lane for sequencing on the SOLiD 5500 platform, to generate paired end reads 
(75bp + 35bp).   
7.3.3 Data analysis 
SOLiD 5500xl reads were demultiplexed and aligned in colour space using LifesScope 
v2.5.1 “Targeted re-sequencing” pipeline (http://www.lifetechnologies.com/us/en/home/ 
technical-resources/software-downloads/lifescope-genomic-analysis-software.html).   
SOLiD Accuracy Enhancement Tool (SAET) was used to improve color call accuracy 
prior to mapping.  SAET implements a spectral alignment error correction algorithm that 
uses quality values and properties of color space.  All the parameters were used as default 
to streamline the data analysis. Duplicate reads were marked by LifeScope and created a 
subset file (ontarget) based on reads mapping quality > 8. In LifeScope “diBayes” 
algorithm was used to find single nucleotide polymorphisms (SNPs) and “smallindel” 
algorithm to call small insertion/deletions (indels). 
Local realignment around indels, and base quality score recalibration process were done 
in The Genome Analysis Toolkit (GATK) v1.5-20-gd3f2bc4 (McKenna et al., 2010). 
Alignment summary metrics, callability and coverage report were calculated using Picard 
v1.65 (http://picard.sourceforge.net), BedTools v2.11.2 (Quinlan and Hall, 2010) and in 
house perl scripts. The same “ontarget” file was used in LifeScope, GATK and Samtools 
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v0.1.18 (Li et al., 2009) programs to make consistent variant calls. Only SNPs that had at 
least one copy of the non-reference allele, a sequencing depth of >4x, mapping and base 
quality score >30 were considered for analysis for each test sample. Variants were 
functionally annotated using the Ensembl API v70_37 (McLaren et al., 2010) and HGMD 
Professional version 2012.2(Stenson et al., 2003). 
7.4 Results 
7.4.1 Analysis of variants 
A total of 2,746 variants were mapped in the sequenced 63 selected genes. To determine 
the functional relatedness of called indels and SNPs, variants were filtered in a stepwise 
approach (Figure 7.1). Selection of radical (frameshift, stop lost/gained, essential splice 
site) and potentially pathogenic (non-synonymous SNPs, other splice site, inframe indels) 
variants, led to a total of 370 calls. For non-synonymous variants affecting coding 
regions, the additional likely effect on protein function was predicted using SIFT (Sorts 
Intolerant from Tolerant) and Polyphen (Polymorphism Phenotyping) online tools 
(http://sift.jcvi.org, http://genetics.bwh.harvard.edu/pph2). Selection of variants with 
damaging and/or conflicting predictions on SIFT and Polyphen limited the total number 
of likely pathogenic variants to 254. Finally, due to the 0.5-2% incidence of BAV disease 
in the general population (Braverman et al., 2005), all variants with a minor allele 
frequency (MAF) of more than 2%  (http://www.1000genomes.org) were excluded, 
leading to a total of 157 calls.  
Table 7.2 includes BAV cases that show likely pathogenic alterations in the selected 
sequenced genes, excluding missense mutations with conflicting predictions on SIFT and 
Polyphen. Previously annotated variants on dbSNP (http://www.ncbi.nlm.nih.gov/SNP) 
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are included with an “rs” prefix, with known disease causing mutations high-lighted in 
bold. Out of the 94 sequenced BAV patients, 62 (66%) harboured likely pathogenic 
mutations in their genome, with 41 (44%) carrying mutations in more than one gene.  
 
 
Figure 7.1 Analysis of variants. The process of variant filtering can be viewed. MAF, minor 
allele frequency. 
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Table 7.2 Next-generation sequencing preliminary results. Sift and polyphen predictions are included for missense mutations (D: deleterious, 
PD: probably damaging, pD: possibly damaging, U: unknown) unless known to cause disease (high-lighted in bold).  
Case ID (#) Gene Mutation 
Consequence type 
             Missense                                     
         Sift/Polyphen                            Other 
Extracellular matrix proteins 
1984 FBN1  c.2425C>T, p.Pro809Leu D/PD  
1985, 2040 
2014 
2052 
2053, 2021 
FN1  
c.4213C>T, Arg1405Trp 
c.371C>A, p.Thr124Asn  
c.1313-7T>C (rs202045892) 
c.1070G>A, p.Gly357Glu 
D/PD 
D/pD 
 
D/pD 
Splice 
2008 
2056 
2059, 2010 
1991, 1993 
ELN  
c.614-8C>T (rs201859539) 
c.391+8C>T (rs55868272) 
c.2132G>A 
c.572G>A, p.Gly191Asp 
 
 
 
D/PD 
Splice 
Splice 
Splice 
 
1984 COL3A1 c.2002C>A, p.Pro668Thr (rs1801183) 
Familial aortic aneurysm 
(Tromp et al., 1993) 
 
2013 
2037 
2040 
        COL4A1  
c.3026G>A, p.Gly1009Glu 
c.4077_4078insAGAG 
c.365T>G, p.Ile122Ser 
D/pD 
 
D/U 
 
Frameshift_elongation 
 
2004, 2031         PLOD1  c.1675C>T, p.Arg559Cys D/PD  
2016 
2058, 1978, 1979, 1996 
        PLOD3  
c.*191C>T 
c.516G>C, p.Asp173His 
 
D/PD 
3 prime UTR 
 
2055          LOX  c.740+6G>A (rs41478244)  Splice 
Transcription factors     
2000 SOX9 c.685+8G>A (rs117696751)  Splice 
2015 NFATc1 c.*1427C>T (rs150249025)  3 prime UTR 
1984 
2008 
2031 
NKX2.5 
c.428G>A, p.Arg143Gln 
c.61G>C, p.Glu21Gln (rs104893904) 
c.763G>A, p.Ala255Thr 
U 
D/PD  
D/pD 
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Transmembrane proteins 
1993  
2018, 2046 
2025 
2026 
2031 
2032 
 
2038 
2055 
2059 
NOTCH1 
c.1649dupA, p.Tyr550X 
c.2080G>A, p.Glu694Lys (rs79782048) 
c.591C>A, p.Asn197Lys 
c.5282G>A, p.Arg1761Gln 
c.6356T>A, p.Val2119Glu 
c.4168C>A, p.Pro1390Thr (rs191645600) 
 
c.3644-4G>C 
c.7652C>T, p.Pro2551Leu 
c.1127delG, p.Cys376SerfsX255 
  AS (McBride et al., 2008) 
D/PD  
D/pD  
D/Pd 
BAV-TAA(McKellar et 
al., 2007) 
 
D/pD 
Frameshift elongation 
 
 
 
 
 
 
Splice 
 
Frameshift truncation 
1991, 1993 ENG c.572G>A, p.Gly191Asp D/PD  
2046 JAG1 c.1244T>A, p.Val415Glu D/PD  
Cytoplasmic proteins 
1988 
2049 
MYH11 
c.5787-11_5787-8delCTCT 
c.2665A>C, p.Lys889Gln 
 
D/PD 
Splice 
 
1989 
1992 
1996 
2043 
2059 
FLNA 
c.901C>T, p.Arg301Trp 
c.-116-7T>C 
c.5972C>T, p.Ser1991Leu 
c.1068T>C 
c.1286C>T, p.Thr429Met (rs36051194) 
D/pD 
 
D/pD 
 
D/PD 
 
Splice 
 
Splice 
 
2047 NF1 n.376+1G>A (rs184954044)  Splice 
1978, 2009, 2054 
1979 
2026 
2032, 1988 
2045, 2053 
TSC2 
c.52C>T, p.Thr18Met 
c.4368+6C>T 
c.1915C>T, p.Arg639Trp 
c.1747G>A, p.Ala583Thr 
c.3883+5C>T 
U 
                
D/PD 
D/PD 
 
 
Splice 
 
 
Splice 
2003 NOS3/eNOS c.271-84_276del  Splice 
2053, 1999 AXIN1 c.2186+7C>T (rs189357878)  Splice 
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1977, 2040, 1999 
1998 
2054 
PDIA2 
c.334C>T, p.Thr112Met 
c.531-3C>T, p.Gln195X (rs45619835) 
c.1388_1389delCT, p.Leu464GlnfsX13 
D/pD 
 
                 Splice 
 
Frameshift truncation 
2014 
2029 
GAA 
c.1192C>T 
c.858+6_858+12delGCGGCGG 
 
Splice 
Splice 
Nuclear protein 
2037 MED12 
c.6339delAinsACAGCAACAGCAG, 
p.Gln2109_Gln2112dup 
 Inframe insertion  
Vascular endothelial growth factor (VEGF) pathway members 
2033 HIF1A c.1267G>T, p.Asp423Tyr D/pD  
1978 
2016 
ACTN1 
c.1397A>G, p.Tyr466Cys 
n.95+4A>C 
D/PD 
 
 
Splice 
Enzymes regulating nitric oxide generation 
2033, 2009 DDAH1  c.260C>T, p.Thr87Met D/PD  
Associated with abdominal aortic aneurysm  
1979 
2012 
2023 
2065 
2068 
MMP9 
c.886G>A, p.Gly296Ser 
c.773C>T, p.Thr258Ile 
c.734delC, p.Thr246ProfsX92 
c.1751-6C>T 
c.1232A>G, p.His411Arg 
D/PD 
D/PD 
 
 
D/pD 
 
Frameshift truncation 
Splice 
2031, 2029, 2066 
2045 
2046, 2059, 1977 
2052 
2052 
ACE 
c.731A>G, p.Tyr244Cys 
c.1306+5C>T 
c.1025C>T, p.Thr342Met 
c.1513C>G, p.Pro505Ala 
c.1586+8C>T 
D/PD 
 
D/PD 
D/PD 
 
                         
Splice 
 
 
Splice 
Associated with aortic stenosis 
2006, 2016 APOE c.805C>G, p.Arg269Gly 
Hyperlipidaemia(Marduel 
et al., 2013) 
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1980 
1988 
1992 
1994 
2000 
2010 
2025 
2034 
2044 
 
         APOB 
 
c.3025G>A, p.Gly1009Arg 
c.11477C>T, p.Thr3826Met 
c.10672C>T, p.Arg3558Cys (rs12713559) 
c.5066G>A, p.Arg1689His (rs151009667) 
c.4850G>A, p.Gly1617Glu (rs146341569) 
c.3843C>T 
c.10294C>G, p.Gln3432Glu 
c.6639_6641delTGA, p.Asp2213del 
c.2981C>T, p.Pro994Leu 
D/PD 
D/PD 
D/PD 
D/pD 
D/PD 
 
D/PD 
 
D/PD 
 
 
 
 
Splice 
 
Inframe deletion 
2063 VDR c.909C>T  Splice 
2000 CCR5 c.-10G>C  Splice 
2036, 2057 CTGF c.290-6C>T  Splice 
Associated with mitral valve prolapse 
1983 
2009, 2043, 2018 
2036 
2061 
TGFB1  
c.71delGinsCGGGC, p.Gly24AlafsX78 
c.713-8delC (rs28365167; rs55659002) 
c.463C>G, p.Leu155Val 
c.887G>A, p.Arg296Gln 
 
 
D/PD 
D/PD 
Frameshift 
Splice 
 
 
2013 
2050 
COL1A1  
c.2708A>G, p.Lys903Arg 
c.935G>A, p.Arg312His 
D/U 
D/U 
 
1994 
2046 
COL1A2  
c.594+5A>T 
c.3853A>C, p.Asn1285His 
 
D/U 
Splice 
 
2044 COL11A1 c.4258C>G, p.Pro1420Ala D/U  
2004 
2003, 1993 
2034 
2068 
 
        DCHS1  
 
 
c.6508C>T, p.Arg2170Cys 
c.5160A>T (rs117031105) 
c.1160G>A, p.Arg387His 
c.5036-5C>G 
D/PD 
 
D/PD 
 
 
Splice 
 
Splice 
Abbreviations: AS, aortic stenosis; BAV, bicuspid aortic valve; TAA, thoracic aortic aneurysm. 
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7.5 Discussion 
NGS is an advantageous technology allowing parallel sequencing of selected genomic 
regions at a continuously reducing cost (Ware et al., 2012). Application of high-
throughput techniques is particularly promising for genetically heterogeneous traits such 
as BAV disease. While the preliminary results described here will require further 
validation by conventional Sanger sequencing, this study exhibits that NGS is capable of 
detecting both known and potentially novel pathogenic variants related to the diverse 
BAV phenotype (Figure 7.2). Selected subsets of investigated genes are discussed in the 
following sections.  
7.5.1 Genetic risk factors for aortic stenosis 
Patients with BAV have an increased lifetime risk of cardiac complications, the 
commonest of which is AS requiring AVR (Ward, 2000, Davies et al., 1996). AS 
predominantly occurs during the middle age of BAV patients and is characterised by 
calcific aortic valve degeneration (Ward, 2000). Sclerotic changes in the valve leaflets 
start earlier, in the second decade of life, with a more rapid progression of AS if the BAV 
leaflets are asymmetrical or in the anteroposterior position (Mautner et al., 1993, Beppu 
et al., 1993). 
Known genetic risk factors for aortic valve disease in the general population have rarely 
been investigated in BAV patients. Chan et al. assessed the role of conventional 
atherosclerotic risk factors in BAV disease and found that hypercholesterolemia and 
systemic hypertension are associated with development of AS (Chan et al., 2001). 
Following on from this, a single case report in the literature has shown the presence of 
e3/e4 apolipoprotein E genotypes, associated with hypercholesterolaemia, in a pair of 
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In this study, the presence of known genetic aberrations that could be assessed for risk of 
AS in BAV was further investigated, including known polymorphisms in IL-10, CTGF, 
CCR5, and VDR (Table 7.1) (Ortlepp et al., 2004, Ortlepp et al., 2001). A previously 
reported polymorphism in APOE gene (c.805C>G, p.Arg269Gly) was found in 2 BAV 
subjects, out of which one (#2016, Table 7.2) had stenotic valve disease (Marduel et al., 
2013). Other potentially pathogenic variants were reported in APOB, VDR, CCR5, and 
CTGF genes with 4 BAV patients having AS (#1980, #2044, #2063, #2036, Table 6.2). A 
genotype–phenotype relationship could be suggested by these preliminary findings in 
selected BAV patients, whereby increased predisposition to AS would be owing to 
genetic variants that are not unique to the BAV population (Figure 7.3a).  
7.5.2 Genes related to BAV formation 
A number of genes encoding for transcription factors with a key role in aortic valve 
development were included in our NGS library (Table 7.1 and Chapter 1, Figure 1.4). 
Mutations in NOTCH1, previously associated with BAV and aortic valve calcification 
(Garg et al., 2005), were present in 10 BAV subjects (Table 7.2). Out of these, 4 patients 
had sclerotic changes in their aortic valves (#1993, # 2026, #2038, #2056) and 3 
harboured previously described mutations (#2018, #2046, #2032, Table 6.2) (McBride et 
al., 2008, McKellar et al., 2007). A few of these patients had variants in more than one 
genes, including a young male BAV patient with stenotic calcified BAV and TAA 
(Figure 7.3c), who also carried a likely pathogenic mutation in ENG gene (#1993, Table 
7.2). Similar to NOTCH1, ENG participates in valve formation during embryogenesis and 
has been associated with BAV (Niessen and Karsan, 2008, Qu et al., 1998, Wooten et al., 
2010). Mutations in these two genes may also contribute to aortopathy seen in this 
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subject, as NOTCH1 missense variants have been reported in patients with BAV-TAA 
phenotype (McKellar et al., 2007), and ENG is part of the TGFβ receptor complex 
(Chapter 1, Figure 1.6) with a key role in angiogenesis (Li et al., 1999).  
Potentially pathogenic variants were found in additional genes involved in cardiac valve 
development, including NFATc1 and JAG1 (Table 7.2) (de la Pompa et al., 1998, 
McElhinney et al., 2002). Surprisingly, despite the strong association between eNOs 
deficiency and development of BAV in mice (Lee et al., 2000), only a single patient was 
found to have a variant in eNOS and two patients shared a variant in DDAH1, encoding 
an enzyme regulating nitric oxide generation (Table 7.2) (Abhary et al., 2010). 
6.5.3 Genes related to aneurysm formation 
The BAV aorta is known to be intrinsically abnormal, yet the culprit underlying genetic 
defect remains elusive. Affected family members may have isolated thoracic aortic 
dilatation or increased aortic stiffness in the absence of BAV (Hiratzka et al., 2010, 
Loscalzo et al., 2007), suggesting a common genetic background for BAV and TAA as 
variable manifestations of the same condition. Several signalling pathways share critical 
roles in the development of the aortic valve and the great vessels, such as NOTCH1, 
TGFβ, and Wnt signalling (Chapter 1, Figure 1.6) (Hinton, 2012). Although NOTCH1 
mutations have been linked to the TAA phenotype in sporadic BAV disease, familial 
studies show that they are exceedingly rare and do not contribute significantly to the non-
calciﬁc BAV-TAA phenotype (Kent et al., 2013, McKellar et al., 2007). In our study, 
11% of the sequenced BAV patients harboured likely pathogenic or known NOTCH1 
variants, out of which 40% had TAA. Sequencing of two critical members of the Wnt 
pathway, AXIN1 and MED12, led to identification of possibly damaging variants in 3 
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patients, with one having a BAV-TAA phenotype (#2037, Table 7.2) (Wooten et al., 
2010, Rocha et al., 2010). 
Histopathological changes seen in the BAV aorta are also present in a number of 
inherited forms of aortopathy, as discussed in Chapter 1. Patients with BAV have been 
previously reported to be negative for FNB1 mutations (Robinson and Godfrey, 2000) 
despite the common findings with the MFS aortic media of decreased fibrillin-1 
expression (Fedak et al., 2003) and increased TGFβ signalling (Chapter 4) (Gomez et 
al., 2009). Interestingly, a 25 year-old BAV patient with TAA in our study was found to 
have a likely pathogenic FBN1 variant, without a diagnosis of MFS (#1984, Table 7.2). 
The same patient also carried a mutation in COL3A1 gene (rs1801183) which has been 
associated with familial aortic aneurysm (Tromp et al., 1993). Family members were not 
examined at the time of the study although the patient reported a negative family history 
of aneurysm formation and/or other CHD lesions.  
Screening for mutations in TGFBR1 and TGFBR2 genes associated with MFS type-2 and 
LDS was negative in BAV patients, in agreement with previous findings (Arrington et al., 
2008). Mutations in MYH11 gene, encoding the major contractile protein βMHC in 
VSMCs, have been linked to familial TAA associated with PDA and less frequently, 
BAV (Zhu et al., 2006, Pannu et al., 2007). In this study, 2 patients with BAV-TAA had 
likely pathogenic variants in MYH11, with no presence of PDA and a positive 
uninvestigated family history of sudden cardiac death in one of the probands (#2049, 
Table 7.2). Surprisingly, all patients tested negative for ACTA2 mutations, despite its 
previous associations with familial aortic aneurysm and BAV disease (Guo et al., 2007). 
 189 
Additional candidate genes for BAV aortopathy include genes encoding key components 
of the aortic ECM and genes associated with AAA formation (Table 7.1). An interesting 
novel candidate arising from our NGS is FN1 encoding for fibronectin-1, a marker of 
VSMC synthetic phenotype (Zhang et al., 1995, Thyberg and Hultgardh-Nilsson, 1994), 
with likely pathogenic variants identified in 6 BAV patients (Table 7.2 and Figure 7.3b). 
Stress-dependent upregulation of FN1 has been previously shown in the BAV ascending 
aorta (Della Corte et al., 2008) and thus, mutations in this gene may represent an initial 
genetic insult which is further enhanced by in vivo haemodynamic perturbations. Multiple 
variants were also identified in genes associated with AAA, including MMP9 and ACE, 
suggestive of genetic aberrations in BAV patients that may individually contribute to the 
TAA (rather than BAV) phenotype (Foffa et al., 2009, Foffa et al., 2012). Although 
speculative, the latter theory would be further supported by the fact that more than 60% 
of BAV patients carrying ACE mutations also had likely pathogenic variants in other 
sequenced genes, including NOTCH1 mutations (#2046, #2059, Table 7.2).  
7.5.4 Syndromic forms of BAV disease 
BAV can be a component part of a number of syndromes, outside the scope of familial 
TAA (McElhinney et al., 2002, Andelfinger et al., 2002, Szabo et al., 2006, Hinton et al., 
2009). Targeted sequencing for mutations in JAG1 (Allagile syndrome) and KCNJ2 
(Andersen syndrome) did not reveal any likely pathogenic variants whereas 6 BAV 
patients had mutations in ELN gene, associated with Williams-Beuren syndrome and 
supravalvular AS, which absence of the latter feature in our subjects with ELN mutations 
(Table 7.2) (McElhinney et al., 2002, Andelfinger et al., 2002, Szabo et al., 2006, Li et 
al., 1998).  BAV can also be part of hypoplastic left heart syndrome (HLHS), 
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encompassing abnormalities of the left ventricular myocardium, aortic and mitral valves, 
and ascending aorta (Hinton et al., 2009). Sequencing of genes associated with HLHS 
revealed variants in HIF1A in a single patient with TAA, coarctation of the aorta (CoA), 
and absent valvular disease (#2033), and in ACTN1 in 2 patients with stenotic BAV with 
no other associated lesions (#1978, #2016, Table 7.2) (Hinton et al., 2009).  
Other phenotypic associations of BAV disease include a wide variety of cardiovascular 
malformations, such as CoA, ventricular septal defect (VSD), and mitral valve 
dysfunction (Braverman et al., 2005). Sequencing of genes related to mitral valve 
prolapse (Table 7.2) identified likely pathogenic variants in a number of candidate genes 
(TGFB1, COL1A1, COL1A2, COL11A1, DCHS1) (Hagler et al., 2013, Sykes et al., 1990, 
Freed et al., 2003, Griffith et al., 1998). None of these patients had reported mitral valve 
abnormalities although, interestingly, a number of them had associated CHD lesions 
including VSD (#2013, #2044), and CoA (#1994, #2044, #2033, Table 6.2). Finally, 
sequencing of the cardiac homeobox gene NKX2.5 previously associated with a wide 
variety of CHD lesions (Schott et al., 1998, Wang et al., 2011), led to identification of 
variants in 3 BAV patients, out of which one (#2008, Figure 7.3d) had concomitant VSD, 
PDA, and CoA and another (#2031, Table 7.2) had VSD and CoA. 
7.5.5 Towards a uniform theory 
Preliminary results arising from this study in conjunction with the known complex BAV 
inheritance pattern (Loscalzo et al., 2007, Huntington et al., 1997) suggest a 
multifactorial model for phenotypic expression of BAV disease characterized by a 
number of susceptibility genes with different liability thresholds (Figure 7.4) (Hinton, 
2012). Molecular networks sense and react to genetic and environmental perturbations 
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that in turn, affect disease risk (Schadt, 2009). Therefore, gene networks related to 
variable BAV manifestations, such as AS and TAA, may be affected by primary genetic 
insults but also, by epigenetic modifications and altered haemodynamics secondary to the 
malformed aortic valve (Nagy and Back, 2012, Shah et al., 2012, Hope et al., 2010).  
The effect of epigenetic modifications on BAV phenotypes has been increasingly 
reported in the literature, with evidence of Smad2 overexpression in TAA, similar to the 
one seen in our BAV samples (Chapter 4), influenced by increased acetylation and 
methylation of the histone protein H3 in the medial layer of BAV-TAAs (Gomez et al., 
2011). Furthermore, VSMC reprogramming has been shown to take place in response to 
TAA formation with epigenetically induced overexpression of protease nexin-1 (PN-1) 
promoting anti-proteolytic activity which may limit the risk of acute dissection and thus, 
imposing TAA patients with absence of these responsive processes to enhanced risk of 
wall rupture (Gomez et al., 2013). 
In a different study comparing gene methylation in aneurysmal ascending aortic tissue 
samples from BAV and TAV patients, differential signature patterns of DNA methylation 
and expression were highlighted with the most profound differences found in the protein 
tyrosine phosphatase, non-receptor type 22 (PTPN22), a gene involved in T-cell receptor 
signalling (Shah et al., 2012). Development of calcific BAV stenosis may also be 
epigenetically influenced with calcified aortic valve tissue exhibiting decreased DNA-
methylation in the promoter region of the pro-inflammatory enzyme 5-lipoxygenase (5-
LO) gene, leading to its overexpression (Nagy and Back, 2012). 
In conclusion, the above proposed multifactorial model (Figure 7.4) could explain the 
presence of intrinsic abnormalities in the BAV aorta but also the different risks of aortic 
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dilatation carried by BAV morphological subtypes, thus merging the “genetic” and 
“haemodynamic” hypothesis of BAV aortopathy into a uniform theory (Prapa and Ho, 
2012, Tadros et al., 2009).  
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Figure 7.3. Proposed genotype-phenotype correlartions. Different genotypes in BAV disease 
may account for the wide variety of observed phenotypes. These associations are hypothetical and 
merit further investigation. A. Mutation in ApoB gene associated with calcific BAV disease (seen 
in red, histology of the aortic valve leaflet). B. Mutation in FN1 gene associated with aortic root 
dilatation and corresponding severe elastic fragmentation of the media on histology. C. Mutations 
in NOTCH1 and ENG genes associated with aortic stenosis and aortopathy. D. Mutations in 
NKX2.5 gene associated with a variety of cardiovascular malformations. A; haematoxylin and 
eosin stain, B-D; elastic van gieson stain, A-D x 20 magnification. Histology specimens and 
aortic images (three-dimensional models from Chapter 3) are patient-specific (subject IDs: 
a;#3/1980, b;#4/2021, c;#1/1993, d;#7/2008). AS; aortic stenosis, AVD; aortic valve disease, 
CoA; coarctation of the aorta, PDA; patent arterial duct; TAA; thoracic aortic aneurysm, VSD; 
ventricular septal defect. 
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Figure 7.4. Hypothetical multifactorial model for BAV phenotypic expression. A. Multifactorial model characterized by a number of susceptibility genes 
with different liability thresholds affecting phenotypic expression of BAV disease. The interplay between primary genetic insults (blue) and epigenetic 
modifications (pink) can be seen. B. Hypothetical threshold model for phenotypic manifestations of BAV disease. Numerous susceptibility genes contribute 
to BAV phenotypes, with partial overlap (eg. Ca2+; a-c, BAV; b-e, TAA; e-h, HLHS; i-j). Assuming that each phenotype is dependent on different liability 
thresholds of predisposing variants (marked in blue), for example greater ≥2 variants for Ca2+, BAV, and HLHS, and ≥3 variants for TAA, then variable 
phenotypes manifest. Ca2+; calcification, HLHS, hypoplastic left heart syndrome; TAA; thoracic aortic aneurysm. Figure b. adjusted by Hinton (Hinton, 
2012).  
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7.5.6 Limitations 
Variants presented in this chapter are the result of preliminary analyses and require further 
validation via Sanger sequencing. Presented data are currently being processed in conjunction 
with NGS results from a different BAV cohort obtained via collaboration with St George’s 
Hospital, London, UK. Following completion of preliminary analyses, likely pathogenic 
variants in well-conserved genes with potential phenotypic correlations will be prioritized 
and further evaluated via causation studies.   
7.6 Conclusion 
Application of NGS techniques in BAV disease allowed comprehensive assessment of a wide 
array of targeted genes in a timely and cost-effective manner. Previously reported variants 
were identified in NOTCH1, COL3A1, and APOE genes with additional discovery of a large 
number of likely pathogenic variants in genes related to BAV formation, aortopathy, calcific 
AS, and HLHS. While the reported preliminary results merit further validation by 
conventional Sanger sequencing, the concomitant presence of variants in different genes in 
44% of sequenced patients suggests that BAV is a polygenic trait.  
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Chapter 8. General discussion  
 
Abbreviations 
AAA Abdominal aortic aneurysm 
ACE Angiotensin converting enzyme 
BAV Bicuspid aortic valve 
CHD Congenital heart disease 
CNV Copy number variation 
MRI Magnetic resonance imaging 
PAH Pulmonary arterial hypertension 
TAA Thoracic aortic aneurysm 
TGFβ Transforming growth factor beta 
VSD Ventricular septal defect 
VSMC Vascular smooth muscle cell 
WSS Wall shear stress 
  
 197 
In summary, multiple facets of BAV aortopathy were examined with application of distinct 
research methodologies. Novel data arising from these studies support a multifactorial rather 
than single (haemodynamic or genetic) origin of aortic abnormalities in BAV disease and 
may contribute to future individualised risk stratification of BAV patients for aortic 
complications. 
8.1 Haemodynamic influence 
Computational modelling techniques were applied to examine the effect of geometrical 
features of BAV aortic phenotypes on generated circumferential stress (exerted perpendicular 
to the aorta) and corresponding histological abnormalities of the media (Chapter 3). Aortic 
pathology is thought to occur when radial stress exceeds the tensile strength of the aortic wall 
(Nathan et al., 2011a). In agreement with a previous study, maximal circumferential stress in 
the majority of our studied BAV subjects occurred above the left-coronary sinus instead of 
the right-coronary sinus, where type A dissections typically occur (Nathan et al., 2011b). 
However, a pattern of shifting stress location was noticed from the convex to the concave 
aspect of the ascending aorta as the typical anterolateral bulge (seen in “post-stenotic” 
dilatation) became more asymmetrical (Figure 8.1).  
Novel correlations between the degree of circumferential stress and the severity of 
corresponding histological abnormalities revealed strong associations between normalised 
mechanical stress, fibrosis, and cyst-like formations in the aortic root and a weaker 
association between stress and fibrosis in the ascending aorta. These findings suggest that 
mechanical stress may have a greater pathophysiologic effect on the dilated root as opposed to the 
ascending aorta of BAV patients, which is also subjected to elevated WSS due to abnormal 
recirculation flow vortices (Hope et al., 2010).  
The effect of elevated pressures on arterial wall remodelling was also investigated in the 
setting of PAH and CHD with evidence of predominant fibrotic changes and a close 
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correlation between increasing vessel diameters and severity of medial wall changes in the 
hypertensive pulmonary artery (Chapter 5). Interestingly, despite its dilatation, the 
PAH/CHD pulmonary artery rarely dissects and this may be owning to the low frequency of 
cyst-like formations in the medial layer (Tredal et al., 1974). The latter formations have been 
described as the only potential histological feature differentiating the dissecting aorta from 
normotensive and hypertensive age- and sex-matched controls (Manley, 1964). In our studied 
PAH/CHD specimens, cyst-like formations of a significant degree were only found in a 
single specimen with recurrent pulmonary arterial wall rupture. In contrast, extensive cyst-
like lesions were seen in up to 55% of BAV aortic specimens and may render the arterial wall 
more susceptible to dissection and rupture compared to the PAH/CHD great vessels 
(Chapters 3 and 4).  
The above histopathological findings underlie a proteolytic process which constitutes the first 
necessary step for arterial wall “tear” formation. The secondary environmental triggers 
leading to aortic dissection and/or rupture remain elusive. So far, the main culprits include 
emotional stress and physical exertion resulting in acute hypertension and increased radial 
stress exceeding the tensile strength of the aortic wall (Nathan et al., 2011a). Thus, 
pharmacological treatment to reduce blood pressure to the lowest tolerated level is 
recommended in patients with TAA (Hiratzka et al., 2010). Moreover, heavy weight lifting 
accompanied by extreme isometric exercise is advised against as unusual sudden stress on the 
aorta may precipitate aortic dissection/rupture.  
Studies investigating critical levels of mechanical stress at which aortic dissection is more 
likely to occur are currently lacking. Despite investigations by our group (Chapter 3) and 
others (Nathan et al., 2011b) exhibiting elevated mechanical stresses in the BAV aorta, the 
next necessary step would be that of sequential computational studies in enlarging or 
dissected BAV aortas to validate the prognostic value of maximal mechanical stress, similar 
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to AAA disease (Fillinger et al., 2003). However, application of structural analysis in clinical 
practice would still be challenging as it requires input of a large number of data, such as 
patient-specific arterial wall material properties, which is both time consuming and currently 
unavailable to clinicians.  
The above obstacles may be overtaken in the future by fluid-structure interaction analyses 
which, in conjuction with functional imaging by positron emission tomography, have 
highlighted a spatiotemporal link between elevated tensile wall stresses and accelerated 
metabolic activity in the aortic wall of 5 patients with thoracic or abdominal aortic aneurysm 
(Xu et al., 2010). Despite these exciting preliminary findings, fluid-structure interaction 
analyses require a significant amount of workload, restricting their current use as a research 
rather than clinical tool (Scotti et al., 2005). Alternatively, phase contrast MRI allows real-
time wall shear (rather than mechanical) stress measurements and may serve as an additional 
risk stratification tool in BAV disease, provided that such data fit the clinical context of 
progressive arterial disease (Barker et al., 2010).  
Overall, advances in computational imaging, such as the ones explored in this thesis, can 
potentially hold a promising future in tailored risk stratification of BAV patients with aortic 
aneurysms. However, there is currently an increased need for a focused stepwise approach 
towards clinical translation of this biomechanical data. Moreover, the reproducibility and 
cost-effectiveness of the above time-consuming techniques needs to be assessed before their 
application in a clinical setting.  
8.2 Developmental aspects 
Our immunohistochemical findings confirmed the presence of increased TGFβ signalling in 
the aneurysmal BAV aorta, similar to other connective tissue disorders such as LDS and MFS 
(Chapter 4) (Gomez et al., 2009). The binary status of nuclear pSmad2 signalling seen in the 
BAV mesoderm derived root and the ectoderm derived ascending aorta favoured the theory 
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of differential TGFβ responsiveness in VSMCs of distinct embryologic origin, proposed by 
Lindsay and Dietz (Lindsay and Dietz, 2011). Moreover, increased TGFβ signalling was 
noticed for the first time in non-dilated BAV aortic segments, pointing to a genetic trigger. 
However, the primary genetic insult in BAV aortopathy remains to be found as BAV 
sequenced subjects tested negative for TGFBR1 or TGFBR2 gene mutations.  
Another important aspect of this study was the histological examination of the BAV aortic 
root which has been largely overlooked in this context (Chapter 4). BAV patients with aortic 
root dilatation and/or predominant regurgitant valve disease had significantly greater medial 
wall degeneration in their ascending aorta, in agreement with previous findings (Roberts et 
al., 2011). Thus, the dilated root phenotype may represent the primarily genetic form of BAV 
aortopathy and constitute a risk factor for the presence of severe intrinsic abnormalities in the 
ascending aorta (Figure 8.1). This finding would be of significance to current surgical 
guidelines and would support the application of a lower threshold for surgical replacement of 
the BAV dilated ascending aorta in the instance of concomitant root dilatation and/or 
predominant regurgitant valve disease (Roberts et al., 2011). Equally, a higher threshold 
could be suggested for root replacement in BAV, as the aortic root per se, exhibited 
significantly less abnormalities compared to the ascending aorta, even in the presence of root 
dilatation. These observations highlight the need for further surgical studies with targeted 
tissue sampling at the level of the BAV aortic root as well as, imaging studies focusing on the 
dilated root rather than ascending aortic BAV phenotype. 
Importantly, a study published at the time of completion of this thesis confirmed the above 
observations; by definition of aortic phenotypes of “ascending” (dilated ascending aorta with 
normal or less dilated root) versus “root” (dilated root with normal or less dilated ascending 
aorta) phenotype, Della Corte and colleagues found that the root phenotype was an important 
predictor of fast progression of ascending aortic dilation in 133 BAV adult patients 
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undergoing echocardiographic follow-up (Della Corte et al., 2013). The presence of aortic 
regurgitation also predicted an increase in ascending aortic diameter over time. These 
findings are in direct agreement with our histological findings of greater medial wall 
degeneration in the ascending aorta of BAV patients with aortic root dilatation and/or 
predominant regurgitant valve disease and reinforce the view of closer surveillance and 
potential earlier intervention in BAV patients presenting with predominant dilatation at the 
root level. 
8.3 Genetic aberrations 
Different sequencing techniques were employed to investigate the presence of genetic 
variants in BAV patients, at both the nucleotide and submicroscopic chromosomal level 
(Chapters 6 and 7). CNV analyses revealed a large heterozygous deletion in the ACE gene 
of a patient with heavily calcified BAV and extensive aortopathy.  ACE mutations have been 
previously linked to BAV-TAA (Foffa et al., 2012) and were further investigated via targeted 
next-generation sequencing, revealing a number of likely pathogenic variants in 8% of our 
sequenced BAV patients. Development of a wide panel of genes associated with various 
phenotypic manifestations of BAV led to identification of previously reported variants in 
NOTCH1, COL3A1, and APOE genes with additional discovery of a large number of likely 
pathogenic variants in genes associated with BAV formation, aortopathy, calcific aortic 
stenosis, and hypoplastic left heart syndrome.  
While these preliminary results require further validation via Sanger sequencing, the presence 
of multiple gene variants in 44% of sequenced patients support a multifactorial model for 
phenotypic expression of BAV disease characterized by a number of susceptibility genes with 
different liability thresholds (Figure 8.1). Gene networks related to variable BAV 
manifestations, such as aortic stenosis and TAA, might be affected by primary genetic insults 
as well as haemodynamic and epigenetic modifications (Nagy and Back, 2012, Shah et al., 
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2012, Hope et al., 2010), thus merging the “genetic” and “haemodynamic” theory of BAV 
aortopathy into a uniform model.  
Genetic screening is currently recommended for diagnosis of a number of syndromic and 
non-syndromic forms of TAA (Chapter 1) (Hiratzka et al., 2010). Despite the rapidly 
accumulating evidence that genetic abberations predispose BAV patients to certain 
phenotypes, including aneurysm formation, we are still on the verge of effective genetic 
screening to risk stratify this highly heterogeneous patient population. Application of cost- 
and time-efficient next-generation sequencing methods led to identification of a number of 
mutations in key BAV-associated genes (Chapter 7).  However, more evidence is needed to 
support the causality of fundamental genetic mutations before we embark on genetic 
screening of BAV patients in a clinical, rather than experimental, context. Alternative 
approaches, such as whole genome gene expression profiles, have led to identification of 
signature sets of biomarker genes in asymptomatic TAA disease and may also hold a 
promising future (Wang et al., 2007). 
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Chapter 9: Appendices 
9.1 Personal contribution to the research 
Several collaborations were necessary for completion of this multidisciplinary work. With 
regards to personal contribution, I set up the research protocol and ethics for the whole of this 
study, recruited patients and collected samples, performed the computational modelling, 
histological, and immunohistochemical analyses, and completed the statistical analyses. Pre-
operative imaging data (CT and echocardiography) was obtained by radiographers of the 
Royal Brompton Hospital, whereas I completed the post-processing of CT angiograms to 
generate 3D models of the aorta and further structural analyses. NGS was performed by 
collaborating team members of the Cardiovascular BRU, Royal Brompton Hospital, and 
CNV analyses by members of Dr. Matthew Hurles’ team, Wellcome Trust Sanger Institute, 
Cambridge. With regards to genetic analyses, I performed the DNA extraction and 
purification, conducted an extensive literature review for gene selection for targeted NGS and 
worked with bioinformaticians at the Royal Brompton Campus (John Shibu) for the design of 
the capture library and at the Sanger Institute (Ni Huang) for post-CNV calling processing of 
data. Preliminary NGS results were processed by Katie Fletcher, PhD student within the 
Cardiovascular BRU, who will undertake the further validation of novel likely pathogenic 
variants, as a direct extension of this work. In collaboration with Katie, I performed the 
interpretation of the processed preliminary NGS results and prioritized genes of interest. 
All figures in this dissertation were produced by me, unless stated otherwise. Figures 1.3, 1.5, 
and 6.2 were produced with the assistance of Lucy Coleman, postdoctoral fellow of the 
Cardiovascular BRU, and figure 6.1 with the assistance of Katie Fletcher. 
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Summer School, Tsinghua University, Beijing, China 
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Pending validation of described genetic variants, a number of publications on integrated 
results is currently in preparation. 
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